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SUMMARY 
 
Osteosarcoma (OS) is the most common malignant bone tumour in children and young 
adolescents. Many efforts have been made during the past decades to improve the survival 
of OS patients and indeed the combination of resection of the primary tumour and neo-
adjuvant chemotherapy increased the 5-year survival of patients with a localised disease 
from 20 to 80%. However patients with metastatic disease still have low chances to survive: 
the 5-year survival remained at 20% since the second half of the 1970s.  
Consequently, clinicians who take care of OS patients face two important challenges: first 
they need imaging tools with much higher sensitivity and resolution than current equipment 
for early detection of primary tumours and metastases and better monitoring of the therapy 
response. Second, tumour staging needs to be improved for the design of more tumour-
specific treatment strategies and the development of new drugs that more selectively target 
and kill tumour cells. 
Therefore, in this thesis, we aimed at assessing on one side the potential use of positron 
emission tomography (PET) as an additional tool in vivo for the characterization of different 
OS phenotypes and for the detection of lung metastases. On the other side we evaluated the 
efficacy of photodynamic therapy (PDT) for the treatment of OS.   
For the first aim we validated the power of PET imaging making use of two xenograft, 143B 
and SaOS-2/Caprin-1, and one syngeneic, LM8, orthotopic OS mouse model that represent 
the heterogeneity of OS phenotypes in the human disease, where the tumour cells 
metastasise towards the lung. We analysed, at the beginning, the uptake of six PET tracers in 
the primary tumour and compared it to the uptake in the control healthy leg. The tracers 
used were Fluoro-2-deoxy-D-glucose (18F-FDG), an indicator of glucose metabolism, 
Fluoromisonidazole (18F-FMISO), an indicator of hypoxia, 18F-Fluoride, an indicator of bone 
remodeling, 3’-Fluoro-3’-deoxythymidine (18F-FLT), an indicator of DNA synthesis, O-(2-
Fluoroethyl)-L-tyrosine (18F-FET), an indicator of protein synthesis and Fluoromethylcholine 
(18F-FCH), indicator of membrane turnover. The last three tracers did not show any 
consistent results in one representative xenograft model, namely 143B. The uptake of the 
other three tracers (18F-FDG, 18F-FMISO and 18F-Fluoride) was, instead, evaluated in all the 
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three tumour models and we found that PET can provide additional information on the 
biology of individual tumours and on predominant processes affecting the tumour 
development, thereby helping in selecting a better therapeutic strategy without neglecting 
the unequivocal value of a tumour biopsy. 
In the predominantly osteolytic model, namely 143B, we observed a significant 3.7 fold 
increase of 18F-fDG uptake indicating high glucose metabolism. In addition we recognized 
areas of hypoxia and found a significant 2 fold increase of 18F-fMISO uptake in the primary 
tumour leg compared to the healthy control leg; bone remodelling was either absent or 
moderate (1.1 fold increase of 18F-fluoride uptake in the tumour leg). In the mouse model 
with only mild osteoblastic lesions, on the other hand, a significant but more modest uptake 
of glucose (2.2 fold increase) compared to the osteolytic model was observed. Hypoxia was 
minimal and moderate bone remodelling with a 1.3 fold increase in 18f-Fluoride uptake in the 
tumour leg. Finally, the mouse model with more pronounced osteoblastic lesions showed a 2 
fold increase of glucose metabolism in the primary tumour leg, but large areas of hypoxia 
and bone remodelling. Indeed the fold increase of 18f-FMISO and 18f-Fluoride uptake in the 
primary tumour was respectively 2.2 and 2.3. Immunohistochemical staining of tumour 
tissue confirmed the results obtained with the different PET tracers. 
Regarding the metastases, we could not detect foci in the lung with PET imaging in the SaOS-
2/Caprin-1 and in the 143B mouse models though we could confirm the metastatic presence 
ex vivo. 
For the second aim we focused on the development of new modalities for the treatment of 
OS, evaluating the efficacy of photodynamic therapy (PDT) in OS cell lines in vitro and 
optimizing protocols for PDT in vivo in orthotopic OS mouse models.  
In vitro we demonstrated that the highly metastatic 143B OS cell took up 2.5 fold more PS 
than the parental low metastatic HOS cells. Furthermore photo-toxicity was observed in the 
143B cells already at a concentration of PS as low as 0.075 ugml-1 and was found mediated 
by apoptotic mechanisms leading to cell death, which occurred already 90 min after 
illumination of PS accumulating cells.  
In view of these promising results, we focused on a well-established orthotopic OS mouse 
model generated by intratibial injection of 143B cells. We were able to define the 
concentration range of PS tolerated and being effective in our model (between 0.05mgkg-1 
and 0.1 mgkg-1). 
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Even though considerable additional efforts are needed to establish PDT for the treatment 
of OS in the clinic, the results of the here reported in vitro and in vivo studies are 
encouraging and set the stage for future work aiming at a more tumor-selective uptake of PS 
mediated by PS-containing nanoparticles coated with antibodies that selectively recognize 
cell surface proteins particularly enriched on OS tumour cells. 
In conclusion, the combination of improved imaging tools and novel treatment modalities 
such as PET and PDT, respectively, will in the future help to more accurately diagnose tumor 
phenotypes and improve treatment efficacy.  
  
 
 
14 
  
 
 
15 
SOMMARIO 
L’osteosarcoma (OS) è la forma più comune di cancro alle ossa in bambini e adolescenti. 
Molti sforzi sono stati compiuti per migliorare la sopravvivenza dei pazienti con OS; infatti, la 
combinazione dell’intervento di resezione del tumore primario con la chemioterapia neo-
adiuvante ha incrementato la sopravvivenza a 5 anni dei pazienti con una forma localizzata 
di tumore da 20 a 80%, mentre i pazienti con una forma metastatica della patologia hanno 
un tasso di sopravvivenza a 5 anni che si attesta sul 20%: nessun netto miglioramento è stato 
rilevato negli ultimi anni 40 anni. 
Di conseguenza i clinici che si occupano dei pazienti con OS devono affrontare due 
importanti sfide: prima di tutto la necessità di disporre di strumenti per l’individuazione del 
tumore primario, delle metastasi e per il monitoraggio della risposta al trattamento di più 
elevata sensitività e risoluzione rispetto agli strumenti attualmente a disposizione.   
In secondo luogo è necessario migliorare il processo e i mezzi di stadiazione tumorale per la 
definizione di strategie terapeutiche più specifiche e per lo sviluppo di nuovi farmaci che 
mirino a distruggere le cellule tumorali in modo più selettivo. 
In questa tesi abbiamo validato la possibilità di utilizzare la PET come strumento aggiuntivo 
per la caratterizzazione di diversi fenotipi di OS and per il rilevamento di metastasi 
polmonari.  
Dall’altro lato abbiamo valutato l’efficacia della terapia fotodinamica per il trattamento 
dell’OS.   
Per il primo obiettivo abbiamo validato il potere della PET su due modelli ortotopici di topo 
xenograft e un singenico.  
Questi tre modelli metastatizzano al polmone e sviluppano diverse forme radiologiche di 
tumore che rappresentano l’eterogeneità dei fenotipi di osteosarcoma nella patologia 
umana.  
Noi abbiamo analizzato, all’inizio, la captazione di sei traccianti per PET nel tumore primario 
e comparato con la captazione di questi traccianti in una regione di osso di riferimento. I 
traccianti utilizzati sono 18F-Fluorodeossiglucosio (18F-FDG), indicatore di metabolismo 
glucidico, 18F-Fluoromisonidazolo (18F-FMISO), marcatore d’ipossia, 18F-fluoruro, indicatore di 
rimodellamento osseo, 3’-Fluoro-3’-deossitimidina (18F-FLT), indicatore di sintesi del DNA, O-
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(2-Fluoroetil)-L-tirosina (18F-FET), indicatore di sintesi proteica e Fluorometilcolina (18F-FCH), 
marcatore di rimodellamento della membrana fosfolipidica. 
Gli ultimi tre traccianti non hanno mostrato nessun risultato consistente in un modello 
rappresentativo xenograft, nominato 143B.  
Gli altri tre traccianti (18F-FDG, 18F-FMISO and 18F-Fluoruro) sono stati analizzati, invece, in 
tutti e tre i modelli murini. Abbiamo, quindi, osservato che la PET può essere un mezzo 
aggiuntivo per ottenere informazioni e selezionare una strategia terapeutica migliore senza 
rinnegare l’inequivocabile valore della biopsia. 
Abbiamo potuto caratterizzare con successo la biologia dei diversi tumori influenzati in 
modo e ad un livello differente dai processi che sono visualizzati con i traccianti.  
Il modello tumorale murino che sviluppa tipiche lesioni osteolitiche presenta un grado 
elevato di metabolismo glucidico: il tumore capta 3.7 volte più 18F-FDG.  Considerevoli aree 
d’ipossia sono riscontrabili e abbiamo misurato una captazione 2 volte più elevata di 18F-
FMISO nel tumore rispetto al controllo; infine attività di rimodellamento osseo è assente o 
solo moderatamente presente. Dall’altro lato il modello murino caratterizzato da lesioni 
moderatamente osteoblastiche presenta una captazione modesta ma significativa di 
glucosio (2.2 più captazione di 18F-FDG nel tumore primario rispetto al controllo) , livelli 
molto ridotti d’ipossia e moderata presenza di attività di rimodellamento osseo: solo 1.3 
volte più captazione di 18F-Fluoruro. Infine il modello murino con lesioni osteoblastiche più 
pronunciate mostra un livello ridotto di captazione del glucosio rispetto ai due modelli 
precedenti: la captazione nel tumore è 2 volte più elevata rispetto al controllo. Inoltre in 
questo modello si possono riscontrare aree estese d’ipossia (2.2 volte più captazione di 18F-
FMISO nel tumore primario) e rimodellamento osseo (2.3 volte più captazione di 18F-
Fluoruro nel tumore primario). Istologia e immunoistochimica con una specifica colorazione 
e con anticorpi confermano i risultati mostrati tramite PET. 
Riguardo le metastasi, non abbiamo potuto rilevare nessuna formazione metastatica nei 
polmoni con la PET né nel modello tumorale, SaOS-2/Caprin-1, né nel modello murino 143B 
sebbene abbiamo potuto confermare la presenza metastatica ex vivo. 
Per il secondo obiettivo abbiamo valutato l’efficacia della terapia fotodinamica (PDT) in 
cellule di OS in vitro e abbiamo ottimizzato i protocolli per PDT in vivo su modelli murini di 
OS.  
 
 
17 
In vitro abbiamo dimostrato che le cellule con alto potenziale metastatico, 143B, captano più 
PS delle cellule parentali con potenziale metastatico più basso, HOS. Inoltre fototossicità è 
rilevabile nelle cellule 143B quando una concentrazione molto bassa di PS viene utilizzata ed 
è associata ad un meccanismo diretto d’apoptosi di morte cellulare che si verifica 90 minuti 
dopo l’illuminazione con il PS. 
Alla luce di questi risultati promettenti ci siamo focalizzati su un modello murino ortotopico 
di OS che è stato messo a punto nel laboratorio in cui le cellule 143B sono state iniettate 
intra tibia: abbiamo potuto definire la finestra terapeutica di PS che può essere utilizzata nel 
nostro modello murino (tra 0.05mgkg-1 e 0.15 mgkg-1). 
Nonostante molti sforzi debbano ancora essere fatti per trasferire il trattamento con PDT in 
clinica, i risultati di questo lavoro presentato di seguito sono incoraggianti e preparano il 
terreno per un lavoro futuro che miri ad una captazione del PS che più selettivamente 
raggiunga le cellule tumorali attraverso l’utilizzo di nanoparticelle contenenti PS ricoperte di 
anticorpi che selettivamente riconoscono proteine di superficie particolarmente presenti 
sulle cellule tumorali. 
Per una comprensione più chiara della biologia tumorale e per un approccio terapeutico più 
adeguato è necessaria la combinazione di migliori strumenti di visualizzazione tumorale e la 
selezione di una modalità terapeutica che potrebbero mirare più selettivamente alle cellule 
tumorali. 
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LIST OF ABBREVIATIONS 
2-DG 2-Deoxyglucose 
ALA Aminolevulinic acid 
ALP Alkalyne phosphatase 
BCG Bacille- Colmette Guérin 
CLSM Confocal laser scanning microscopy 
CT Computed Tomography 
CP Corynebacterium parvum 
Cu-ATSM Cu(II)- diacetyl-bis(N4 methylthiosemicarbazone 
DCA Dichloroacetate 
EDTA Ethylenediaminetetraacetic acid 
EGFP Enhanced green fluorescent protein 
ETAR ET-1 receptor 
FCH Fluoromethylcholine 
FDG Fluoro-2-deoxy-D-glucose 
FET O-(2-Fluoroethyl)- L-tyrosine 
FLT 3'-Fluoro-3'-deoxythymidine 
FMISO Fluoromisonidazole 
GLUT Glucose Transporter 
HD-MTX High-dose methotrexate 
H&E Hematoxylin and Eosin 
HIF 1 α Hypoxia-inducible factor 1 α 
HPD Hematoporphyrin derivative 
HSV1-tk Herpes simplex virus type 1 thymidine kinase 
IHC Immunohistochemistry 
IL-6 Interleukin-6 
INF α  or ƴ Interferon α or ƴ 
LDH Lactate dehydrogenase 
MBq or Bq Megabequerel or bequerel 
MRI Magnetic Resonance Imaging 
mTHPC 5,10,15,20-tetrakis(meta-hydroxyphenyl)chlorine 
OS Osteosarcoma 
PARP Poly-ADP-ribose polymerase 
PDT Photodynamic Therapy 
PEDF Pigment epithelium-derived factor 
PET  Positron Emission Tomography 
PFA Paraformaldehyde 
PS Photosensitizer 
RFU Relative fluorescent unit 
ROI Region of interest 
SEM Standard error of the mean 
SPECT Single-photon emission computed tomography 
SUV Standardised uptake value 
TCA Tricarboxylic acid cycle 
TLRs Toll-like receptors 
 
 
20 
TNF Tumour necrosis factor 
TPZ N-oxyde tirapazamine 
ZOL Zolendronic acid 
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1 INTRODUCTION: OSTEOSARCOMA 
1.1 INCIDENCE AND ETIOLOGY 
Osteosarcoma (OS) is a rare malignant primary bone tumour accounting for 0.2% of all the 
human tumours but it is the most common cancer of the bone (35%) followed by 
chondrosarcoma (25%) and Ewing sarcoma (16%) in children and young adults (Fletcher 
2002; Mirabello, Troisi et al. 2009). Indeed the incidence reaches 11/1.000.000/year in 
adolescents between 15 and 19 years of age while the overall incidence is attested on 
3/1.000.000/year (Hogendoorn, Athanasou et al. 2010). Despite the high frequency in the 
young population it shows a second peak of incidence in the seventh and eight decade of life 
(Fig.1.1). In the elderly patients OS is usually related to previous radiotherapy for other 
cancers’ treatment or secondary to pathologies like Paget’s disease of bone, hereditary 
retinoblastoma, Li-Fraumeni-, Werner-, Rothmund Thomson- and Bloom-syndromes (Price 
1955; Huvos 1986; Hogendoorn, Athanasou et al. 2010).  
 
Fig.1.1 Osteosarcoma age-related incidence according to the Surveillance, Epidemiology and End Results (SEER) 
program (Mirabello et al., Cancer 2009) 
These pathologies are usually associated with hereditary modifications that are listed in the 
Table 1.1 below and in the case of OS they show a complex karyotype with chromosomal 
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rearrangements that affect mainly the chromosome stability and the cell cycle regulation but 
that are not recurrent in all the OS patients (Helman and Meltzer 2003). 
 
Table 1.1: Genetic disorders and their most frequent gene mutation found in elder patients with OS 
The most common genetic alterations found in conventional OS include loss of 
heterozygosity of chromosome regions in 3q, 13q, 17p, 18q and amplification in 1q21-23 and 
17p (Dorfman 1998). 
In young patients the aetiology is unknown but it is most frequently related to the rapid 
growth of the bones therefore it is most frequent at the metaphyses of the long bones 
where there is high grade of cell proliferation and turnover during adolescence. Indeed it 
was shown that OS is more common in tall people compared to short ones which relates 
with the previous statement concerning the pubertal growth (Klein and Siegal 2006).  
In the elder people the lower long bones are still the most common OS location but to a less 
extent.  
In both groups of age the overall rate of frequency is 42-45% in the femur, 19% in the tibia, 
10-11% in the humerus, 8% in the skull or jaw and 8% in the pelvis (Ottaviani and Jaffe 2009; 
Abed and Grimer 2010). Male show higher rate of OS incidence than female (1.35 : 1) but it 
is described that female younger than 15 years are slightly more affected than men as well 
as elder female black people with a previous diagnosed cancer (Mirabello, Troisi et al. 2009; 
Ottaviani and Jaffe 2009; Savage and Mirabello 2011). Below in the table 1.2 you see the 
results from a study conducted in Europe where they describe the higher incidence of OS in 
the girls younger than 15 and in the boys above 15 years (Stiller, Bielack et al. 2006). 
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Table 1.2: Summary of annual incidence rates per million for OS between 1988 and 1997 in the five areas of 
Europe (adapted from (Stiller, Bielack et al. 2006)). 
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1.2 METASTASES 
Metastases in OS still remain the main cause of death in patients, and more specifically, 90% 
of cancer related deaths are due to metastatic spread in different organs mainly because the 
metastatic cells are the most resistant to therapies (Mehlen and Puisieux 2006; Nguyen and 
Massague 2007; Mathot and Stenninger 2011).  
This multi-step event starts with the “pre-metastatic” cells inducing angiogenesis in situ, 
followed by the escape from the original primary tumour mass. After adhering and entering 
the blood vasculature either directly through blood vessels or passing, first, through the 
lymphatic system, these cells migrate to the target organ, they extravasate and colonise the 
target organ (Fig.1.2).  
 
Fig.1.2 Schematical view of the metastatic process [adapted from (Steeg 2003)] 
According to the “seed and soil” theory, the migration is not casual but “pre-metastatic” 
cells rather prefer to migrate toward specific organs (see table 1.3) (Dai, Haqq et al. 2006; 
Nguyen, Bos et al. 2009). Indeed Stephen Paget in 1889 launched the “seed and soil” theory 
after having realised that most of his patients with breast cancer showed metastases only in 
the liver and not in the spleen while patients with sepsis died with abscesses in both organs. 
Therefore he thought that primary tumour cells behave like seeds that would migrate, grow 
and survive only where they find the appropriate ground (soil).  
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More than 30 years later James Ewing came up with another theory: it is a combination of 
mechanical forces and circulatory flow that gives organ-specificity for the metastases 
formation. This can explain the migration towards lung and liver but in the bone the 
circulation cannot explain the high rate of metastases: in this case the presence of the bone 
microenvironment, consisting of bone stromal cells, hematopoietic elements, adipocytes 
and the high expression of growth and regulatory factors makes the skeleton a comfortable 
“soil” for tumour cells (Dai, Haqq et al. 2006).  
 
Table 1.3: Main location of metastases for some primary tumours (adapted from table 1 in (Nguyen and 
Massague 2007; Nguyen, Bos et al. 2009)). 
What still remains to be fully understood is the latency of some tumours in metastasising: 
lung and breast adenocarcinomas metastasise both to the same organs (bone, liver and 
brain) but while the lung cancer metastasises usually within few months, in the breast 
cancer the metastases develop after many years (Mathot and Stenninger 2011). One 
explanation for this phenomenon is given by Nowell that speaks about the need for the 
tumour cells to acquire many mutations in order to gain adaptability and consequently 
metastatic potential and this hypothesis might explain why some tumours need longer time 
to metastasise compared to other tumours (Nowell 1976). Furthermore another explanation 
comes from recent studies that highlight also the importance of a specific microenvironment 
made of host cells that actively participate in the tumour expansion and growth towards 
other organs (Mareel, Oliveira et al. 2009; Hanahan and Weinberg 2011).  
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Different are the classes of genes involved in the different steps of the metastatic process 
and Nguyen et al. identifies three classes: metastasis initiation, progression and virulence 
genes (Nguyen, Bos et al. 2009).  
The initiation genes allow the tumour cells to gain the features for a more aggressive 
phenotype like TWIST, SNAI1 and SNAI2 that induce the epithelial-mesenchymal transition 
or metadherin in breast cancer and the metastasis-associated in colon cancer 1 (MACC1) in 
colorectal carcinoma that contribute to the invasive phenotype of the “pre-metastatic” cells 
(Yang and Weinberg 2008; Hu, Chong et al. 2009; Stein, Walther et al. 2009).  
The progression genes are involved in providing the “pre-metastatic cells” with the right 
features to cross the endothelial cells, migrate in the blood vessel and settle in the 
parenchima of the new organ (Nguyen, Bos et al. 2009). CXCR4-CXCL12 axis is the most 
studied and understood chemokine pair in the progression of cancer: in human prostate 
cancer specimens CXCR4 expression correlated with the aggressiveness of the tumour as 
well as in breast cancer (Kato, Kitayama et al. 2003; Sun, Wang et al. 2003). Adhesion 
molecules, integrins, selectins belong to this class of genes, since they contribute in the 
different steps of the intravasation, cell migration and extravasion (Dai, Haqq et al. 2006). 
Depending on which genes are de-regulated, tumour cells and metastases will migrate and 
invade different organs. 
Finally there are the metastasis virulence genes whose deregulation conveys a selective 
genes expression for metastatic cells in the specific organ: metastatic cells from a breast 
primary tumour can, at a later time point, express parathyroid hormone-related protein and 
interleukin-11 which leads to the formation of osteolytic metastases in bone (Yin, Selander 
et al. 1999; Mundy 2002; Kang, Siegel et al. 2003; Nguyen, Bos et al. 2009).  
1.2.1 METASTASES IN OSTEOSARCOMA 
In OS metastases occur preferentially in the lung (80-90%) and to a less extent in the bone 
(10-20%) and in the lymph nodes (9%) (Kaste, Pratt et al. 1999; Bielack, Kempf-Bielack et al. 
2002; Longhi, Errani et al. 2006; Ritter and Bielack 2010).  
Lung is frequently invaded by metastatic cells in different cancers and this is due first of all to 
the physiological high blood flow in this organ. Recent studies highlight the most important 
mediators in the pulmonary metastases coming from a primary breast cancer: epiregulin, 
prostaglandine G/H synthase 2, matrix metallo-proteinase 1 and 2 which act on the 
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vasculature remodelling but also on the extravasion towards the lung and finally cytokine 
angiopoietin-like 4 that helps tumour cells to enter the lung by destroying the endothelial 
cells interaction (Gupta, Nguyen et al. 2007; Padua, Zhang et al. 2008; Nguyen, Bos et al. 
2009).  
In OS proteins involved in metastatic progression are: von Willebrand factor, whose 
expression was found in tumour cells passing to a metastatic phenotype, is a glycoprotein 
that is involved in the platelet aggregation at the subendothelial matrix and might therefore 
help the tumour mass to be hidden among platelets in the blood vessels and escape the 
surveillance from the immune system (Eppert, Wunder et al. 2005).  
An important pair involved in the selective migration of OS cells towards the lung is CXCR4-
CXCL12 whose contribution in metastatic progression was discussed in the previous 
paragraph in the prostate and breast cancer. In OS, CXCR4 expressing tumour cells follow a 
gradient of CXCL12 that is abundant in the lung: treatment with CXCR4 inhibitors or 
antagonists of OS bearing mice showed a decreased amount of metastases in the lung 
(Perissinotto, Cavalloni et al. 2005; Kim, Lee et al. 2008).  
Finally the receptor activator nuclear factor κB ligand (RANKL) was found highly expressed in 
bone metastatic cells of breast and prostate cancer where it is responsible for increased cell 
migration and metastatic proneness: in OS it correlates with a poor survival in patients with 
high-grade localised OS proposing a cause-effect link between RANKL and metastases which 
still needs to be confirmed (Lee, Jung et al. 2011).  
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1.3 DIAGNOSIS  
1.3.1 CLINICAL PRESENTATION 
Diagnosis of OS is rather difficult and it is mandatory to have a multidisciplinary group that 
can interpret the results and plan proper strategies of treatment and follow up.  
The most common clinical phenomenon is localised pain, usually in the night and not 
connected to any specific activity, and which can last up to several months (Abed and Grimer 
2010; Ritter and Bielack 2010). In 1/3 of the cases, a tumour mass is visible at the first visit 
already which is usually caused by the soft tissue swelling but only few patients complain 
about it (Widhe and Widhe 2000; Picci 2007). When the tumour is osteolytic, the patient 
may present with a pathological fracture (10-15% of the cases) and if this is present then the 
survival rate is lower because of high risk of recurrence (Scully, Ghert et al. 2002; Picci 2007; 
Ritter and Bielack 2010). Loss of appetite, weight loss, fever and pallor are only rarely 
noticed. Finally laboratory analyses on blood samples are not specific for OS: lactate 
dehydrogenase (LDH) and alkaline phosphatases (ALP) are found elevated and they might be 
helpful for the final diagnosis (Picci 2007; Heare, Hensley et al. 2009; Biermann, Adkins et al. 
2010). In this concern Bacci et al. noticed a correlation between high ALP and risk of relapse 
as well as high level of LDH probably might be associated with a worse prognosis but none of 
this marker is so far considered an OS marker (Meyers, Heller et al. 1992; Bacci, Picci et al. 
1993; Bacci, Ferrari et al. 1994).  
1.3.2 DIAGNOSTIC IMAGING TOOLS 
After the clinical assessment, the next step is to perform radiography of the tumour that is 
followed by histological analysis of the biopsy in case of suspicious lesions. The radiograph 
can show osteoblastic, osteolytic or mixed lesions with irregular areas of calcifications in the 
soft tissue. A characteristic OS element is called “Codman triangle”, because the calcified 
areas in the periosteal region form a triangle between the healthy tissue and the tumour 
cells (Ritter and Bielack 2010) (Fig.1.3).   
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Fig.1.3: Lateral x-ray picture of OS in the distal femur with a classical dense tumour mass with patchy filaments 
that develop like a sunburst reaction (A); X-ray picture of OS in the distal femur with the characteristic Coldman 
triangle shown by the arrow head and with an extended soft tissue mass depicted by the arrows (B); X-ray 
picture of OS in the tibia with two typical imaging effects from the tumour namely end-hair (small arrow) and 
onion skinning (big arrow) (Dorfman 1998; Klein and Siegal 2006). 
 
Together with radiography usually the Magnetic Resonance Imaging (MRI) is used to 
evaluate the extension of soft tissue involvement and the invasion of the tumour cells into 
the bone marrow (Sundaram 1997; Brenner, Bohuslavizki et al. 2003; Ritter and Bielack 
2010). MRI and color-coded duplex sonography are included in the diagnostic workup when 
information about vasculature involvement is explored (Brenner, Bohuslavizki et al. 2003). 
Bone scintigraphy is also performed to define the border of the primary tumours (Picci 
2007). Finally a chest Computed Tomography (CT) and a bone scintigraphy are performed to 
detect, respectively, lung or bone metastases and consequently define the tumour staging 
(Brenner, Bohuslavizki et al. 2003; Abed and Grimer 2010).  Around 15-25% of the patients 
show metastases at the time of diagnosis but it is believed that many more patients (around 
80-90%) have at this time metastases but they are not detectable (Friedman and Carter 
1972; Meyer 1991; Brenner, Bohuslavizki et al. 2003).  
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Fig.1.4: Computed Tomography (CT) of the lung showing presence of lung metastases (arrows) (Bacci, Rocca et 
al. 2008) 
The chest CT is preferred to the chest radiography because of higher sensitivity that reaches 
2mm for the diameter of detectable nodules but both methodologies do not give specific 
information about the nature of the nodules (Fig.1.4) (Davis 1991).  A study conducted on 20 
tumours including lymphomas, neuroblastomas, renal tumours, hepatic tumours and 
malignant bone tumours states that most of the lung nodules are < 5mm which would not 
have been visible on the radiography and the nodules > 5mm are usually malignant while 
nodules < 5mm were likely to be malignant in 1 case out of 9 benign nodules (Silva, Amaral 
et al. 2010).  
These findings are not in agreement with another study where McCarville et al. claim that 
the lung nodules < 5mm were likely to be malignant or benign with the same probability but 
they analysed a lower number of scans compared to the previous study. In addition 
McCarville et al. believes that if the lung nodules diameter does not increase in 2 years, the 
probability is higher that it is only a benign nodule. Finally it is noticeable that there are 
some differences between adults and children in the diagnosis of lung nodules: in adults the 
irregular nodules are most probably malignant while in children the clearly defined ones are 
malignant as well as the smaller nodules (< 5mm) are more probably malignant (Bateson 
1965; Ost, Fein et al. 2003; Iwano, Makino et al. 2004; Li, Sone et al. 2004; Ost and Fein 
2004; McCarville, Lederman et al. 2006).  
In summary CT is still the gold standard for lung nodules detection among the available new 
imaging tools, but the main disadvantage of CT is the difficulty in distinguishing between 
benign and malignant tumours. Therefore new interest is given to Positron Emission 
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Tomography (PET) in combination with CT in the identification of malignant lung nodules 
since both techniques are complementary to each other. Indeed a study shows the 
possibility to distinguish between benign and malignant pulmonary lesions in patients with 
suspected primary or recurrent lung cancer using 18F-Fluorodeoxyglucose (18F-FDG) PET 
imaging: a standardised uptake ratio (SUR) was calculated for each patient on a region of 
interest (ROI) of 1cm in diameter and it was found that 2.5 was the best cut-off value to 
visualise malignant lesions with 97% sensitivity, 82% specificity. When the SUR was < 2.5, the 
benign lesions could be detected with a sensitivity of 82%, specificity of 97% (Duhaylongsod, 
Lowe et al. 1995).  
1.3.3 BIOPSY 
Biopsy is the gold standard for the final diagnosis. An experienced orthopaedic oncologist 
performs the invasive procedure keeping in mind that the tumour piece should represent 
the tumour material and contain no normal tissue; part of the tumour tissue should be used 
for cell culture and part for the histology and in the tumour centres a small piece should be 
frozen immediately after the biopsy for further analysis and a request form should be filled 
with all the patients’ details, tumour location and radiological findings. Different techniques 
can be used: fine needle aspiration, core needle biopsy, incisional biopsy and excisional 
biopsy (Yaw 1999; Hogendoorn, Athanasou et al. 2010).   
The location of the biopsy must be planned in detail getting information from the imaging 
finding since the region of the biopsy will also be included in the surgery plan during the 
resection of the tumour when the limb is saved in order to decrease the risk of local 
recurrences. Moreover any structure next to the tumour that is infiltrated with tumour cells 
must be taken in order to take as many information as possible with the obtained tissue 
(Yaw 1999; Hogendoorn, Athanasou et al. 2010; Ritter and Bielack 2010).  
In most of the cases core needle biopsy is performed; the open biopsy is chosen in difficult 
cases depending on the tumour location and on the technical skills but it is the methodology 
that assures the collection of sufficient material. An excision biopsy is quite risky because the 
chances of contamination are higher above all when the tumour is malignant (Yaw 1999; 
Hogendoorn, Athanasou et al. 2010).  
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1.3.4 HISTOLOGY 
After biopsy the pathologist will analyse the tissue and the final staging is defined in a 
multidisciplinary team made of pathologists, oncologists, radiologists and orthopaedists. 
Histologically OS appears characterised by spindle-like cells that produce immature bone, so 
called osteoid that is not exclusively produced by osteoblasts as one would expect because 
there is no proof that the malignant cells originate from osteoblasts that de-differentiate. 
Further OS tumours produce different amount of fibrous tissue and cartilage matrix that 
makes the diagnosis more difficult.  
In general the subtypes of OS can be defined according to the different histological subtypes 
(table 1.4). 
 
Table 1.4: Classification of OS types and subtypes according to the WHO, on the basis of histological diagnosis, 
localisation and aggressiveness of the tumor (adapted from (Wirth and Winkelmann 2004)).  
I will briefly summarise the most important histological features of the most common OS 
types.  
The conventional OS presents with spindle or polyhedral cells with pleomorphic and 
hyperchromatic nuclei. The tumour cells produce bone or osteoid and are surrounded by 
extracellular matrix of osseous, cartilaginous or fibrous origin: usually all the three matrices 
are present in the histology but depending on which is prevalent the name of the histological 
subtype can be osteoblastic, chondroblastic or fibroblastic (Fig.1.5) (Klein and Siegal 2006). 
The most common one is the osteoblastic (50%) while chondroblastic and fibroblastic are 
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less recurrent (25% each) and all the three subtypes account for 80% of all OS (Fletcher 
2002; Carrle and Bielack 2006). 
 
Fig.1.5: Histological pictures of osteoblastic (A), chondroblastic (B) and fibroblastic (C) OS tumour tissue section 
(Klein and Siegal 2006). 
The telangiectatic type accounts for 4% of OS. It is often confused with the aneurysmal bone 
cyst since this OS type is characterised by blood-filled or empty spaces separated by a thin 
layer of atypical tumour cells. Radiologically the bone looks destroyed and the lesions are 
mainly radiolucent therefore it is rather difficult to visualise new bone formation in the x-
rays. Histologically the osteoid is visible on the tumour sections but it is much more spread 
and forms a fine layer (Fig. 1.6) (Dorfman 1998; Fletcher 2002). 
 
Fig.1.6: Example of a radiographical (A) and histological (B) appearance of telangiectatic OS (pedorthpath.com 
adapted from (Dorfman 1998; Fletcher 2002) 
Small cell OS represents 1.5% of all OS; it affects usually female in the second decade of life. 
It is radiologically characterised by the presence of osteolytic lesions mixed to radiodense 
regions and mineralised tissue that extends in the soft tissue tumour or intramedullary 
(Fig.1.7). Histologically it displays presence of small cells surrounded by osteoid with round 
to oval nuclei and since the diagnosis is rather problematic because it can be mistaken with 
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Ewing’s Sarcoma, usually diagnosis is based on cytogenetic study for a traslocation t(11,22) 
that is usually not present in this OS type. 
 
Fig.1.7: Example of a radiographical (A) and histological (B) appearance of small cell OS (Klein and Siegal 2006) 
Low grade Central OS is another rare type (1-1.2%) that histologically appears similar to 
fibrous dysplasia and other benign lesions characterised by fibroblastic stroma surrounded 
by osteoid with spindle-like cells that invade the bone marrow and the bony trabeculae (Fig. 
1.8). Imaging findings are not helpful for a final diagnosis but can highlight the more 
aggressive phenotype of this tumour compared to a dysplasia or other benign lesions 
(Fletcher 2002; Klein and Siegal 2006).  
 
Fig.1.8: Representative x-ray (A) and histology (B) pictures of low grade central OS 
Parosteal and periosteal OS are other uncommon types of surface OS that is more frequent 
in patients in the third or fourth decade of life. These OS types do not metastasise but show 
high recurrence rate.  
The parosteal in 75-80% of the cases show radiopaque masses close to the distal posterior 
femur that are much denser in the centre and become less dense in the periphery (Klein and 
Siegal 2006; Yarmish, Klein et al. 2010).  
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Finally the features of the periosteal OS are: presence of cartilaginous matrix and de-
differentiated tumour component like in a moderately differentiated chondroblastic OS; 
moreover the periphery of the tumour shows absence of calcified bone and presence of 
spindle-like cells (Fletcher 2002; Klein and Siegal 2006). 
1.3.5 STAGING 
According to the WHO, the staging of tumours depends on the size of the tumour (T), on the 
metastatic spread (M) and on the number and distance of lymph nodes (L) affected by the 
tumour cells. Here below you see the list of the TNM criteria (table 5) and the staging (table 
6) classification (Ritter and Bielack 2010).  
 
Table 1.5: Definition of the criteria for tumour staging according to the tumour size, metastatic spread and 
lymph-nodes involvement (Adapted from (Ritter and Bielack 2010)) 
 
Table 1.6: Staging of OS according to the TNM criteria described in table 5 (Adapted from (Ritter and Bielack 
2010)). The difference in A and B depending on the size of the tumour in stage I and II and intracompartmental 
(A) or extracompartmental (B) location of the tumour in stage IV (Clark, Dass et al. 2008). 
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1.4 PROGNOSIS AND TREATMENT 
Before the seventies, the prognosis was really bad: despite the local control was successful 
after primary tumour resection, OS patients were dying because of pulmonary metastases. 
After the seventies the survival increased to 68% in female and male patients with a 
localised disease and the death rates was decreasing 1.3% per year demonstrating that the 
combination of surgery and neoadjuvant chemotherapy was giving satisfactory results 
(Carrle and Bielack 2006; Savage and Mirabello 2011). Patients with metastatic disease reach 
a 5-year survival rate of only 20%; therefore the metastatic treatment still remains a 
challenge for researchers that need to focus on more specific therapies to fight against the 
more resistant and chemoresistant tumour cells (Lamoureux, Trichet et al. 2007).   
Before going into the detail of the treatment protocol, I will summarise the most important 
clinical factors that are also affecting the prognosis of OS patients. 
1.4.1 CLINICAL FACTORS 
The most important clinical factors in OS are: tumour localisation, tumour stage, patient age, 
tumour size, pathological fracture, surgery, local recurrence, metastases, chemotherapy 
response and sera markers. 
As mentioned in the paragraph concerning “Incidence and Etiology”, distal femur and 
proximal tibia are the most common sites of OS growth and in both sites the prognosis is 
quite good with a 5-year survival of 66% for the distal femur and 77.5% for the proximal 
tibia. In a study performed by Wittig, 23 patients with OS in the humerus showed a 10 years-
overall survival of 65% which does not differ too much from the other two most common 
sites of OS development (proximal tibia and distal femur) (Wittig, Bickels et al. 2002). The 
good prognosis in these three common locations might be related to the high production of 
anti-angiogenic factors like PEDF in the growth plate and in the articular cartilage at the 
knee. The best prognosis is for patients with OS in the radius that show a 5-year overall 
survival of 81.3% while the worst is in pelvis between 27 and 47% and in the spine where the 
median survival is 1-2 years. Interestingly in both cases patients showed an increased 
survival when surgery was followed by radiotherapy (Bielack, Kempf-Bielack et al. 2002; 
Clark, Dass et al. 2008). 
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Another prognostic factor is tumour staging: the stages IA and IB (table 1.6) show almost 
100% of 5-year overall survival while already the stage II B, which is most commonly 
diagnosed, gives a much worse survival (47%) even when the patients are treated before 
surgery with chemotherapy (Foukas, Deshmukh et al. 2002). Patients with a stage III at 
diagnosis show lung metastases according to the Enneking classification system and a 5-year 
overall survival of 68%. According to the WHO classification and the American Joint 
Committee on Cancer patients in stage III only patients with skip metastases (table 1.6) while 
patients with pulmonary metastases are classified in stage IV A and B (Clark, Dass et al. 
2008).  
Concerning the patient age, there are many studies highlighting that the prognostic factor is 
really bad in children or younger than 14 or older than 40 because of highest rate of 
metastatic incidence and a lower tolerance to chemotherapy in these patients (Bielack, 
Kempf-Bielack et al. 2002; Aksnes, Hall et al. 2006; Clark, Dass et al. 2008). 
Primary tumour size as a prognostic factor has been also considered  but so far only one 
study, performed by Bieling et al., gave some threshold and values to be considered. In this 
study on 128 patients they calculated the primary tumour volume with a specific ellipsoid 
formula and they found a value of 150 cm3 to be the threshold above which the survival rate 
decreases from 92% to 58% (Bieling, Bielack et al. 1991). 
Regarding the pathological fracture, a retrospective study compared the 5-year overall 
survival in a group of patients with pathological fracture with a group of people without and 
observed a higher 5-year overall survival (77%) in the patients that did not show any fracture 
compared to the group of patients with pathological fracture (55%) (Scully, Ghert et al. 
2002).   
This finding arose the question whether the different surgical options, amputation and limb 
salvage surgery, might affect OS patients survival. Contradictory are the results in this 
concern: Bacci et al. noticed no statistical difference between the two surgeries while 
Schrager et al. recently published a paper on the survival rates of OS patients comparing the 
limb salvage surgery with the amputation and interestingly patients that underwent a limb 
salvage surgery showed a 5-year overall survival of 72.7% compared to only 60.1% in case of 
patients that underwent amputation (Bacci, Ferrari et al. 2003; Schrager, Patzer et al. 2011).  
What is important to mention is that amputation is usually performed in patients with 
advanced diseases, therefore the inverse prognosis does not depend on the amputation per 
 
 
39 
se. Neverthless Abudu et al. observed that the limb salvage surgery has a slighltly increased 
risk of local recurrence compared to the amputation (Abudu, Sferopoulos et al. 1996). 
Local recurrence is one of the key prognostic factor because it is usually associated with a 
more aggressive phenotype of the tumour cells and to a high probability to develop 
pulmonary metastases. Indeed it was visible that patients with local recurrence and 
metastases have a much lower survival (4%) compared to patients with only metastases 
(22%) (Bacci, Donati et al. 1998).  
From this evalutation, we can conclude that the combination between local recurrence and 
metastases is negative. 
Concerning metastases as a prognostic factor alone, usually bone metastases give a much 
worse survival than lung metastases. In the case of lung metastases usually the patients that 
present with metastatic foci after chemotherapy had a poorer survival since the one 
showing metastases already at the diagnosis underwent a metastasectomy via a radical 
thoracotomy procedure which is much more sensitive than metastases detection through 
CT. Finally skip metastases, which occur as local metastases along the length of the bone, are 
quite rare in OS patients: only 1.8-25% of OS patient show skip metastases with a poor 
overall survival of 27.2 months from diagnosis (Clark, Dass et al. 2008).  
Another important prognostic factor is the response to chemotherapy: this effect is 
evaluated from the percentage of necrosis that the tumour section overall shows. The 
threshold for good and bad response is set at 90% and usually the good responders show 
more than 90% of necrosis and they usually also have a better prognosis (Clark, Dass et al. 
2008). Interestingly the treatment response of patients depends strongly also on the 
histological type of OS that they display: patients with teleangiectatic type show the best 
prognosis (86.7%), while patients with small cell tumours show the worst response (25%). 
Good response is also achieved by patients with osteoblastic (63.9%), fibroblastic (61.7%) 
and chondroblastic (50.6%) (Bacci, Longhi et al. 2006).       
The last prognostic factor that will be described is alkaline phosphatase (ALP) which is 
correlated, when high before treatment, to a worse 5-years overall survival (54%) compared 
to patients with low ALP level in the serum (67%) (Clark, Dass et al. 2008). 
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1.4.2 TREATMENT 
Originally the standard protocol for OS treament consisted of the use of pre-chemotherapy 
which lasts around 10 weeks followed by surgical resection of the primary tumour and 20 
weeks of neo-adjuvant chemotherapy (Chou and Gorlick 2006). The most effective and so far 
used drugs in OS are high-dose methotrexate (HD-MTX), adriamycin and cisplatin.  
In 2001 a new project started with the name of EURAMOS1 which was the result of a 
collaboration between the European and the North American Society. This joint effort is 
needed in such a rare tumour since this makes possible to reach statistically significant 
results involving a higher number of patients: from 1st april 2005 till 30th June 2011, 2260 
patients were registered and 1332 were randomised making this the largest clinical trial ever 
existing for OS. Their main interest is to increase the overall survival improving the 
therapeutic strategies on poor responders. The main aims of this project are two: evaluate 
whether ifosfamid and etoposide could help patients with a poor prognosis 10 weeks after 
the pre-chemotherapy and whether the pegylated formulation of the interferon α (INF α) 
increases the overall survival of patients with good response after the pre-chemotherapy 
(Chou and Gorlick 2006).  
The scheme of the treatment defined by EURAMOS1 consists of a pre-chemotherapy phase 
where HD-MTX, adriamycin and cisplatin are used, surgery and post-chemotherapy where 
depending on the histological response, patients will receive randomly either an addition of 
INF α or not in case of good response, and ifosfamide and etoposide or nothing in case of 
poor response (Fig. 1.9). Pre-surgery chemotherapy treatment is strongly recommended 
because the chemotherapy will induce a clear demarcation of the tumour borders through 
the formation of an avascular capsule around the tumour cells. Furthermore the pre-
treatment allows to get information about the histological response before the surgery so 
that the patient can be directed towards different therapeutical strategies depending on the 
percentage of necrosis that the tumour shows (Carrle and Bielack 2006).  
The three drugs, included in the pre-treatment, were found to be effective around 1980s 
and since then no additional drug has been found to be more efficacious. Concerns are 
present for the side effects of the adriamycin and cisplatin on the heart, ears and kidneys 
and for the real need of HD-MTX in the treatment regimen (Bielack, Kempf-Bielack et al. 
2002). A German and Brasilian study on the HD-MTX showed that the overall survival did not 
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differ much in the presence or absence of HD-MTX. Despite these results, it is still 
maintained in most of the OS regimens for the relative lack of myelotoxicity and late effects: 
side effects from HD-MTX are linked usually to nephrotoxicity and can be reduced using the 
glucarpidase that cleaves the MTX and leucovorine which is an analogue of folic acid and 
avoid cell death due to a lack of folic acid caused by the MTX (Carrle and Bielack 2006). After 
the pre-chemotherapy that can last differently depending on the tumours, the patients 
undergo the surgery. Till the 1970s the amputation was the only choice for OS patients but 
now limb salvage surgery is performed in 85% of the cases and it consists of primary tumour 
resection including a wide area of margins and reconstrunction of the missing bone 
structures. There is a slight higher incidence of tumour recurrence in the limb salvage 
surgery which is linked to the resection of the margins as discussed in the sub paragraph 
about “Clinical Factors” but this concerns only the patients with close margins of excision 
where amputation can be preferred.  
 
Fig.1.9: Scheme of the treatment protocol according to the EURAMOS clinical trial; (IFN α= interferon α) 
(adapted from (Bielack, Carrle et al. 2008)). 
Moreover the limb salvage surgery is more demanding for the following reconstruction of 
the bone above all in young adolescence where the excision of the growth plate from the 
surgery causes a decreased growth (Abed and Grimer 2010). After the surgery the 
 
 
42 
maintenance therapy includes the use of INF α in case of histological good response 
evaluated on the biopsy, or of ifosfamide or etoposide in case of poor response.  
IFN α is a cytokine involved in anti-viral, anti-tumour, apoptotic and cellular immune 
response activities. The anti-tumour effect was discovered by Gresser on mice with a non- 
viral dependent tumour. In OS the INF α effect was demonstrated in vitro on human OS cells 
and in vivo on four different xenograft mouse models of OS  (Strander and Einhorn 1977; 
Whelan, Patterson et al. 2010).  Clinically INF α was used in one clinical trial performed in 
Scandinavia where they tested the efficacy of INF α on 89 patients in two series and they 
found that patients treated with higher dose showed a higher survival compared to the ones 
treated with a lower dose proposing a dose-response effect (Muller, Smeland et al. 2005). In 
the EURAMOS1 study the INF α is given in a pegylated form which strongly reduces the side 
effects combined to it (Whelan, Patterson et al. 2010). 
Regarding ifosfamide, a cooperative German-Swiss-Austrian study showed that the inclusion 
of ifosfamide in the treatment regimen for OS patients increased the 10-year overall survival 
to 78% in case of a localised disease (Fuchs, Bielack et al. 1998). The pitfall of this study was 
the low number of patients, therefore the real benefit of ifosfamide will be assessed in the 
EURAMOS1 study. Another study, finally, highlighted the importance of the combination of  
ifosfamide and etoposide in the management of patients with primary and metastatic OS 
(Goorin, Harris et al. 2002). 
Beside EURAMOS 1, another collaboration between the Italian and Scandinavian Sarcoma 
Groups was founded with the name of EURO-B.O.S.S. that includes patients over 40 with 
bone sarcomas. In this joint effort the main focus of the clinical trial is to analyse the efficacy 
of the treatment based on the use of adriamycin, cisplatin and ifosfamide. HD-MTX is 
included in the regimen only in cases of extreme poor response since in elder patients the 
toxicity of this drug is much higher. Furthermore the used dosage in these cases is lower 
8g/m2 compared to the 12g/m2 used in young patients.  
Radiotherapy in OS is rarely used and only in cases where the resection is difficult to be 
performed (Bielack, Carrle et al. 2008). 
Finally in case of metastatic disease, the overall survival is much lower as described in the 
paragraph “Clinical factors” and the treatment remains the same and in addition surgical 
resection of the metastatic foci has to be performed. Usually around 30% of the patients 
with resected metastases can survive longer than 5 years and even in case of multiple 
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operations, patients can have higher probability to survive as long as metastases can be 
resected (Bielack, Kempf-Bielack et al. 2009; Ritter and Bielack 2010). The benefit from the 
use of chemotherapy in case of recurrent OS is not yet determined (Ritter and Bielack 2010). 
Monitoring of the treatment in OS is performed through metabolic imaging because 
anatomical differences of the tumour size can only be visualised at a later time point.  
Indeed CT and Magnetic Resonance Imaging (MRI) do not give information about the 
necrotic and viable parts of the tumour. On the other side it is well accepted that Positron 
Emission Tomography (PET) using 18F-FDG as a tracer is the most sensitive tool for evaluation 
of treatment response but the importance of PET imaging in OS will be analysed in more 
detail in the next chapter (Messa, Landoni et al. 2000). After the treatment, local or 
metastatic relapse is followed up each 6 weeks to 3 months in the first 2 years after OS 
diagnosis; each 2-4 months for the next 2 years and every 6 months until 5 years and 
thereafter yearly. The follow-up strategy includes a physical examination, a chest X-Ray to 
check for lung metastases and if the X-Ray finding is unclear, chest CT is performed.  
  
1.4.3 CHEMORESISTANCE IN OS 
Chemoresistance is a major problem for the treatment of tumours because it is the main 
cause of poor response in OS patients and consequently new therapeutic approaches have 
to be tried and investigated which could effectively attack the resistant tumour cells. 
Chemoresistance can be intrinsic when it is from the beginning of the treatment and it might 
depend on pathogenic mechanisms or it can be acquired during therapy and in this case it is 
usually caused by accumulation of genetic mutations from some cells that, consequently, 
gain the ability to resist to the treatment and survive. Cisplatin, Adriamycin and 
Methotrexate induce the activation of specific mechanism that causes the efflux of the drug 
from the tumour cell (Chou and Gorlick 2006).  
Resistance to Cisplatin, for example, is usually acquired through the overexpression of 
multidrug resistance-associated protein 2 that is responsible of a decreased concentration of 
cisplatin in the cell (Borst, Evers et al. 2000; Itoh, Tamai et al. 2002). Further it was shown 
that cells after Cisplatin crosslinks with DNA proceed in the replication without undergoing 
cell death or repair mechanism. This is usually dependent on p53 acquired mutations 
(Manic, Gatti et al. 2003). 
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In the case of Adriamycin, the resistance is dependent on the overexpression of the p-
glycoprotein that might also occur after p53 gets mutated though the results confirming the 
correlation between the two events are conflicting (Serra, Scotlandi et al. 2003; Tsang, Chau 
et al. 2003). A possibility to overcome this resistance would be the use of increased doses of 
Adriamycin with the time and in vitro it was shown that type I interferon decreases the 
expression of p-glycoprotein in resistant OS cells (Manara, Serra et al. 2004). 
Finally Methotrexate resistance is well studied and occurs in the different steps of the 
metabolic pathway of this drug which is an analogue of folic acid: impaired transport of 
methotrexate caused by the lower expression of the folate carrier; mutations in the 
dihydrofolate reductase gene which reduces the affinity of the methotrexate for the enzyme 
which is the main target of the drug; increased drug expulsion through the ABC family of 
transporters (Chou and Gorlick 2006).  
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2 INTRODUCTION: POSITRON EMISSION 
TOMOGRAPHY AND PHOTODYNAMIC 
THERAPY 
2.1 POSITRON EMISSION TOMOGRAPHY  
Positron Emission Tomography (PET) is a non invasive imaging tool that allows the 
evaluation of metabolism within human body. It was established in the late 70s but only in 
the 90s it started to be broadly used (Phelps, Hoffman et al. 1975; Weber 2006). 
 It differs from CT and MRI because it does not give information about the anatomy and from 
single-photo emission tomography (SPECT) because with PET data can be quantified. 
Furthermore the resolution and the sensitivity of PET scanner are much higher compared to 
the SPECT and compared to biopsies PET imaging is not invasive and gives much more 
information over time about the changes in the tumour development and volume. The main 
pitfall is the spatial resolution which is around 4-10 mm: despite the improvements over the 
last years, it is rather difficult to detect small lesions and heterogeneity of the tumour in 
larger lesions (Kelloff, Hoffman et al. 2005; Weber 2006; Fass 2008).  Therefore more and 
more the combination of PET/CT is used in order to overcome the limitations of the single 
techniques: in this way the information obtained are complete and include functional (PET) 
and anatomic (CT) data. The principle of PET imaging is based on the use of positron emitting 
radioisotopes, such as oxygen-15 (15O), carbon-11 (11C), nitrogen-13 (13N) fluorine-18 (18F) 
and zirconium-89 (89Zr). These radionuclides are the most common because they can easily 
be linked to molecules that resemble biological substances like 18F-Fluorodeoxyglucose; 
drugs like 89Zr-DN30 antibody directed against cMet; exogenous molecule like 18F-
Fluoromisonidazole that targets hypoxic areas (Hong, Zhang et al. 2012).   
15O, 11C and 13N do not affect the function and activity of the molecule they will react with 
because they are replacing the same atom in the molecule. In the case of 18F, the 
radioisotope substitutes the hydrogen since there are no radioisotope for hydrogen 
therefore it is important that the substitution of hydrogen with 18F does not have any impact 
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on the biological function of the molecule. Another criteria for the selection of the proper 
radionuclide is the half-life which is the time needed to decay and reduce to half the initial 
dose injected in the patient. On one side when the half-life is short like in the case of 15O and 
13N, then the center should have a cyclotron inside because the study has to be performed in 
short time (table 2.1). On the other side when the half-life is long such as in the case of 89Zr 
then it is also not so convenient because this increases the patient waiting time for the 
radioactive decay. This is also the reason why most of the PET imaging centers use 18F as the 
most common radioisotope for molecules labelling (Phelps 2000; Schlyer 2004).  
 
Table 2.1: Half-lifes of the most commonly used radionuclides 
The radioisotopes are characterised by the presence of more protons and less neutrons 
compared to a stable nucleus and therefore they release positrons which are positively 
charged and annihilated with electrons giving rise to two photons with the same energy 
(511keV) but opposite directions, 180 degrees from each other (Gopal 2003; Kelloff, 
Hoffman et al. 2005; Ametamey, Honer et al. 2008).  
The PET instrument consists of a ring of detectors that are collecting only the coincident 
photons that reach the opposite detectors at the same time. After the chemical binding of 
the radioisotopes with our targets that highlight the metabolic processes we are interested 
in, the tracer is intravenously injected and after a waiting time for the tracer distribution the 
patient is set in the ring and the information about the coincident events are sent to the 
computer for the image reconstruction. Here below you can see a schematic view of micro-
PET on a mouse using 18F-Fluoride as a radioisotope (Fig. 2.1).  
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Fig.2.1: scheme of micro-PET in mice using 
18
F as a positron emitting radioisotope (adapted from www2.fr-
jurglich.de/zel/zel_bildgebung_beschreibung) 
 
2.1.1 PET IN THE CLINICS 
During the last years the development of PET imaging in the pre-clinical or clinical field 
strongly increased. Some of the PET applications will be discussed below.  
18F-Fluorodeoxyglucose (18F-FDG) is the most used PET tracer in the clinic and it is a measure 
of glucose metabolism in the human body.  As a glucose analogue, it is transported into cells 
through glucose transporters (GLUTs). After being phosphorylated at position C-6, the 2-
deoxyglucose-6-phosphate is trapped in the cell since it can proceed neither in the glycolytic 
pathway nor in the glycogen synthesis. Background uptake is visible in organs that 
physiologically use glucose as a source of energy such as muscle, heart and brain but also it 
accumulates in the bladder because of excretion. Therefore it is not recommended to use 
18F-FDG for the evaluation of alterations in these organs (Schlyer 2004).  
Indeed in the case of brain studies, for example, neutral aminoacids are usually used to 
image the brain because of the lower physiological uptake. Indeed the most produced 
radionuclides for the brain imaging are 11C-methionine, 11C-tyrosine and 18F-ethyltyrosine or 
18F-methytyrosine. The main application for the brain imaging is the tumour delineation in 
preparation for radiotherapy (Grosu, Weber et al. 2005; Grosu, Weber et al. 2005; Weber 
2006). 
Nevertheless 18F-FDG use is strongly suggested to define the damage induced by the 
ischemia and together with a measurement of the perfusion it is used to assess the efficacy 
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of therapy. In this context also new tracers have been developed such as nitrogen-13 
ammonia which is specific for the evaluation of the blood flow (Schlyer 2004). 
Further PET imaging helps in studying the ligand-receptor interactions. Indeed nowadays it 
became common to label the drug with a specific radioisotope and get information about 
the specificity and the distribution of the new drug using PET (Knuuti and Bengel 2008). The 
first study was performed by Shani and Wolf who labelled a new drug, the Fluorouracil, with 
18-fluorine. With PET imaging they demonstrated that 18F-Fluorouracil is helpful in 
distinguishing the tumours which are sensitive to the treatment from the resistant ones 
though it was rather complicated to quantify the tumour accumulation because of quick 
excretion and/or accumulation in other organs (Shani and Wolf 1977). Furthermore it is 
always difficult to label the drug without affecting its function. Despite these challenges, PET 
imaging with 18F-Fluorouracil is useful to quantify the tumour accumulation of this tracer 
when treatment with eniluracil, that inhibits the processing of Fluorouracil, was performed 
(Saleem, Yap et al. 2000). PET imaging gives also information about the accumulation of the 
drug in the tumour cell and the expression of multidrug resistance-associated protein 1 
which are connected with treatment resistance because of drug expulsion from the cell 
(Weber 2006). 
PET is also used to evaluate the effect of a therapy. One example is the imaging with 
reporter genes that usually are exogenous to the body but not toxic. Basically the 
therapeutic gene is either itself a reporter or linked through an internal sequence, called 
IRES, to a reporter gene that can be a transporter, an enzyme, a receptor and so on. There 
are not many studies on the use of such reporters for PET imaging: one study was 
successfully performed in patients with hepatocellular carcinoma. The aim of this project 
was to evaluate via PET imaging the efficacy of the use of a herpes simplex 1 thymidine 
kinase (HSV1-tk) overexpressing adenovirus to monitor and treat the hepatocellular 
carcinoma because the enzyme HSV1-tk, besides being a reporter gene, also kills the tumour 
cells via activation of a non-active pro-drug like penciclovir in an active and toxic compound. 
In this study they injected intratumourally the adenovirus and used 9-(4-18F-Fluoro-
3[hydroxyl methyl] butyl) guanine (18F-FHBG), a penciclovir analogue, to image the area of 
the tumour since the PET tracer will accumulate only in the tumour cells where HSV1-tk is 
expressed (Alauddin, Shahinian et al. 2001; Penuelas, Mazzolini et al. 2005).  
  
 
49 
Besides reporter genes also receptors are successfully imaged through the radiolabelling of 
ligands like 16α-Fluoroestradiol-17β (FES) which is used for the visualisation of the estrogen 
receptor in estrogen-positive advanced breast tumour and the 16β-18F-Fluoro-5-
dihydrotestosterone (FDHT) which is specifically taken up by metastatic foci of androgen-
dependent prostate cancer (Mintun, Welch et al. 1988; Larson, Morris et al. 2004; 
Dehdashti, Picus et al. 2005). 
More detailed information about the use of PET imaging in oncology will be given in the 
paragraph below.   
2.1.2 PET IN ONCOLOGY 
The clinical application of PET in oncology developed only recently due to the improvement 
in sensitivity and resolution of the new scanners and due to the reimbursement approved by 
the Center for Medicare and Medicaid Services for the use of PET in staging and restaging of 
small-cell lung, esophageal, colorectal, breast, head and neck cancers and for the treatment 
response monitoring in breast cancer (Kelloff, Hoffman et al. 2005). The evaluation of a PET 
image consists usually of two parts: the first one is visual and subjective; the second one is 
more objective and based on the calculation of the standardised uptake value (SUV). In the 
case of treatment response the analysis consists of a comparison of the SUV before and after 
the treatment.  
SUV is a semi-quantitative index to measure the accumulation of the tracer in a region of 
interest (ROI) measured in MBq/g normalized to the injected dose (ID) in MBq and the body 
weight (BW) of the patient in gram. The factors that strongly influence the SUV calculations 
are: plasma glucose level, definition of the border for the ROI is quite subjective; attenuation 
to correct the PET signal from the collection of non-coincident events is required; 
reconstruction methods can affect the noise and the resolution; time of acquisition after the 
tracer injection has to be standardised and the competition for the transport of the tracer 
and its biological analogue that uses the same transporter to enter the cell (Thie 2004; 
Peterson 2007).  
It is, therefore, necessary to standardise all the different steps for the SUV calculation to be 
able to compare different values, for example in the case of the evaluation of treatment 
response, the uptake before and after treatment.  
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18F-FDG has been the most commonly used PET tracer for 25 years. Meanwhile many other 
tracers visualising particular metabolic processes have been synthesised (Table 2.2). Below, 
some of these tracers will be shortly described in the context of potential applications in the 
oncology field.  
 
Table 2.2: List of the most common tracers for PET imaging with the targeted process and the main applications 
(Juweid and Cheson 2006) 
2.1.1.1 PET TRACERS: 18F-Fluorodeoxyglucose (18F-FDG) 
18F-FDG enters the cell through GLUT and accumulates in the cell after being phosphorylated 
by hexokinase, as mentioned previously. Tumours show an increased uptake because of an 
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increased rate of glycolysis that occurs also in absence of oxygen (Warburg effect) which is in 
addition linked to an increased expression of hexokinase and GLUTs. According to Gambhir 
et al the 18F-FDG sensitivity and specificity in cancer reach the 84% and the 88% (Gambhir, 
Czernin et al. 2001). 18F-FDG imaging is also used for staging in melanoma, lymphoma, 
esophageal and colorectal cancers (Kelloff, Hoffman et al. 2005). An exception to this is the 
prostate where the 18F-FDG uptake is physiologically high therefore it is not recommended 
to use PET imaging for staging and restaging of this tumour (Kelloff, Hoffman et al. 2005; 
Juweid and Cheson 2006).  
Concerning treatment monitoring, it was shown in patients with breast cancer that an 
accurate evaluation of treatment response could be already evaluated one cycle after 
chemotherapy and this is extremely important in order to change and define a better 
therapeutic approach in cases of poor response (Juweid and Cheson 2006).  
Furthermore Weber et al. state that in the case of gastroesophageal cancer a reduction of 
35% in the SUV of 18F-FDG two cycles after chemotherapy has a prognostic value. Patients 
with a metabolic response display a median time to progression or recurrence was 16 
months compared to the 9 months in the case of poor metabolic responders (p=0.01): 
differences in the overall survival were also significantly different (p=0.05) (Weber, Ott et al. 
2001).  
In sarcomas a study conducted on 46 patients shows that 18F-FDG-PET was more sensitive 
than CT, MRI, bone scintigraphy and ultrasound in detecting primary tumour, lymph node 
involvement and in bone invasion but CT was more sensitive in detecting lung metastases 
(100% compared to the 25%) and these findings were confirmed also by other retrospective 
studies (Franzius, Sciuk et al. 2000; Franzius, Daldrup-Link et al. 2001; Iagaru, Chawla et al. 
2006).  
Another study performed on 21 patients with soft tissue sarcoma demonstrated that 18F-
FDG-PET responders showed a higher progression-free survival (92%) compared to the non-
responders (12%) but since the number of patients in this study is low, no significant 
conclusion can be extrapolated (Stroobants, Goeminne et al. 2003).  
In another prospective study on 46 patients with localised high-grade soft tissue sarcoma a 
reduction in SUV that was higher than 40% obtained before and 2 cycles after chemotherapy 
correlated with an improved recurrence free and overall survival (Schuetze, Rubin et al. 
2005).  
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Though 18F-FDG is the most commonly used tracer, there are some drawbacks that induced 
the chemists to synthesise new tracers: 18F-FDG is highly accumulating in inflammation due 
to the high uptake of the white blood cells; high background is present in muscle and grey 
matter due to the physiological need of glucose. Furthermore 18F-FDG is not helpful in 
distinguishing the malignant from the benign pathologies and the uptake strongly depends 
on the blood flow and on the concentration of insulin (Lindholm, Minn et al. 1993; 
Culverwell, Scarsbrook et al. 2011). In diabetic people the use of PET imaging can give 
unreliable results due to the hyperglycaemia that can reduce the uptake of 18F-FDG in some 
cancers like pancreatic and lung (Diederichs, Staib et al. 1998; Torizuka, Zasadny et al. 1999).  
2.1.1.2 PET TRACERS: 18F-Fluoromisonidazole (18F-FMISO) 
18F-FMISO is the most used tracer for hypoxia. It passively diffuses through the membrane in 
the cell and the -NO2 group, which has high affinity for electrons, reacts with an electron to 
form a radical anion and afterwards if oxygen is present, the electron will be transferred to 
the oxygen otherwise a second electron can react with the nitroimidazole group and form a 
product that will react further with peptides and RNA and therefore gets trapped and 
accumulates in the cell. In necrotic areas the 18F-FMISO is not trapped because the electron 
transport chain is not working and therefore the electrons cannot be transferred (Imam 
2010).  
Hypoxia is a phenomenon occurring in many pathological conditions, including stroke, tissue 
ischemia, inflammation and solid tumours due to a non-effective transfer of oxygen from the 
vasculature to these areas.  Despite the reduced level of oxygen is cause of tumour cell 
death due to lack of nutrients transfer, some tumour cells can acquire mutations which 
enables them to survive and increase their malignant features. As a consequence, hypoxia 
areas in the tumour can show more resistance to treatment and therefore it is needed to 
investigate in advance the hypoxia status of the tumour in order to apply, later, a more 
specific treatment schedule (Wilson and Hay 2011). 
As a hypoxia marker, 18F-FMISO PET imaging is preferred to the Gold Standard method which 
uses directly the oxygen electrode but that it is quite demanding and needs high expertise.  
It is showed to be successfully used for evaluation of the prognosis after radio- and chemo-
therapy. Rajendran et al. reported that 18F-FMISO can be used as an independent prognostic 
factor after using it in 73 patients with head and neck squamous cell carcinoma (Rajendran, 
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Schwartz et al. 2006). Same findings were shown by other groups that worked on head and 
neck cancer and non-small cell lung cancer (Hicks, Rischin et al. 2005; Rischin, Hicks et al. 
2006).  
In sarcomas 18F-FMISO was used only in animal studies and mainly in dog that developed 
spontaneously different kind of sarcomas. They could detect tumour hypoxia in the center of 
the tumour where the perfusion was low (Bruehlmeier, Kaser-Hotz et al. 2005).   
2.1.1.3 PET TRACERS: 18F-Fluoride 
Among all the tracers, 18F-Fluoride is the most specific one for bone imaging. It diffuses 
through the bone vasculature into the matrix and there it is trapped since it replaces the 
hydrogen in the hydroxyapatite. Its uptake strongly depends on the blood flow and on the 
osteoblastic activity. It can highlight benign and malignant bone lesions but there is no clear 
SUV cut off between malignant and benign conditions. The absence of tumour specificity is 
the main disadvantage and therefore PET imaging cannot give a final diagnosis. Despite the 
recent developments of 18F-Fluoride imaging, it is not yet used routinely in the clinic but it 
may replace the bone scintigraphy in few years (Even-Sapir, Mishani et al. 2007).  
Most of the studies with 18F-Fluoride were performed in patients with bone metastases from 
breast and prostate cancer. Bone metastases in these patients are osteoblastic, osteolytic or 
a mixture of both and it was found that osteoblastic lesions take up more 18F-Fluoride than 
osteolytic ones. Bone scintigraphy is also applied for diagnosis of bone metastases but PET 
imaging is more sensitive than bone scintigraphy therefore its use is strongly suggested 
(Langsteger, Heinisch et al. 2006).  
2.1.1.4 PET TRACERS: 18F-Fluorodeoxythymidine (18F-FLT) 
18F-Fluorodeoxythymidine (18F-FLT) is an analogue of thymidine and it is used as a marker of 
DNA replication since this nucleoside is the only one that is not part of RNA. The information 
about the tumour proliferation gives a hint for the evaluation of the tumour growth. Cellular 
proliferation is usually measured from biopsy, invasive method, that might be difficult to 
perform and the tumour biopsy usually does not represent the proliferation rate in the 
whole tumour. Therefore PET imaging with 18F-FLT can address this question being less 
invasive and its uptake is visualised in the whole area of interest.  
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After being intravenously injected, 18F-FLT is transported into the cells via Na+-dependent 
nucleoside transporter in normal tissues and in part also by passive diffusion mainly in the 
tumour cells (Belt, Marina et al. 1993; Reske and Deisenhofer 2006). After entering the cells 
it is phosphorylated by thymidine kinase 2, which is expressed only in proliferating cells, and 
as FLT-triphosphate it can be incorporated in the DNA and accumulates in the cytosol. Since 
18F-FLT phosphorylation depends mainly on the expression of the thymidine kinase, the 18F-
FLT accumulation relates in most of the cancers to the proliferation rate in the tumour area 
(Barwick, Bencherif et al. 2009). 
Some preclinical studies report that 18F-FLT can be used to measure the treatment response 
at earlier stages and they confirmed the result from the PET imaging with the 
immunostaining for the proliferating cell nuclear antigen (PCNA) (Sugiyama, Sakahara et al. 
2004; Yang, Ryu et al. 2006; Molthoff, Klabbers et al. 2007).  
In the clinic, 18F-FLT is used mainly in brain tumours because compared to 18F-FDG it displays 
a low uptake in physiological conditions and also in breast, oesophageal, lung, lymphoma 
and sarcomas but in these other tumours the 18F-FLT uptake is lower than 18F-FDG thus 
limiting the use of 18F-FLT for tumour staging. Furthermore since the physiological uptake of 
18F-FLT in the liver and in the bone marrow is moderate to high, it is not used to detect liver 
and bone marrow’s metastases (Barwick, Bencherif et al. 2009). 
In relation to the treatment response, few studies were performed among which one 
compared the 18F-FLT uptake before and one week after treatment in 13 patients with 
breast cancer and they found a significant correlation between the clinical response and the 
PET results (Kenny, Coombes et al. 2007). Same findings were obtained in a study performed 
on patients with advanced adenocarcinoma of the lung and with advanced rectal cancer 
(Barwick, Bencherif et al. 2009).  
2.1.1.5 PET TRACERS: 18F-Fluoroethyltyrosine (18F-FET) 
18F-Fluoroethyltyrosine (18F-FET) is a marker for protein synthesis and it enters the cell 
through a Na+-indipendent amminoacid transporter, which is highly expressed in tumour 
cells, and afterwards it does not enter the protein synthesis (Spaeth, Wyss et al. 2004). Very 
few studies are performed on this tracer and they focus on the use of this tracer in brain 
tumours since the uptake in the brain and in benign conditions are low and it gets quite high 
in tumours condition (Wester, Herz et al. 1999; Caroli, Nanni et al. 2010).  
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In summary this tracer has high potential for the differential diagnosis of brain malignant 
tumours (Langen, Hamacher et al. 2006). 
2.1.1.6 PET TRACERS: 18F-Fluorocholine (18F-FCH) 
18F-Fluorocholine (18F-FCH) is an analogue of choline, essential component for the synthesis 
of phospholipids in the cell membrane that accumulates in the tumour cells since it was 
shown by Swinnen et al. that tumour cells have an increased demand of fatty acid and 
phospholipids (Swinnen, Brusselmans et al. 2006). Similar to choline, 18F-FCH is transported 
into the cell via specific transporters, is phosphorylated by the choline kinase but afterwards 
it accumulates in the cells to a low extent and becomes the substrate of the 
cytidylyltransferase and proceeds in the phospholipids synthesis (Kwee, DeGrado et al. 2007) 
The first clinical use of 18F-FCH was in prostate cancer in alternative to 18F-FDG that shows a 
high background in this organ. Contradictory are the findings about the possibility to use 18F-
FCH for differential diagnosis between benign and malignant lesions.  
Schmid et al. published a study on 9 patients where the use of 18F-FCH PET/CT was not 
sufficient for the differential diagnosis of prostate hyperplasia or prostate cancer. In contrast 
to this finding, Kwee et al. found that in 17 patients with prostate cancer, malignant sextants 
showed higher SUV compared to the biopsy negative sextants (Mertens, Slaets et al. 2010).  
Furthermore 18F-FCH showed low sensitivity (10%) in detecting lymphatic nodes in 10 
patients with prostate cancer and in 20% PET imaging showed false-positive results due to 
accumulation of 18F-FCH in inflammatory lesions (Hacker, Jeschke et al. 2006). 
Concerning distant metastases, Pelosi revealed from a study on 56 patients with prostate 
cancer, that the sensitivity of PET/CT was dependent on the level of PSA and highest (82%) 
when the PSA level was > 5ng/ml (Pelosi, Arena et al. 2008). 
In brain tumours, 18F-FCH could discriminate between high-grade gliomas for the different 
pattern of tumour uptake which was peritumoural, brain metastases, benign lesions and also 
between recurrences and radiotherapy-induced effect (Kwee, Ko et al. 2007). 
In hepatocellular carcinoma, 18F-FCH gave promising results in a small study on 14 patients 
with diagnosed carcinoma or recurrent disease where 18F-FCH uptake could discriminate 
between single lesion, found in 9 patients, or multifocal in the other three patients. No study 
was performed on other liver cancers (Talbot, Gutman et al. 2006). 
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Finally so far the use of 18F-FCH in the detection of other tumours is not well studied and the 
results do not always show a higher sensitivity of 18F-FCH compared to 18F-FDG. Therefore 
new studies have to be performed to address the role of 18F-FCH in other tumours. 
2.1.1.7 PET IMAGING IN OSTEOSARCOMA 
In OS, PET imaging is mainly used for monitoring of treatment response (Fig 2.2). In a study 
performed on 36 patients between 3 and 19 years of age, PET imaging with 18F-FDG was 
performed before and after chemotherapy: the mean SUV after chemotherapy was 
significantly higher in the poor responder group compared to the good responder (p=0.04) 
and the cut-off value after treatment for a favourable response was < 2.5 (Kim, Kim et al. 
2011). 
Franzius et al. assessed that 18F-FDG PET imaging may complement the other factors and 
tools in defining the prognosis in OS: he performed a study on 29 patients with OS and he 
found that high 18F-FDG uptake, measured as a ratio between tumour and non-tumour ratios 
is prognostic of poor outcome (Franzius, Bielack et al. 2002).  
Along the same lines Costelloe et al. claims that 18F-FDG PET imaging can be used as a 
prognostic indicator of tumour response and of survival. The study was conducted on 31 
patients with OS finding that SUVmax values > 15 were associated with a worse progression-
free survival and when the cut-off is set at 3.3 the overall survival was worse when the SUV 
was higher (Costelloe, Macapinlac et al. 2009).   
As for tumour grading some studies have been performed but Buck et al., on the other side, 
claim that 18F-FLT correlates more than 18F-FDG with the tumour but no difference is present 
in 18F-FLT uptake between grade 2 and 3 tumours (Buck, Herrmann et al. 2008). 
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Fig.2.2: Example of 
18
F-FDG PET/CT images from a 25 years old man with high-grade conventional OS in the 
metaphysis: coronal (A) and axial (B) images of tumour (arrows) before chemotherapy shows high 18F-FDG 
uptake in the tumour. After chemotherapy the coronal (C) and axial (D) images show a much reduced and 
intense 
18
F-FDG uptake suggesting the treatment was effective (adapted from (Costelloe, Macapinlac et al. 
2009). 
Despite the promising results, there are still many limitations in these studies: first of all the 
low number of patients available and also the absence of long lasting follow up.  
Further not many additional tracers have been tested in OS and so far combination of more 
tracers in PET imaging was never applied before treatment to characterise the biology of 
each individual tumour. This would be extremely helpful in designing a therapy that would 
target specifically the processes that are found to be mainly deregulated in each patient.  
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2.2 PHOTODYNAMIC THERAPY 
2.2.1 BASIC PRINCIPLE 
Photodynamic Therapy (PDT) is an old treatment modality which only recently got 
recognised and is applied for neoplastic and non-malignant diseases.  
It consists of the combination of three different components that are individually not toxic: 
oxygen, photosensitizer (PS) and light.  
After being injected in the whole body light of a specific wavelength activates the PS locally 
where the light is applied and then the activated PS is able to direct a series of phenomena 
that involve the vasculature in the tumour and the immune system (Fig. 3.1).  
 
Fig.2.3: Schematic overview of the mechanism of action of Photodynamic therapy (adapted from (Castano, 
Mroz et al. 2006). 
Similar to chemotherapeutics, also PDT is not only damaging the tumour cells but can induce 
toxicity in normal tissue but compared to other chemotherapeutics, since the illumination 
and consequently the activation of the PS is local, the side effects are much more limited. 
Furthermore none of the PS accumulates in the nuclei thus not inducing any carcinogenic 
consequence.  
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The local illumination represents also a disadvantage because the PDT is not effective 
against metastatic lesions which are the main cause of death in cancer patients as well as in 
OS patients (Agostinis, Berg et al. 2011).  
2.2.2 PHOTOSENSITIZERS 
Photosensitizers (PS) are molecules that need to be activated by a specific wavelength light 
in order to produce toxic substances and reactive oxygen species (ROS) that will damage the 
cells. Since they are captured by all the cells in the body it is important to define a specific 
illumination time when the accumulation in the tumour cells is greater than in normal 
tissues. 
After the PS is in an excited state, electrons are transferred from PS to other molecules 
inducing consequently two reactions: the first one consists in transferring electrons and 
hydrogen atoms from the PS to a substrate which gets excited and since the excited state 
has a short lifetime, around ~3 µs, the PS can react with the substrate only if the substrate is 
max 2-4x10-6 cm2s-1 distant from the oxygen molecule. The second type of reaction involves 
transfer of energy from PS to the ground state oxygen (1O2) which consequently will give rise 
to the production of reactive oxygen intermediates which include also peroxides (Luksiene 
2003; Josefsen and Boyle 2008; O'Connor, Gallagher et al. 2009). 
The most used PSs in the clinic have a tetrapyrrole structure which is similar to the 
protoporphyrin present in the haemoglobin.  
The main features of an “ideal” PS include: it should not be toxic or carcinogenic; its 
excitation light should be between 600 and 800 nm because above 800nm there is not 
enough energy to excite the oxygen and produce radicals; it should not be darktoxic; it 
should accumulate preferentially in the tumour area and less in the normal tissue; it should 
be cleared up from the normal tissue to reduce the side effects; depending on the area of 
treatment it should induce a strong inflammatory response or not (in the case of the brain 
tumours); it should not photobleach though some recent findings show that this 
phenomenon is helpful to destroy the PS without having problems of overtreatment; it 
should be easily synthesised and the drug formulations should be stable over years (Allison, 
Downie et al. 2004; Josefsen and Boyle 2008). 
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The PSs are divided in two main groups depending on the chemical structure that they have: 
porphyrin or non-porphyrins. The first ones are further subdivided in first, second or third 
generation.  
The first PS used in clinic was Photofrin® that comes from chemical modifications of the 
hematoporphyrin and it is composed of 60 compounds though it is unknown which of the 60 
is the effective compound. It is considered at the moment the gold standard for PDT and it 
has been used for the treatment of various cutaneous lesions and benign or malignant 
tumours like lung, esophageal and bladder cancers as well as skin disease (including 
malignant tumours) and it is under investigation for the use in Kaposi’s sarcoma, Barrett’s 
esophagus with high-grade dysplasia, psoriasis, brain, breast, head and neck cancers 
(Josefsen and Boyle 2008; O'Connor, Gallagher et al. 2009). 
Despite the successful results, the Photofrin® as well as all the PSs from the first generation  
display several disadvantages: unclear definition of the effective component among the 60 
that are present in the Photofrin®, high injected dose (1.5-2mgkg-1), treatment start 48hrs 
after its injection, long-lasting photosensitivity and consequently sunlight protection from 
the patients for at least 4 weeks and low wavelength of absorbance (630nm) (O'Connor, 
Gallagher et al. 2009; Agostinis, Berg et al. 2011). 
Therefore new compounds have been tested that are classified as the second generation 
photosensitizers among which Foscan®, Visudyne®, Tookad® and Levulan®.  
All of them share the same advantages compared to the first generation group including a 
faster clearance time from the body, a faster biodistribution time before illumination, lower 
photosensitivity and consequently reduced side effects. 
Among these the most potent one is Foscan® which is also known as 5,10,15,20-
tetrakis(meta-hydroxyphenyl)chlorine (mTHPC): it is at the moment used as a treatment in 
head and neck cancer and under investigation in gastric and pancreatic cancers and in other 
non-malignant pathologies. The main advantages are the low effective doses (0.1mgkg-1) and 
light intensity (10Jcm-2) though the phototoxicity is present up to 20 days which is better 
than in the first generation compounds but much worse compared to the Visudyne® which 
has only 1-2 days of photosensitivity. Furthermore the half-life in the blood is quite long (45-
65hrs).   
Another promising PS is Tookad®, a palladium-metalated bacteriopherophorbide coming 
from a bacterial analogue of the plant chlorophyll. It gained a lot of interest since the 
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absorption is maximum at 763nm therefore the depth that the light reaches is 4mm, the 
plasma half-life is ~20min and the compound is cleared from the circulation in mice 15-
20min after injection reducing the accumulation of this compound in the tissues. In human 
patients it was used so far only in 24 prostate cancer patients and at the early follow-up 
patients displayed not many side effects or complications. So far it is not yet approved in the 
clinics but the findings coming from the first clinical studies are encouraging.  
 A last example is represented by Levulan® which is composed of 5-aminolevulinic acid (ALA). 
This substance is also produced endogenously since it is a precursor of the porphyrin present 
in the heme biosynthetic pathway implying that the synthesis is quite easy as well as the 
formulation. It is mainly used for the treatment of superficial lesions like actinic keratosis or 
for superficial carcinomas since the absorption peak is at 410nm with four smaller peaks at 
510, 540, 580 and 635nm. 
 Other improvements were achieved with the third generation compounds above all on the 
solubility and specificity of the PSs. For example researchers tried to combine the second 
generation PSs with antibody that would directly bind to tumour cells antigen or with other 
carrier molecules like pegylation or nanoparticles. Examples of this group are Foslip® and 
Fospeg® (Biolitec, Jena-Germany) which are different formulation of Temoporfin with 
liposomes or pegylation. For the third generation compounds, studies are in a pre-clinical 
stage therefore still further tests have to be performed (O'Connor, Gallagher et al. 2009). 
In this thesis we used Foslipos® for the in vitro experiments and Foslip® for the in vivo 
experiments. Since the main difference between these two compounds is that Foslip® is 
dissolved in 5% glucose while Foslipos® in water, we hypothesise that the biological 
properties of the two compounds can be considered equal. Foslip® as well as Foslipos® are 
not yet approved in the clinic but compared to Foscan® they showed both in vitro and in vivo 
more efficacy and faster distribution time. Therefore our choice was directed towards these 
new formulations. 
Concerning the nonporphyrin compounds, there are not many on which the clinic focused 
on. Hypericin was, first, isolated in a plant from Hypericum species and whose activity is 
strongly dependent on the oxygen concentrations. It was shown to be effective in repressing 
the tumour growth in a RIF-1 mouse tumour model when the illumination was performed 
30min after intravenous injection of the PS. The same result was observed in a xenograft 
subcutaneous model of squamous cell carcinoma. 
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2.2.3 MECHANISMS OF PDT ACTION ON THE TUMOUR 
There are three mechanisms of action of PDT in the tumour: cytotoxicity, vasculature 
contribution and immune system activation (Fig.3.1). 
2.2.3.1 CYTOTOXICITY 
Cytotoxicity starts already few minutes after irradiation when the active cellular transport is 
reduced, the membrane gets depolarized and the activity of the enzymes in the plasma 
membranes is inhibited. Plasma, mitochondrial and nuclear membranes get oxidised and 
even if the membranes integrity is still kept, the ionic homeostasis is lost and consequently 
all the ions are secreted from the cells which induces an acute inflammatory response. The 
increase in Ca2+ concentration triggers the release of arachidonic acid which binds and 
activates the phospholipase A2 promoting the generation of superoxide radicals via the 
proteinkinase C. From this moment apoptotic signals are switched on as well as necrotic and 
autophaghy-related pathways (Luksiene 2003). 
Caspases-mediated apoptosis is the most frequent cytotoxic phenomenon but also necrosis 
was shown to play a role once the mitochondria are damaged and when the Ca2+ 
concentration increases. Autophagy might also play a role in the PDT-caused cytotoxicity 
through the macroautophagies which usually are involved in the degradation or recycle of 
protein and organelles. Despite there are clear indications of contribution from all these 
cellular death pathways, it is not yet understood how these three mechanisms are 
interrelated. 
Recently new studies investigated also the cytoprotective mechanisms which depend on the 
tumour cell type and which are most probably regulated by the expression of detoxifying 
enzymes and of heat shock proteins (HSPs) (Agostinis, Berg et al. 2011). 
2.2.3.2 VASCULATURE  CONTRIBUTION 
After PDT the microvessels collapse occurs and consequently tumour cells become hypoxic 
(Fig.3.1). This phenomenon is strongly dependent on which PS is used. Photofrin® induces 
vascular leakage in consequence of which the activated platelets start to attract leukocytes 
in the damaged area where they contribute to the thrombus formation.  
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The main factor influencing the effect on the vasculature in each PS depends on the drug-
light interval and on the chemical structure of the PS. For example Kurohane et al. showed 
that PDT with Verteporfin (Visudyne®) induced an inhibition in the tumour growth already 
15min after irradiation through a severe damage to the endothelial cells more than directly 
inducing cytotoxicity (Kurohane, Tominaga et al. 2001).  
Chen et al. used a mouse model of RIF (radiation induced fibrosarcoma) tumour to compare 
the effects of the treatment 15min and 6hrs after irradiation with intravenously injected 
hypericin used at a concentration of 5mgkg-1. In accordance with the previous findings, Chen 
et al. also found that the short drug-light interval was more effective (Chen, Pogue et al. 
2003). 
Concerning Foscan®, many studies suggest that there is no correlation between the time of 
maximal response of the tumour with the time of maximal uptake in the tumour. Indeed 
Cramers et al. treated mesothelioma xenograft mouse model using different drug-light 
intervals showing that the maximal PDT response was 1-3hrs after irradiation of the PS. 
Despite these results, the protocol used nowadays suggests to irradiate the tumour 48-120 
hrs after injection when the PS reaches the maximal uptake in the tumour (Cramers, 
Ruevekamp et al. 2003). 
Same results were obtained by Jones et al. on a rat model of fibrosarcoma: 2hrs after 
injection with Foscan® they reached the highest serum concentration and 24hrs after PS 
injection they reached the maximal tumour concentration. 
New studies are pointing to the possibility of an increase of vessel permeability after PDT 
which augmented the accumulation of Doxil ,a liposomal formulation of doxorubicin (Snyder, 
Greco et al. 2003). These findings are still under investigation and new aspects of this 
correlation between PDT and vasculature will be further evaluated. 
2.2.3.3 IMMUNE SYSTEM ACTIVATION 
The most important experiment that showed the influence of immune system on the PDT 
efficacy was carried out by Korbelik et al. (Korbelik, Krosl et al. 1996). They injected EMT6 
mammary sarcoma cells subcutaneously in syngeneic BALB/cJ mice, in SCID and nude mice. 
The nude mice do not have a thymus so they lack T cells but they have normal production of 
natural killer (NK) and B lymphocytes. The SCID mice, on the other side, have a mutation in a 
gene encoding for a phosphatidylinositol kinase which is necessary for the recoupling of the 
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DNA strands during the recombination V(D)J needed for the maturation of B and T 
lymphocytes.  Therefore they do have normal myeloid and NK production but they lack 
mature B and T lymphocytes. They produce only a low percentage of CD4+ lymphocytes 
which are from oligoclonal origin (Korbelik, Krosl et al. 1996).  
The treatment was started when the tumour was 5-7mm large and the thickness not more 
than 3.5mm. The PDT protocol consisted in injecting Photofrin® (10mgkg-1) and applying 
either 110Jcm-2 or 220Jcm-2. The results showed that the treatment was effective in BALB/c 
and SCID mice but in the second group the tumour regrew already 2 weeks after PDT: even 
when a double energy dose was applied (220Jcm-2) the effect was delayed by approximately 
5 days (Fig. 3.2). 
 
 
Fig.2.4: Treatment response in BALB/c and SCID mice after PDT performed with Photofrin® (10mg/kg i.v.) and 
with either 110 Jcm
-1
 or 220 Jcm
-1 
energy dose (adapted from (Korbelik, Krosl et al. 1996).  
Same results were observed with the nude mice (Fig. 3.3). 
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Fig.2.5: Treatment response in BALB/c and nude mice after PDT performed with Photofrin (10mg/kg i.v.) and 
with 110 Jcm
-1 
energy dose (adapted from (Korbelik, Krosl et al. 1996).  
 
After these findings they proved to restore the T-cells presence which is almost abolished in 
the SCID mice by transferring the spleen from BALB/c mice but they did not get an 
improvement in the PDT efficacy. Therefore they decided to transplant bone marrow from 
BALB/c to either 3 weeks-old SCID mice or 7 weeks-old SCID mice, and they also transplanted 
bone marrow from SCID to BALB/c mice and from SCID to SCID mice as a further negative 
control. They could show that the transplant of bone marrow from BALB/c mice restored the 
treatment efficacy in the SCID mice reaching almost 100% of cure (Fig. 3.4). 
 
The 
Fig.2.6: Treatment response in BALB/c and SCID mice after PDT performed with Photofrin (10mgkg
-1
 i.v.) and 
with 110 Jcm
-1 
energy dose. The SCID mice received the bone marrow from the BALB/c mice when they were 
3weeks (SCID (BALB/c)#2) or 7 weeks old (SCID (BALB/c)#1). BALB/c mice received the bone marrow from SCID 
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mice (BALB/c (SCID)) and as a negative control SCID mice got the bone marrow from another SCID mouse 
(SCID(SCID)) (adapted from (Korbelik, Krosl et al. 1996)). 
 
Further they could show that the SCID mice that received the bone marrow transplantation 
when they were 3 weeks old responded to the treatment better (80% of mice cured) than 
the ones that received the bone marrow transplantation when they were 7 weeks old (63% 
of mice cured).  Along with these results, the BALB/c mice, with a bone marrow received by 
a SCID mouse, show recurrence of the tumour 14 days after PDT as well as the SCID mice 
used as a negative control that got the bone marrow from another SCID mouse. 
In summary this experiment points to the contribution of the T-lymphocytes to the PDT 
efficacy and to the importance of these cells in order to have a long-lasting effect of the 
treatment more than to the initial induction of tumour cells death (Korbelik, Krosl et al. 
1996). 
These findings led the researchers to focus on the contribution on the innate and adaptive 
immune system after PDT and nowadays it is thought that there are two different steps in 
the effect of PDT mediated by the immune system.  
First of all the innate immune system, mainly represented by neutrophils, is activated 
towards the tumour cells. The neutrophils, through the release of several cytokines, attract 
the monocytes and immature dendritic cells that are then activated via a cell-to-cell contact 
and TNF-α secretion. It has been found that serum of tumour bearing mice after PDT 
contained high level of IL-6, macrophage inflammatory protein 1 and 2, prostaglandins 
secreted by endothelial cells, leukocytes and tumour cells (Castano, Mroz et al. 2006; Kousis, 
Henderson et al. 2007).   
This last step is the beginning of the second part of the immune system activation which 
involves the adaptive immune system: T-cells infiltrate the tumour area, differentiate and 
secrete INF-ƴ (Kousis, Henderson et al. 2007). This flow of subsequent processes is quite 
similar to the response of the immune system to infections. 
Therefore despite the PDT is a local treatment, the effects can be systemic in light of the 
activation of the immune system. 
Since the immune response has such an important role for the PDT efficacy, recent studies 
tried to evaluate the possibility to combine the PDT with other therapies. 
One strategy is to stimulate the innate immune system using microbial stimulators of the 
Toll-like receptors (TLRs) that are present on the membrane of monocytes, macrophages, 
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dendritic cells, mast cells and some epithelial cells. TLRs are able to trigger the NFκB 
signalling and activate, consequently, the innate immune system.  
Based on this principle, Myers et al. performed PDT before and after administration of 
Corynebacterium parvum (CP) in a mouse model of subcutaneous bladder cancer and they 
found that when CP was given after PDT the efficacy was significantly higher compared to a 
PDT pre-treatment  with CP (Myers, Lau et al. 1989).  
In another study, the Bacille-Calmette Guérin vaccination (BCG) was applied in mice with 
EMT6 subcutaneous tumour and PDT was performed using 6 different PSs: an increase was 
observed in the number of cured tumours and of memory T-cells in the group of mice that 
received the BCG compared with PDT alone (Korbelik, Sun et al. 2001).     
A similar result was achieved on mice with NRS1 squamous cell carcinomas. These mice were 
injected intratumorally 3 hrs before PDT with OK432, preparation containing killed 
streptococcal bacteria, and they showed an increase in tumour-free time compared to the 
mice that did not get OK432 or to the ones that got OK432 only after PDT (Uehara, Sano et 
al. 2000). 
A second strategy to increase the photodynamic therapy efficacy involves the administration 
of cytokines like TNFα as Bellnier et al. showed. Three hrs before injection of different 
concentrations of Photofrin® and energy dose (2.5mgkg-1 and 288Jcm-2 or 5mgkg-1 and 
144Jcm-2) they administered recombinant human TNFα (rHu-TNFα) and they got a 100% 
response from the mice from tis group compared to a response of 81% in the case of mice 
injected with 2.5mgkg-1 of Photofrin® and 288Jcm-2 energy dose and the rHu-TNFα just 
before irradiation. In the mice treated only with rHu-TNFα the percentage of success was 
even lower (20%). In the case of mice treated twice with 5mgkg-1 and 144Jcm-2 the 
percentage of mice with a tumour regression was 100% suggesting that the rHu-TNFα gives 
an additive synergistic effect (Bellnier 1991).   
The third and last approach aims at increasing the anti-tumour response by combining the 
administration of dendritic cells with PDT. It was shown that dendritic cells when exposed ex 
vitro to tumour antigens and re-administered have the ability to induce tumour regression in 
several mouse models of cancer. Along this principle, Saji et al. tried to directly inject the 
dendritic cells in the tumour using ATX-S10 Na(II) as PS to treat BALB/C mice with two 
different tumours: colon (CT26) and melanoma (B16). Dendritic cells were administered the 
day after irradiation and then again at day 14, 15 and 17 and they got a statistically 
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significant higher (p<0.0006) overall survival compared to the other groups that received the 
single treatment. Further the mice that received the treatment with dendritic cells on one 
tumour could show a regression also on the other non-treated tumour (Saji, Song et al. 
2006). 
A last aspect to mention concerns the immunosuppressive effect that PDT has when IL-10 is 
produced and this occurs mainly when the PDT is performed using red light and to a much 
lower extent when the treatment involves only the skin (Castano, Mroz et al. 2006). 
2.2.4 PDT IN THE CLINICS 
In the clinic practice PDT has been used from 1970s applying hematoporphyrin derivative 
(HPD) in 5 patients with bladder cancer. Consequently around 200 clinical trials were 
initiated and they include many and different malignant and non-malignant diseases. Here 
below you see the list of the PSs used in the clinic already with reference to the cancer 
application where the PS is being used (Table 3.1). 
 
Table 2.3: List of the PSs used in the clinic 
For example in skin cancer ALA and its derivative are approved in Europe, USA and Canada 
for the treatment of actinic keratosis as well as in Europe and Canada, these PSs are used for 
the treatment of basal cell carcinoma. On squamous cell carcinoma (SCC) of the skin many 
studies have been performed but the recurrence rates were higher than 50% (Agostinis, Berg 
et al. 2011). 
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Another example is the use of PDT in head and neck tumours: a small randomized clinical 
trial was performed to compare the efficacy of treatment performed with cisplatin and PDT 
using 5-FU or with PDT using porfimer sodium. Patients were showing mainly SCC of the 
cavity, pharynx or larynx, Kaposi sarcoma and SCC of head and neck. The PDT gave a better 
clinical response. With the development of second generation PSs, new clinical trials started 
where they tested temoporfin for the treatment of oropharyngeal cancers and they found 
that 85% of the patients (97 out of 114) showed a complete response 12 weeks after 
treatment with a disease free survival rate of 75% at 2 years. 
In another study PDT was used on patients with stage I, II or III of second or multiple primary 
head and neck tumours treated with temoporfin. They obtained a cure rate of 85% in stage I 
tumours and 38% in stage II or III.  
An additional clinical trial was performed on 128 patients with advanced head and neck 
cancer. The patients enrolled for this trial did not have response after the conventional 
treatment or were not suitable for it. PDT was performed 96hrs after Temoporfin injection 
and in 43% of patients the tumour completely regressed while in the rest the tumour volume 
was reduced of around 50% (Agostinis, Berg et al. 2011). 
In prostate cancer the main limitation of surgery and ionizing radiotherapy is the high 
morbidity because of close presence of rectum, nerves and bladder.  
One small study has been performed on patients with recurrent prostate cancer using 
motexafin lutetium (MLu). Beside some mild side effects related to urinary toxicity, the study 
showed an improvement in the biochemical and pathological disease after use of PDT. 
Another study focused on the use of palladium (Pd)-bacteriopheophorbide (padoporfin) PS 
to treat patients affected by prostate adenocarcinoma with a local failure after radiotherapy. 
In a phase I clinical trial, 24 patients were treated with this PS  without any complications 
therefore they further treated 28 patients in a follow up studies with increasing energy 
doses concluding that the tumour response correlated with the energy dose used (Agostinis, 
Berg et al. 2011). 
The superficial types of bladder cancer are relatively suitable for PDT. Some studies 
investigated the possibility of using HPD for the treatment of 50 superficial bladder 
transitional cell carcinomas (TCCs) in 37 patients reaching a 74% complete response.  
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In another study they used HPD-PDT in 34 patients with bladder carcinoma in situ and they 
showed a 73.5% of complete response 3 months after treatment but 2 years after 77.8% of 
the patients developed a recurrence.  
Recent studies further suggested that in this tumour the combination of PDT with multiple 
BCG treatment or with other chemotherapies may augment the PDT efficacy for this cancer 
(Agostinis, Berg et al. 2011). 
2.2.5 PDT IN OSTEOSARCOMA 
Not many studies have been published so far about the use of PDT for the treatment of OS. 
One animal study was performed in dogs which develop spontaneously OS with high 
percentage above all when they have long rear extremities. In this experiment they applied 
0.4mgkg-1 of Vetoporfin (Visudyne®) intravenously in 7 dogs with OS and used 500Jcm of 
energy dose. One dog was used as negative control in which only the energy dose equal to 
500Jcm was applied (Burch, London et al. 2009).  
The main purpose of this pilot study was to evaluate whether PDT could cause necrosis in 
large osseous tumours and to calculate the volume of treated tissue. The necrosis was 
clearly visualised via H&E staining on the tumour sections and it correlates with the necrotic 
signal visible on the MRI. Since OS in dogs resemble the one in humans, it can give also more 
general information about the efficacy of OS in humans (Burch, London et al. 2009).  
The results shown by Burch et al. are in agreement with the results previously published by 
other groups that used subcutaneous OS mouse models (Kusuzaki, Minami et al. 2000; 
Nomura, Yanase et al. 2004).  
Despite the few published data on the efficacy of PDT in vivo there are many limitations in 
these studies to be considered:  in the case of Buch et al. low number of animals, the need of 
amputation of the leg 48hrs after PDT for ethical reasons, no follow-up information about 
the effect of PDT on the dog’s survival, high heterogeneity in tumour volume among the 
dogs; in the case of Kususzaki and Nomura et al. the use of subcutaneous model which does 
not reflect the tumour microenvironment of the bone.  
2.2.6 APPLICATION ROUTES FOR PDT 
The possibilities of application routes in PDT are different: intratumoural, intraoperatively 
and endobronchially. The first one is shown by Buch et al. and consists in the intravenous 
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injection of the PS followed by a local irradiation with a specific light through a 0.94mm fiber 
optic cable that was localised in the tumour via a 2mm steel guide rod that was placed 
through an incision over the proximal anterior surface of the affected radius (Fig. 3.5) (Burch, 
London et al. 2009).  
 
Fig.2.7: Intratumour application of PDT in a dog with a spontaneous OS using a fiber optic cable (arrow in left 
picture) and application of the light (right picture) (adapted from (Burch, London et al. 2009)).  
 
Another application is intraoperative: the tumour cells can be visualised taking advantage of 
the fluorescence quality of the PS. In this way the medical doctors can be guided in the 
resection and after the surgery local irradiation can locally be applied (Fig. 3.6) 
(Zimmermann, Ritsch-Marte et al. 2001). 
 
 
Fig.2.8: Intraoperative application of PDT on a human patient with malignant glioma: tumour visualised with a 
normal white light (left picture) and with a blue-light fluorescence with the tumour cells in red (right picture) 
(adapted from (Zimmermann, Ritsch-Marte et al. 2001). 
  
 
73 
The third and last possibility is the endobronchial application for PDT that can be used as a 
palliative treatment of endobronchial metastases that can significantly reduce airway 
obstruction caused by metastases (Fig. 3.7) (Litle, Christie et al. 2003). 
 
Fig.2.9: Endobronchial application of PDT on a human patient with a breast endobronchial metastasis: pictures 
of the affected area before and after PDT (adapted from (Litle, Christie et al. 2003)). 
 
  
  
 
74 
  
  
 
75 
2.3 AIMS OF THE THESIS:  
In this thesis we investigated on one side the potential of PET imaging in characterising 
different OS phenotypes and detect metastases in the lung; on the other side we evaluated 
the efficacy of PDT for OS treatment. Both aims are focused on the need of improving the 
survival of patients with metastases by assessing an additional role of PET imaging in the 
design of a therapy and by evaluation new therapeutic strategy.   
For the first aim we selected three tracers (18F-FDG; 18F-FMISO; 18F-Fluoride) and compared 
the uptake of these tracers in the primary tumour and the control leg, used as our reference, 
in three orthotopic, highly metastasising mouse models of OS that develop different 
radiological phenotypes. 
The other three tracers (18F-FLT, 18F-FET and 18F-FCH) that were also included in this study   
did not show consistent results in one OS mouse model. Each of the three tracers, that we 
used for the study, targets a specific metabolic process thus allowing us to define the specific 
features of each tumour model based on changes in these processes: 18F-FDG is indicator of 
glucose metabolism; 18F-FMISO accumulates in hypoxic regions and 18F-Fluoride is an 
indicator of bone remodelling. The hypothesis behind is that depending on the different 
pattern of tracer uptake for each tumour, a specific therapy strategy could be designed: this 
treatment protocol should target the biological processes altered in this individual tumour. 
Additionally we wanted also to evaluate the possibility of detecting lung metastases with 
one of these three tracers that were highly sensitive in the detection of the primary tumour. 
In the second aim of my thesis we investigated the efficacy of PDT for the treatment of OS.  
To fulfil this aim we performed studies in vitro and in vivo using non-PEGylated liposomal 
formulations Temoporfin: Foslipos® (Biolitec, Jena-Germany) for the in vitro experiments and 
a newly more stable non-PEGylated liposomal formulation, namely Foslip®, for the in vivo 
part of the project.  
In order to overcome the limitations from the published data on mice where they used only 
subcutaneous models we established an orthotopic OS mouse model where OS cells are 
injected intratibially. 
The sub aims of the in vitro and in vivo parts are listed below: 
In vitro: 
1. evaluation of the uptake of the Foslipos® in different OS human cell lines  
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2. measurement of the cytotoxic effects of PDT on one human OS cell line chosen for 
the in vivo studies, namely 143B. 
The in vitro results were published recently by our group and part of the material & methods 
and results were taken from the published paper and further extended where more 
experiments were performed compared to the published ones (Reidy, Campanile et al. 
2012). 
In vivo: 
1. measurement of Foslip® uptake in the tumour, lung and liver using a specific optic 
fiber provided by Biolitec (Jena-Germany) on a xenograft and a syngeneic models 
2. optimization of the protocol for PDT in vivo using a xenograft model of OS 
2.3.1 OS MOUSE MODELS 
An ideal OS mouse model reflects the human disease displaying similar pattern of markers’ 
expression, metastatic spread, aetiology and treatment response. Further a model that 
would produce the tumour spontaneously or after induction with an oncogene or a chemical 
substance reflects more the human disease. A good model of OS is the dog that develops the 
tumour spontaneously. 
In mice the rate of spontaneous OS is really low: the first OS mouse models was obtained in 
1938 by Brunschwig et al. who injected intratibially 1,2-benzpyrene and cholesterol. Another 
model was generated between the 60s and 70s after exposure to radiation, radioactive 
isotopes and oncogenic viruses.  
Later in the 80s five clones from a spontaneous Balb/C mouse OS were isolated and 
characterised in vitro. 
Nowadays most of the OS mouse models are generated from the injection of tumour cells 
orthotopically or subcutaneously in the mice. The intravenous injection is mainly used for 
the study on the pattern of migration and on the metastatic spread. Moreover the mouse 
model can be syngeneic or xenograft depending on the influence and importance of the 
immune system in the planned experiment. 
Concerning the syngeneic models there are two cell systems: the first one consists of two 
clonally related cell lines K12 and K7M2 that show a different primary tumour and 
metastases development in vivo; the second model includes the low metastatic parental 
Dunn and highly metastatic derivative LM8 cell lines. 
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Concerning the first cell line system Khanna et al found that when injected intravenously 
100% of the mice injected with K7M2 died within 17 days because of metastases 
development while only 20% of the mice injected with K12 died only 102.5 days after 
tumour cell injection. When tumour cells were orthotopically injected the rate of primary 
tumour development was > 90% in K7M2 tumour bearing mice compared to the 33% in K12 
tumour bearing mice and the K7M2 tumour grew much faster than the K12. These 
differences in tumour growth rate are depending on a different pattern of deregulated 
genes as shown by Khanna et al. In K7M2 derived Khanna et al found a much higher 
expression of integrin β4, ezrin, clusterin, decorin and cerulopasmin which are influencing 
migration, adhesion and angiogenesis (Khanna, Prehn et al. 2000; Khanna, Khan et al. 2001).  
The second syngeneic model consists of low metastatic Dunn and highly metastatic LM8 
cells: LM8 cells derive from subsequent isolation of metastatic clones of Dunn cancer cells. 
The LM8 model is the most commonly used for testing the power of anticancer drugs, 
compounds coming from biological sources and radiation (Ek, Dass et al. 2006). 
Our group showed that Dunn cells injected subcutaneously develop primary tumour and 
micro-metastases (≤0.1mm in diameter) mainly in the lung. The identification of micro-
metastases was possible thanks to the LacZ tagging of the cells which allows visualising 
tumour cells after X-Gal staining of the perfused lung. LM8 cells were metastasising in the 
lung and liver in the form of macro- (> 0.1mm in diameter) and micro-metastases (<0.1mm 
in diameter) while Dunn tumours were producing only micro-metastases in the lung and in 
the liver (Arlt, Banke et al. 2011). 
Orthotopic LM8 tumours are not the ideal model because they metastasise in ovaries, liver 
and kidney and to a lower extent in the lung (data not published) while Dunn tumours 
behaviour in the orthotopic location have to be further investigated. 
The main advantage of the syngeneic models lay on the presence of the immune system that 
reflect more closely the situation in the patients where the immune system is actively 
influencing the tumour growth. On the other side the mouse development of primary 
tumour can be different for the molecular mechanisms, for the location of the metastases 
and this makes the syngeneic model not suitable for all kind of studies. 
Additionally to this there are several human OS tumours. The main advantage in this case is 
the possibility to inject directly human OS cells that mainly metastasise exclusively to the 
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lungs similarly to the human situation and they more closely would generate a 
microenvironment that could be similar to the one in the humans. 
Among the human cell lines the most commonly used ones are U2OS, HOS, 143B, SaOS-2 
and LM6.  
U2OS are OS cells isolated from a 15 years old Caucasian girl with a moderately 
differentiated OS. These cells have been well characterised in vitro but in vivo they did not 
produce lung metastases if subcutaneously injected and the primary tumour developed in 
63%. When these cells were intravenously injected, metastatic nodules developed in the 
lung in 100% of the mice after 8 weeks from tumour cell injection but when the cells were 
transfected with alkaline phosphatase (ALP) in both injection sites the primary tumour 
growth and the metastases formation were much lower. The orthotopic model of this cell 
line did not give clear results concerning the development of spontaneous lung metastases 
(Manara, Baldini et al. 2000). 
HOS cells were isolated from a 13 years old Caucasian girl and they are also well 
characterised in vitro but in vivo so far no one successfully obtained primary tumour after 
subcutaneous or orthotopic implantation of these cells. Primary tumour growth and 
metastatic formation was reproduced, though, after in vitro transformation of the HOS with 
the oncogene v-Ki-ras. From this transformation two different cell lines were generated: 
KRIB and 143B. Both of them are able to form primary tumour and metastases after 
orthotopic injection within 4-6 weeks. The main limitation of both models is that they are 
transformed cell lines which do not truly represent the human situation since the acquisition 
of Ki-Ras mutation or amplification during tumour development is not so frequent in OS 
patients (Kido, Tsujiuchi et al. 1997). Consequently the Ki-Ras oncogene transformation 
might indeed affect pathway and molecular mechanisms that do not occur in the humans 
(Ek, Dass et al. 2006). 
Finally SaOS-2 cells were isolated from an 11-year old Caucasian girl. When orthotopically 
injected they develop primary tumour in 2-5 months and lung metastases (Sabile, Arlt et al. 
2011).  A highly metastatic model of the SaOS-2 cell line was generated injecting the cells 
intravenously and 6 months after tumour cell injection pulmonary metastatic clones were 
isolated in vivo and re-injected intravenously. This process was repeated 5 times obtaining 
the LM6 that were highly metastatic, if intravenously injected.   
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In our laboratory we make use of different xenograft and syngeneic orthotopic OS mouse 
models among the described ones. 
To fulfill the first aim of my thesis we mainly used three models: 143B, LM8 and SaOS-2. We 
chose these three models because they display extreme opposite radiological phenotypes 
(Yuan, Ossendorf et al. 2009) the primary tumour in the xenograft 143B model is 
characterised by the presence of lytic lesions in the tibia that start to be visible already in the 
second week of tumour development (Fig. 3-143B). Metastatic foci are formed mainly in the 
lung. The syngeneic LM8 model is slightly osteoblastic and it forms bony structures around 
the tibia that are visualised by x-ray from the third week after tumour cell injection (Fig. 3-
LM8). Metastases are visible in the ovaries, liver, kidneys and lungs. 
As for the xenograft SaOS-2 model, for my purposes we used a transformed cell line which 
was produced in our laboratory by Dr. Sabile, namely SaOS-2/caprin-1, which has been 
characterised in vitro and in vivo. In vivo the SaOS-2/caprin-1 model shows the same 
osteoblastic phenotype by appearance as the SaOS-2 model but the primary tumour grows 
much quicker: within 2 months primary tumour is detectable by x-ray in some mice while for 
the SaOS-2 model usually it can take from 2 to 5 months (paper in submission). The high 
heterogeneity in the primary tumour growth in the SaOS-2/caprin-1 model forced us to 
perform the PET imaging in two different steps depending on the primary tumour 
development. In the Fig. 2.3 representative x ray-pictures from two different SaOS-2/caprin-
1 mice are visible: one mouse displayed detectable primary tumour already at day 43 after 
tumour cell injection while the other one showed typical osteoblastic lesions starting from 
day 85. Metastatic nodules are visible mainly in the lung. 
Despite this heterogeneity the SaOS-2/caprin-1 model grows faster and allows performing 
the experiment in much shorter time point. 
Another reason to choose these three models relates with the time of tumour progression: 
143B and LM8 models endpoint is around 3-4 weeks though 143B tumour is characterised 
mainly by lytic lesion and the LM8 is mildly osteoblastic. The SaOS-2/caprin-1 model is much 
slower and therefore it was interesting for us to compare the biology of fast and slow 
developing models by PET imaging.  
Besides the orthotopic models, we made use also of a subcutaneous model where murine 
LM8 cells were injected in the right flank of C3H mice. Subcutaneous tumour was developing 
from the first week after tumour cell injection and metastases were developing mainly in the 
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lung and in the liver. Mice were sacrificed 23 days after tumour cell injection and the use of 
this model relates mainly to the different site of tumour cell injection. 
To better identify the location of the primary tumour and to visualise the metastases to the 
level of a single cell, we make use in our laboratory of the LacZ system. Cells are LacZ tagged 
via a retroviral transduction and this enables us to visualise ex vivo the tumour cells after X-
Gal staining (Arlt, Banke et al. 2011). Only once cell line (SaOS-2/Caprin 1) was not tagged 
with LacZ which was dependent on the earlier production of this cell line compared to the 
decision of using the LacZ tagging for our experiments but this does not affect our results 
since we did not count the number of metastases in the PET experiments or use the LacZ 
tagging for further analysis. 
 
 
 Fig.2.10: Representative x-ray pictures of mice from each OS mouse model during the primary tumour 
development. 
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3 EVALUATION OF PET IMAGING IN OS 
MOUSE MODELS 
3.1 RESULTS  
In this chapter I will present the results, the discussion, the outlook and the methods used in 
the project involving the evaluation of the potential use of PET imaging for the 
characterization of different OS phenotypes.  
3.1.1 UPTAKE OF 18F-FET, 18F-FLT AND 18F-FCH IN THE 143B MODEL 
The uptake of 18F-FET, 18F-FLT and 18F-FCH was analysed in the 143B model to evaluate the 
sensitivity of these tracers in primary tumour detection.  
18F-FET which targets tumour cells with high rate of protein synthesis shows an ambiguous 
result: 2 mice show higher uptake in the tumour leg (Fig. 2.6A) and 2 mice have lower uptake 
(Fig. 2.6B) compared to the control leg which in the end resulted in an equal standardised 
uptake value for both legs when we performed the quantitative analysis (Fig. 2.6C). 
 
Fig.3.1: Summary of the 
18
F-FET uptake in the 143B model: two representative PET coronal images as maximal 
intensity projection of OS bearing mice (tumour is in the left tibia-white arrow) injected with 
18
F-FET (5A; 5B); 
quantitative analysis comparing the standardised uptake value in the control and tumour leg (5C) n=4.  
Data represent means +/- SEM (n ≥ 3). 
 
18F-FCH, which is specific for membrane turnover, shows a similar pattern of uptake 
compared to 18F-FET since 2 mice show a higher uptake (Fig. 2.7A) and 2 mice show a lower 
uptake (Fig. 2.7B) in the primary tumour leg compared to the control leg. The quantification 
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of the uptake in the two legs confirms the visual analysis: indeed no difference is present 
between the two legs in the total of 4 mice (Fig. 2.7C). 
 
 
 
Fig.3.2: Summary of the 
18
F-FCH uptake in the 143B model: two representative PET coronal images of OS 
bearing mice (tumour is in the left tibia-white arrow) injected with 
18
F-FCH (6A; 6B); quantitative analysis 
comparing the standardised uptake value in the control and tumour leg (6C) n=4. Data represent means +/- 
SEM (n ≥ 3). 
 
Finally 18F-FLT is a tracer which marks the area of the tumour which are highly proliferative. 
Interstingly 18F-FLT does not show any difference in tracer uptake between the two legs on 
the PET images  (Fig. 2.8A-B) but the quantitative analysis demonstrates that the tumour leg 
displays a tendency to a lower uptake compared to the control which does not make sense 
considering the high tumour growth rate of this model (Fig. 2.8C).   
 
 
Fig.3.3: Summary of the 
18
F-FLT uptake in the 143B model: two representative PET coronal images of OS 
bearing mice (tumour is in the left tibia-white arrow) injected with 
18
F-FLT (8A; 8B); quantitative analysis 
comparing the standardised uptake value in the control and tumour leg (8C) n=4. Data represent means +/- 
SEM (n ≥ 3). 
Since the results with these three tracers were not conclusive already with one model we 
decided not to further proceed with these three tracers and to focus only on 18F-FDG, 18F-
FMISO, 18F-Fluoride.   
  
 
83 
3.1.2 18F-FDG UPTAKE IN THE THREE OS MOUSE MODELS 
18F-FDG uptake, indicating high glucose metabolism, was detectable in the primary tumours 
of all three OS mouse models and defines the margins of the tumour (Fig. 9A). The mean 
SUVs of tumour and reference regions are shown in Table 3. The osteolytic 143B tumours 
showed the highest 18F-FDG uptake with a 3.79±0.67 fold higher accumulation in the tumour 
than the reference region of the opposite leg. The LM8 model had 2.22±0.39 fold higher 
tracer uptake in the tumour than in the hip region and the SaOS-2/caprin-1 model had a 
ratio of 2.04±0.15 between tumour and control SUVs. The difference in the ratios is 
statistically significant (p<0.05) between 143B and SaOS-2/caprin-1 models (Fig. 9B). The 
sensitivity for 18F-FDG was higher in 143B and SaOS-2/caprin-1 models than in the LM8 
model (Table 4). However, it should be noted that a different protocol for 18F-FDG PET was 
used in the LM8 model. 
 
Fig.3.4: Representative PET coronal images of mice from the three different models injected with 
18
F-FDG; the 
coloured pictures have a fixed SUV value for all the three pictures from a minimum value of 0 (black) to a 
maximum value of 3 (red) (A); quantitative analysis shows the ratio between the SUV in the tumour leg and in 
the control reference which is the other leg in the case of 143B and SaOS-2/Caprin-1 and the hip in the case of 
the LM8. Data represent means +/- SEM (n ≥ 3). *<0.05  
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Table 3.1: Mean±SEM values of tumour and reference SUVs for each tracer and each model 
 
 
Table 3.2: Sensitivity of PET imaging in detection of primary tumour with the three tracers 
 
3.1.3 18F-FMISO UPTAKE IN THE THREE OS MOUSE MODELS 
18F-FMISO, an indicator of hypoxia, accumulated significantly in 143B and SaOS-2/caprin-1 
tumours but to a lower extent in LM8 tumours (Fig. 10A). SUV ratios were 1.99±0.15 for 
143B and 2.23±0.24 for SaOS-2/caprin-1 models (Table 3). Both were significantly higher 
(p<0.01) than the respective ratio in the LM8 model (1.18±0.08) (Fig. 10B). The sensitivity 
was good for all three tracers (Table 5).   
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Fig.3.5: Representative PET coronal images of mice from the three different models injected with 
18
F-FMISO; 
the coloured pictures have a fixed SUV value for all the three pictures from a minimum value of 0 (black) to a 
maximum value of 3 (red) (A); quantitative analysis shows the ratio between the SUV in the tumour leg and in 
the control reference (control leg). Data represent means +/- SEM (n ≥ 3). **<0.01  
 
 
Table 3.3: Sensitivity of PET imaging in detection of primary tumour with the three tracers 
 
3.1.4 18F-FLUORIDE UPTAKE IN THE THREE OS MOUSE MODELS 
18F-Fluoride uptake of the lesions, indicating bone remodelling, differed strongly among the 
three OS mouse models (Fig. 11A).  In the osteolytic 143B model 18F-Fluoride uptake in 
primary tumours was detectable in 7 out of 15 mice (sensitivity 47%, Table 6). The slightly 
osteoblastic model, LM8, displayed a higher 18F-Fluoride uptake resulting in a sensitivity of 
75%. Most pronounced uptake was detected in the highly osteoblastic SaOS-2/caprin-1 
model. The analysis of the ratios between tumour and control SUVs confirmed the visual 
examination: SUV ratios were 2.28±0.39 in the SaOS-2/caprin-1 model, 1.32±0.15 in the LM8 
model and 1.08±0.13 in the 143B model (Table 3). The differences in SUV ratios were 
significant between SaOS-2/caprin-1 and LM8 (p<0.05) and between SaOS-2/caprin-1 and 
143B (p<0.01) (Fig. 11B). 
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Fig.3.6: Representative PET coronal images of mice from the three different models injected with 
18
F-Fluoride; 
the coloured pictures have a fixed SUV value for all the three pictures from a minimum value of 0 (black) to a 
maximum value of 5 (red) (A); quantitative analysis shows the ratio between the SUV in the tumour leg and in 
the control reference (control leg). Data represent means +/- SEM (n ≥ 3). *<0.05; **<0.01  
 
 
 
 
Table 3.4: Sensitivity of PET imaging in detection of primary tumour with the three tracers 
 
3.1.5 IMMUNOHISTOCHEMISTRY OF OS MODELS USED IN THIS STUDY 
Trichromic Goldner staining and immunohistochemistry for Ki67 and CaIX were performed to 
validate the differences in PET tracers uptake among the three OS mouse models.  Results 
are shown in Fig.12. Ki67 is a nuclear marker of proliferation that is expressed in cells that 
are undergoing the cell cycle. In our three OS mouse models Ki67 index correlates 
significantly with the 18F-FDG uptake (Fig.2.12) and therefore we used this marker to confirm 
the different extent of glucose metabolism present in 143B, LM8 and SaOS-2/Caprin-1 
tumour models.  
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Fig.3.7: Correlation between the Ki67 index and the 
18
F-FDG SUV in representative mice from the three OS 
mouse models (n=12 among which 9 mice from 143B model, 2 from LM8 model and 1 from SaOS-2/Caprin-1 
model; R
2
=0.62; p<0.005). 
 
 
Fig.3.8: IHC (Ki67 and CaIX) and histology (Goldner staining) on the tumour sections derived from the different 
mouse models. Qualitatively tumour tissue staining confirms the PET imaging results: 143B model shows higher 
percentage of Ki67 positive cells (A) compared to LM8 and SaOS-2/caprin-1 models (B, C); SaOS-2/caprin-1 
model displays major extent of immature bone (F) compared to LM8 and 143B models (D, E); 143B and SaOS-
2/caprin-1 models have larger areas of CaIX positivity (G; I) compared to LM8 model (H).  
Scale bars: 100µm. 
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Indeed we could detected high presence of Ki67 positive cells in the 143B osteolytic tumour 
model while LM8 moderetaly osteoblastic and SaOS-2/Caprin-1 strongly osteoblastic models 
display a lower extent of positivity  (Fig.2.13A, B and C).  
CaIX is a marker of hypoxia and we used it to compare the degree of hypoxia in the three OS 
mouse models. The LM8 tumours showed lowest staining for CaIX (Fig. 2.13D, E and F) which 
is in agreement with the low accumulation of 18F-FMISO in this tumour model. The other two 
OS mouse models, 143B and SaOS-2/Caprin-1, display a much higher percentage of CaIX 
positive cells as well as high uptake of 18F-FMISO. 
As well as for Ki67, we decided to calculate the CaIX index and correlate it with 18F-FMISO 
SUV (Fig.2.14). No correlation was found between the CaIX index and the 18F-FMISO uptake 
which might depend on a subjective mistake in counting the positive cells, on the need of 
increasing the samples number or on the heterogeneity of hypoxic regions within the 
tumour that could be missed or overestimated in each representative slide. 
 
Fig.3.9: Correlation between the CaIX index and the 
18
F-FMISO SUV in representative mice from the three OS 
mouse models (n=11 among which 9 mice from 143B model, 1 from LM8 model and 1 from SaOS-2/Caprin-1 
model). 
 
Another aspect that we evaluated in regard to hypoxia is the vessel density which can 
correlate with the degree of hypoxia present in the tumour section. Therefore we calculated 
the vessel area in percentage compared to the total area of the tumour sections that we 
analysed and we observed a tendency to a higher vessel area in the LM8 mouse model (Fig. 
2.15) compared to the other two models. SaOS-2/Caprin-1 and 143B models show 
respectively 2.6 and 1.8 times less vessel area than LM8 model that showed among the 
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three models also the lowest ratio in 18F-FMISO uptake between tumour and control leg 
(Fig.2.10). 
 
Fig.3.10: Analysis of the vessel area (%) in the three mouse models: values are represented as means ± SEM. 
Trichromic Goldner staining was used to detect mineralised bone matrix that can explain the 
increased 18F-Fluoride uptake, which is dependent on the area of mineralisation. The 
osteolytic 143B tumour section showed low immature bone, osteoid, and mineralised bone 
production from the tumour cells. The slight osteoblastic LM8 model had higher production 
of osteoid (red) and mineralised bone without an organized structure (blue) and SaOS-
2/caprin-1 tumours had highest presence of bone secreted by tumour cells (Fig. 2.13G, H 
and I). This was in good agreement with the findings from 18F-Fluoride PET. 
3.1.6 DETECTION OF METASTASES VIA PET IMAGING 
In this study we also evaluated the possibility to detect lung metastases since the lung is the 
main organ of metastases in human patients. 143B and SaOS-2/Caprin-1 models develop 
only lung metastases with high reliability while LM8 model metastasises preferentially in 
kidney, ovary, liver and only to a less extent in the lung therefore we focused only on the 
first two models. 
In the case of 143B model we could not detect any pulmonary nodules on the PET slides. 
Therefore we decided to perform autoradiography directly on the lung sections of one 
mouse using 18F-FDG, 18F-FMISO and 18F-Fluoride after performing the whole-body PET scan. 
In the autoradiography it can be noted that the three tracers have different background 
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reference. 18F-FDG shows the highest background due to the physiological uptake in the 
lung. 18F-Fluoride displays no uptake in the negative control lung which is expectable since 
18F-Fluoride is specific for bone remodelling. We could detect signal using the 18F-FDG and 
18F-Fluoride that could be correlated with the presence of metastases confirmed via H&E 
(Fig. 2.16). Surprisingly while with 18F-FDG, there was a reliable correlation between tracer 
signal and presence of pulmonary nodules, with 18F-Fluoride, we could see that only some 
metastatic nodules could be detected but not all. Therefore we decided to perform the 
Goldner staining to verify whether the 18F-Fluoride uptake might depend on the presence of 
mineralised matrix that is produced by the tumour cells. Indeed when we performed 
Goldner staining we could see that some lung nodules did not contain any mineralised 
matrix (Fig. 2.17A) while some others displayed a clear mineralisation in the middle of the 
metastases (Fig. 2.17B) which can explain why some metastatic nodules take up 18F-Fluoride. 
 
 
Fig.3.11: Representative autoradiography pictures from lung section of mice that did not receive tumour cells 
injection but that were injected with 
18
F-FDG, 
18
F-FMISO or 
18
F-Fluoride (negative control) and of tumour 
bearing mice (tumour bearing mouse lung) (Left panel); H&E on lung sections after autoradiography of the 
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tumour bearing mice: the presence of lung metastases is displayed with a white arrow (Right panel). Scale bars: 
100um. 
 
 
 
Fig.3.12: Goldner staining of lung sections from mice that received 
18
F-Fluoride: in A no mineralised matrix is 
visible while in B a mineralised area is visible in the centre of the metastatic nodule. Scale bars: 50um 
 
With 18F-FMISO, no metastases could be visualised by autoradiography and by H&E. 
In the SaOS-2 model it was difficult to detect metastases via PET imaging though the 
metastases were quite big. Moreover we could not detect any metastases by 
autoradiography due also to the absence of lung metastases bigger than 0.2mm in diameter 
in the mice used for this analysis.  
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3.2 DISCUSSION & OUTLOOK 
Biomedical imaging is used, so far, for screening and for monitoring of disease progression, 
but in the future it will hopefully be applicable also for the diagnosis of developing tumours 
at an early stage and for the stratification of the treatment based on the imaging results of 
metabolic imaging. In this study, we analysed the potential of PET imaging as a tool for the 
characterization of tumour different tumour types in well-defined intratibial osteosarcoma 
(OS) mouse models.  
Nowadays PET imaging in the clinic is mainly used for monitoring treatment success in soft 
tissue and bone sarcomas. Indeed it was shown by Benz et al. that in patients with high-
grade soft tissue tumours a cut-off of a 35% reduction of the SUV in tumours imaged with 
18F-FDG predicts a good response to treatment (Benz, Czernin et al. 2009). Consistent with 
these findings, Kim et al. showed that in patients with OS or with Ewing sarcoma 18F-FDG-PET 
can be used for an assessment of the response to chemotherapy before surgery: they 
compared the 18F-FDG-SUV in the tumour region in 23 patients before (SUV1) and after 
chemotherapy (SUV2) and they found that the SUV2 was significantly (p<0.04) higher in the 
poor than in the good responders (Kim, Kim et al. 2011). Recently PET gained attention as a 
tool for the characterization of metabolic processes occurring in tumours, which are more 
informative than anatomical changes of tumour size, visualised and monitored by CT and x-
ray (Juweid and Cheson 2006).  
In our study we explored the possibility of using PET imaging for the characterization of 
different tumour phenotypes in well-defined OS mouse models. 
In an initial study, we compared the uptake of 6 PET tracers that are available and approved 
for clinical use by the Food and Drug Administration (FDA). The tracers assessed were 18F-
FDG, 18F-Fluoride, 18F-FMISO, 18F-FET, 18F-FLT and 18F-FCH in an orthotopic OS mouse model 
generated by intratibial injection of human OS 143B. 18F-FDG was chosen because it is 
currently the most commonly used tracer in OS, 18F-Fluoride is the most specific tracer for 
bone formation and remodelling, and 18F-FMISO was reported to indicate hypoxia in 
spontaneous canine osteosarcoma; the other tracers were chosen because they are 
indicators of distinct metabolic processes, which can affect the progression of the primary 
tumour to a different extent and because they have so far not been used in bone related 
diseases. 
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We found that in the intratibial osteolytic 143B cell-derived OS model 18F-FCH and 18F-FET 
uptake was only detectable in 2 out of 4 mice; 18F-FLT and 18F-Fluoride uptake was found to 
be lower in the tumour than in the control leg. However, a robust uptake of 18F-FDG and of 
18F-FMISO was observed in the 143B OS mouse model. The remarkable intra-tracer and 
inter-tracer differences in tumour uptake in 143B OS indicated a considerable tumour 
heterogeneity similar to that observed in human tumours. Moreover it characterised again 
biological processes during tumour development.  
A similar study has been performed by Ebenhan et al. It compared the uptake of 18F-FDG, 
18F-FCH, 18F-FLT, 18F-FET uptake in rodent lung, colon and breast cancers and in fibrosarcoma 
and melanoma. 18F-FCH uptake was low or non-detectable in any of the models. A moderate 
uptake of 18F-FET was observed in all models. 18F-FLT exhibited the highest uptake in all the 
different tumours models and was considered as a generic tracer (Ebenhan, Honer et al. 
2009). 18F-FDG uptake was high only in the syngeneic orthotopic models (fibrosarcoma and 
melanoma) which were shown to be more extensively vascularized than xenograft models, 
suggesting that 18F-FDG uptake might depend on the blood supply of the tumour. 
Based on the results of our pilot study with six tracers in the intratibial osteolytic human 
143B OS cell line derived model, we performed a follow-up study in three different intratibial 
OS mouse models with three distinct and defined OS phenotypes. The three phenotypes 
included the osteolytic 143B cell-derived tumours, the mildly osteoblastic tumours derived 
from mouse LM8 OS cells and tumours with a pronounced osteoblastic phenotype 
generated from SaOS-2/Caprin-1 OS cells that stably overexpressed Caprin-1, which 
accelerated primary tumour growth (Sabile et al. 2012, submitted). We limited the number 
of tracers to the three most reliable ones in the pilot study. We used 18F-FMISO, indicating 
hypoxia, 18F-Fluoride, indicating bone formation and remodelling and the clinically so far 
most frequently used 18F-FDG as a reference. We speculated that with the three selected 
tracers we would be able to visualise and distinguish the three distinct phenotypes defined 
by the three models.  
A robust uptake of 18F-Fluoride by SaOS-2/caprin-1 cell-derived tumours, compared to the 
18F-Fluoride uptake by the LM8 and 143B cell-derived tumours, was in good agreement with 
the pronounced osteoblastic phenotype of the SaOS-2/caprin-1 model. Our findings were 
also consistent with those reported by Hsu et al who investigated 18F-Fluoride and 18F-FDG 
uptake over time in osteolytic, osteoblastic and mixed type bone metastatic lesions in three 
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distinct prostate cancer models. These osteblastic lesions showed an increase in 18F-Fluoride 
and 18F-FDG uptake over time in parallel with the growth of the bone metastases. In the 
osteolytic lesions, on the other hand, an increase in tracer uptake over time was only 
observed for 18F-FDG. This is again largely consistent with our observations of a 3.8-fold 
higher tumour-specific uptake of 18F-FDG in the osteolytic 143B OS model than in the 
osteoblastic LM8 and SaOS-2/Caprin-1 cell line-derived models. Thus, in both studies 
osteoblastic and osteolytic bone lesions could be distinguished by differential 18F-Fluoride 
and 18F-FDG uptake.  
18F-FMISO, the third tracer used in the three distinct mouse models, was of particular 
interest because it indicates hypoxic conditions in tissue and because hypoxia in tumour 
tissue is considered to promote chemoresistance, which has been shown to be related to a 
poor prognosis for OS patients in particular (Brahimi-Horn, Berra et al. 2001; Cosse and 
Michiels 2008). We observed remarkable uptake of 18F-FMISO indicating hypoxic tumour 
tissue in the SaOS-2/caprin-1 osteoblastic and in the 143B osteolytic models and less 
labelling in the mildly osteblastic LM8 tumours, likely due to their smaller volume than that 
of the primary tumours recognised in the other two models. Interestingly, we also observed 
a higher density of blood vessels in the LM8 than in the 143B and SaOS-2/caprin-1 cell-
derived tumours. These findings are in agreement with those of a study that demonstrated 
that the hypoxic regions within a tumour are usually less vascularized than the oxygenated 
areas. This was observed in immunodeficient mice that received human prostate cells 
injected into the right flank. These cells expressed EGFP only under hypoxic conditions 
(Raman, Artemov et al. 2006). Vascularization was visualised with a fiber optic oxygen probe 
used for the measurement of the oxygen pressure and with MRI for vessel imaging. Hypoxic 
tumour areas contained fewer vessels, but the vessels were more permeable. Altogether, 
the authors concluded that limited blood supply caused hypoxia and consequently enhanced 
the expression of VEGF, which increased the permeability of the vessels in these tumour 
areas (Raman, Artemov et al. 2006).  
In order to further verify our interpretation of the PET imaging data obtained with 18F-
Fluoride, 18F-FDG and 18F-FMISO, we also performed an ex vivo analysis of primary tumour 
tissue by histology and immunohistochemistry. Tumour tissue hypoxia was assessed by 
staining of CaIX, which, mediated by HIF1-α, is induced by hypoxia. In a syngeneic and 
subcutaneous model of rhabdomyosarcoma it was shown that the expression of CaIX 
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correlated with the uptake of 18F-FMISO (Dubois, Landuyt et al. 2004; Potter and Harris 
2004).  
In our study we observed considerably large areas of hypoxia in the 143B and SaOS-2/caprin-
1 cell line-derived tumours, but there was no correlation between tracer uptake and the 
percentage of stained tumour cells per analysed area. This result might be explained by the 
low number of tissue samples that could be evaluated.  
High glucose uptake and metabolism in tumour tissue imaged by 18F-FDG PET is considered 
as an indicator of aggressive tumour proliferation, and we indeed observed a correlation 
between in vivo 18F-FDG uptake and the percentage of proliferating cells visualised ex vivo in 
tumour tissue sections by immunostaining of the proliferation marker Ki67 (Ki67 index). This 
result is consistent with the findings of Yamamoto et al who reported a significant (R2=0.81; 
p<0.0001) correlation between Ki67 index and FDG SUV in non-small cell lung cancer tissue 
of 18 patients (Yamamoto, Nishiyama et al. 2007).  
In order to histologically assess the formation and remodelling of bone-like structures in 
osteoblastic primary tumour tissue in the here investigated OS models and to compare it 
with the uptake of 18F-Fluoride examined by PET, we perfomed Goldner staining of 
mineralised and non-mineralised bone matrix in primary tumour tissue sections. The results 
were as expected and showed much larger areas of mineralised and non-mineralised bone 
matrix in osteoblastic SaOS-2/caprin-1 and the LM8 cell line-derived tumours than in the 
osteolytic tumours formed by 143B cells. Thus, taken together, the histological and 
immunohistochemical analysis of primary OS tumour tissue confirmed the findings of the in 
vivo characterization by PET of the different tumour types generated in the three OS mouse 
models investigated here. 
Despite the promising results in this study, there are certain limitations. We used preclinical 
models that do not fully reproduce the human disease and the heterogeneity of the tumour 
tissue with osteolytic and osteoblastic lesions. In addition, PET imaging was performed at a 
late stage of tumour development when the different phenotypes were well established. 
Nevertheless, the here achieved successful characterization of different tumour phenotypes 
in experimental OS by PET with three different tracers is encouraging. Such an approach may 
in the future help the clinicians to define the predominant phenotype in an OS primary 
tumour and to choose more tumour-type specific combinations of currently accepted and 
future novel therapeutic compounds. Indeed new approaches are being investigated on the 
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use of drugs that target glucose metabolism, hypoxia and bone remodelling processes 
(osteoblastic or osteolytic) (Guise, Mohammad et al. 2006; Akiyama, Dass et al. 2008; Wilson 
and Hay 2011; Jones and Schulze 2012). Future preclinical studies need to address the real 
benefit of the here propose strategies in comparison to currently used treatment regimens 
with the final aim of increasing the survival rate of the OS patients. 
The additional goal of visualising metastatic lesions in the present study was not reached 
with any of the tracers. Interestingly, there are not many studies reported that investigated 
PET imaging of metastases in tumour models in mice. Recently, Deroose et al were able to 
detect lung metastases 45 days after intravenous injection of melanoma cells in nude mice 
(Deroose, De et al. 2007). Consistent with these results, Franzius et al. reported that lung 
and soft tissue metastases could be detected by PET imaging with 18F-FDG and osseous 
metastases in a xenograft mouse model of Ewing sarcoma were detectable with 18F-Fluoride 
and 18F-FDG (Franzius, Hotfilder et al. 2006). However, kidney and ovary metastases 
remained undetectable. The authors claimed that a high background of 18F-FDG uptake in 
abdomen and kidney might have hindered the visualisation of metastases in those organs. In 
our study, we need to consider the following explanations for the non-successful 
visualisation of metastases in the lung that were easily recognized ex vivo: the resolution of 
our PET scanner was limited and the background of 18F-FDG uptake in the lung was also high. 
Interestingly, we were able to detect metastatic foci in 143B model with ex vivo 
autoradiography of 18F-FDG and 18F-Fluoride in lung tissue sections. The observed uptake of 
18F-Fluoride was a surprising finding, but, upon histological analysis of the tissue, the uptake 
turned out to reflect the formation of mineralised matrix observed in some but not all of the 
metastatic lesions confirmed by Goldner staining.  
The autoradiography of lung sections of mice that received 18F-FDG revealed a linear 
correlation between the autoradiographic signals and the metastatic load assessed by 
histology. The finding indicated an elevated glucose metabolism in metastatic lesions 
compared to normal lung tissue. 
The mouse subjected to 18F-FMISO PET did not develop any metastases and further studies 
are needed to evaluate metastatic imaging with 18F-FMISO. 
Altogether, we conclude that the sensitivity and the resolution of the scanner available to us 
in this study were too low for imaging of lung metastatic lesions in mice.  
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These promising results of the here reported PET studies set the stage for further 
investigations on two aspects. 
In the OS mouse models where the PET imaging successfully characterised the biology of the 
different OS phenotypes, new treatment approaches can be tested that, based on the PET 
results, target glucose metabolism, hypoxia or bone remodelling/destruction. These drugs 
are at the moment available in the market but they have not been tested so far in OS hence 
the first step would be to try some of the selected drugs that block the above mentioned 
processes. In order to get a reliable result, the selected drugs shall be tested only on the two 
xenograft mouse models used in this project since these two models closely reflect the 
human progression of the disease and therefore it would be easier to interpret the effect of 
the drug and design the further results in humans. 
Examples of possible drugs that can be tested in OS mouse models can be divided in three 
classes: inhibitors of glucose metabolism; inhibitors of hypoxia and regulators of the 
imbalance between the osteoclastic and osteoblastic activity. To the first class 2-
deoxyglucose (2DG) and Dichloroacetate (DCA) belong: the first one enters the cells via the 
glucose transporters, gets phosphorylated by the hexokinase and saturates this enzyme 
(Jones and Schulze 2012); the second one reactivates the tricarboxylic acid cycle (TCA cycle) 
whose activity is reduced in many cancers. DCA has shown to restore the passage of 
pyruvate in the mitochondria and therefore the TCA cycle inducing apoptosis and tumour 
shrinkage (Jones and Schulze 2012). 
Concerning the second class of drugs, many classes of small drugs have been developed to 
target specifically hypoxic tumour cells but not all produced promising results. One class of 
compounds, that is already in multiple phase I and II trials with favourable results, is 
represented by bioreductive prodrugs which are usually undergoing a double reduction 
which is reversible in oxic cells but not in hypoxic cells where these prodrugs will generate 
toxic radicals. Example of prodrug is N-oxyde tirapazamine (TPZ) which is 50-200 folds more 
toxic to hypoxic than oxic cells in culture and TH-302 which is a 2-nitroimidazole-based 
nitrogen mustard prodrug (Wilson and Hay 2011).  
Finally concerning drugs which might regulate the imbalance between the osteoclastic and 
osteoblastic activity, promising findings have been published. In the case of osteolytic 
lesions, bisphosphonates have been shown to inhibit the bone resorption and therefore they 
are already used in the treatment and prevention of osteoporosis, Paget’s disease, tumour 
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metastases in bone and skeletal disorders. The zolendronic acid (ZOL), a third generation 
bisphosphonates, displayed also strong inhibitory effect on the osteolysis and on the 
formation of lung metastases (Akiyama, Dass et al. 2008).  
In the case of drugs which inhibit bone formation an example is Atrasentan, which is an 
antagonist of ET-1 receptor (ETAR), reduced the incidence of bone metastases though it is 
not yet clear how ET-1 is involved in osteoblasts stimulation (Guise, Mohammad et al. 2006).   
Once the pre-clinical studies will give promising results with these new drugs, the next step 
is to investigate the role of PET imaging in humans. There are many parameters that need to 
be verified: first of all the feasibility of the use of three tracers in human patients in different 
days; secondly the possibility of combining PET with the histology and CT for the final 
planning of tumour type specific treatment modalities. This can only be achieved if the new 
drugs under investigation, which specifically target cellular processes, are found to be 
effective in experimental OS.  
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3.3 MATERIAL & METHODS 
3.3.1 CELL LINES 
The human OS cell line 143B was obtained from the European Collection of Cell Cultures 
(Salisbury, UK); murine LM8 OS cells were a kind gift from T. Ueda (Osaka National Hospital, 
Osaka, Japan). These cell lines were transduced with retroviral particles producing LacZ 
(including the neomycin resistance) as described by Arlt et al. and all the cells were kept in 
culture with DMEM-HamF12 (PAA GmbH, Cölbe, Germany) supplemented with 10% fetal calf 
serum and 1.2mg/kg of Neomycin (Invitrogen, Zug, Switzerland) for the 143B cells and 
2mg/kg of Neomycin for the SaOS-2 cells (Arlt, Banke et al. 2011).  Human SaOS-2 cells 
transduced with a caprin producing vector (including neomycin resistance) were kindly 
provided by Dr. Sabile (Sabile et al, Orthopedic University Clinic Balgrist Zurich, Switzerland-
submitted paper) and named SaOS-2/caprin-1. These transformed SaOS-2 cells were cultured 
in the same medium described above supplemented with 0.6mg/mL Neomycin.  
3.3.2 MOUSE MODELS 
Animal care and experiments were conducted in accordance with Swiss Animal Welfare 
legislation and were approved by the Veterinary Office of Canton Zurich, Zurich, Switzerland. 
Six to eight weeks old female immunosuppressed SCID and immunocompetent C3H mice 
were purchased from Charles River Laboratories (Sulzfeld, Germany), kept in pathogen-free 
conditions. The mice have always reached the mouse facility at least 1 week before starting 
any experiment. Before injection, cells were detached with trypsin-
ethylenediaminetetraacetic acid (EDTA), washed twice with PBS containing 0.05% EDTA and 
finally re-suspended in PBS-EDTA at a final concentration of 5x107 cells/ml. An aliquot of the 
cell suspension (10 µl) was orthotopically injected into the medullar cavity of the left tibia of 
the micePrimary tumour development was monitored by X-ray (Faxitron, Arizona, USA) 
weekly for 143B and LM8 cell-derived tumours and once every two weeks for SaOS-2/caprin-
1 cell derived tumours. The 143B injected mice were sacrificed between days 21 and 23 after 
tumour cell inoculation; LM8 mice on day 27 and SaOS-2/caprin-1 mice between days 61 and 
115. As said in the paragraph “OS animal models” the SaOS-2/caprin-1 tumour model 
showed a high heterogeneity in tumour development. 
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3.3.3 PRIMARY TUMOUR VOLUME 
Primary tumour was measured with a caliper once per week in the orthotopic 143B and 
subcutaneous and orthotopic LM8 models and twice per week in the SaOS-2/caprin-1 model. 
The volumes of the tumour and the control legs were calculated with the following formula: 
(LxW2)/2 where L is the length and W is the width of the leg. The control leg is used as a 
reference of the physiological bone growth therefore the final tumour volume is calculates 
as follows: Vtum -Vctr where Vtum is the volume in the tumour leg and Vctr is the volume in the 
control leg. 
3.3.4 RADIOTRACER SYNTHESIS 
The radiotracer synthesis was performed at ETH Hönggerberg in the Animal Imaging Center 
by Cindy Fischer and Mathias Nobst.   
18F-FDG was obtained from routine productions for clinical use at the University Hospital 
Zurich. 
3.3.5 PET SCANS 
Animals were transported to the PET facility for acclimatisation 5-7 days before the first PET 
scan. PET tracers were injected into a lateral tail vein in mice, except for 18F-FDG scans in 
143B and SaOS-2/caprin-1 mice (see below). 18F-Fluoride (20.4-46.7 MBq) and 18F-FMISO 
(16.1-44.6 MBq) were injected 90 min before the scan started; 18F-FDG (9.5-16.4 MBq) and 
18F-FLT (4.3-12.93MBq) 30 min before the scan started; 18F-FCH (9.25-14.17 MBq) and 18F-
FET (7.84-13.25MBq) 15 min before the scan started. Ten minutes before scan started, mice 
were anaesthetized in an incubation chamber containing 5% isoflurane (Abbott, North 
Chicago, USA) in a 1/1 mixture of air and oxygen and transferred to the PET/CT  scanner. To 
reduce muscle uptake of 18F-FDG in mice, anaesthesia with isoflurane was initiated as 
described above on a heating pad (Harvard Apparatus, Massachusetts, USA) 10 min before 
18F-FDG injection. Mice were then kept at 37°C body temperature under anaesthesia until 
the end of the PET scan.  
PET whole body images were acquired on a Vista eXplore preclinical PET/CT scanner (GE 
Healthcare, Glattbrugg, Switzerland) with 2 bed positions, 15 min each. During the scans, 
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mice were kept in anaesthesia with 2-3% isuoflurane in air/oxygen (200cc/min each) and 
monitored as previously described (Honer, Bruhlmeier et al. 2004; Honer, Hengerer et al. 
2006). PET was followed by a Computed Tomography (CT) scan in some of the experiments. 
The reconstruction and the coronal images were performed as described in Mumprecht et 
al. (Mumprecht, Honer et al. 2010). Coronal images in false colours were obtained with the 
PMOD software (PMOD technologies Ltd., Zurich, Switzerland). For direct comparison, the 
colour scales were normalized to injected radioactivity dose and body weight of the animal 
to reveal the standardised uptake value (SUV). All SUV scales were set to maximal values of 3 
for 18F-FDG, 0.75 for 18F-FMISO and 5 for 18F-Fluoride. Scale minimum was 0 for all tracers. 
PET imaging with 18F-FCH, 18F-FET and 18F-FLT was performed only in the orthotopic 143B 
and subcutaneous LM8 models: we did not use these tracers in the other models because 
the results within the 143B model were heterogeneous therefore for these tracers maximal 
intensity projection picture will be shown for the 143B model. For the subcutaneous model a 
short summary of the results will be given since we did not further investigate on this model. 
Mice were sacrificed after the last PET scan. 
3.3.6 X-Gal STAINING 
The procedure for the sacrifice of the mice is specifically optimized for the X-Gal staining that 
we perform on the lungs to visualise the metastases and on the legs to confirm presence of 
primary tumour. After intraperitoneal administration of a sleeping solution that contains 
10% Ketamin, 2% Xylazin and 10% Acepromazin, mice are open at the level of abdomen and 
thorax in order to remove the skin and reach the heart. After cutting the vena cava 10-15ml 
of PBS were injected into the right ventricle of the heart in order to get rid of the blood in 
the lung. Afterwards a clamp is applied on the vessels below the lung and above the liver in 
order to fix the lung with 3% PFA: one part of the 3% PFA (1.5ml) is given via the right 
ventricle while 2ml is injected through the trachea. Thereafter, another clamp is applied on 
the trachea. While the lung is being fixed, the primary tumour and the control leg are 
isolated and finally the lung is washed with PBS to clean it from the 3% PFA, excised, left in 
4% PFA and stained with 5-bromo-4-chloro-3-indolyl-b-D-galactoside (X-gal) for at least 3hrs 
as described previously (Arlt, Kopitz et al. 2002). Afterwards the organs are washed with PBS 
and kept at 4o C in 4% PFA for long-term storage. When the autoradiography of the lungs 
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was performed we used the same procedure for the sacrifice of the mice but we used the 
right middle and cranial lobes for the X-Gal Staining and the right caudal and the left lobes 
for the autoradiography (see next paragraph). 
3.3.7QUANTITATIVE ANALYSIS AND CALCULATION OF THE 
SENSITIVITY 
PET images were analysed drawing a region of interest (ROI) around the tumour and 
mirroring the area to the healthy control leg for all the PET slices where the tumour was 
visible: the sum of all the ROIs gives a volume of interest (VOI) and the activity concentration 
(counts/sec) that is a measure of the tracer accumulation in that specific VOI (Mikolajczyk, 
Szabatin et al. 1998). 18F-FDG uptake in the control leg of the mice, that were awake during 
and after tracer injection, was higher than in the tumour leg. In these mice, the hip was used 
as control. Fused PET/CT images were used to draw the ROIs in these mice (Fig.2.4). The 
average radioactivity concentrations in the tumour and healthy leg/hip were expressed as 
SUV and their ratios were calculated and compared in the three OS mouse models. Mice 
with too high radioactivity in the urinary bladder were excluded from the analysis. Sensitivity 
was calculated as number of mice with a detectable tumour in the PET imaging slices, as 
concluded by visual inspection by two independent blinded researchers, divided by the total 
number of mice. 
 
Fig.3.13: Imaging of the hip region that was used for the quantification of 
18
F-FDG uptake in the LM8 mouse 
model using x-ray (left panel); example of a PET/CT fused image that was used to draw the background region 
of interest. 
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3.3.8 HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
Primary tumour legs, after being at 4o C with 4% PFA for at least one night, were decalcified 
in Osteosoft® (Merck Chemicals, Darmstadt, Germany) for 1 week, embedded in paraffin for 
histological and immunohistochemical stainings. In the case of the 18F-FDG, 18F-FMISO and 
18F-Fluoride where we compare the tracers’ uptake in the different OS mouse models, we 
confirmed the results with immunohistochemistry (IHC) and histology. Therefore we used 
Ki67, marker of proliferation, CaIX, marker of hypoxia, and Trichrome Goldner staining were 
used. 6µm tumour sections were cut: histological analysis was performed with a Trichrome 
goldner staining kit following the instructions of the provider (Carl Roth GmbH, Karlsruhe, 
Germany); immunohistochemical analysis was carried out using rabbit polyclonal Ki67 
Antibody (Abcam, Cambridge, UK) and rabbit polyclonal CaIX Antibody (Novus Biologicals 
Ltd., Cambridge, UK). The staining was visible by peroxidase-based reaction using 
Vectastain® Elite ABC and a substrate-chromogen system (Dako, Baar, Switzerland). All the 
pictures were taken via visible light and 10x lens with a Zeiss Observer.Z1 inverted 
microscope (Zeiss 43) (Carl Zeiss MicroImaging GmbH, Göttingen, Germany).  
3.3.9 Ki67 AND CaIX INDEX 
Ki67 index was calculated as the total number of Ki67 positive nuclei (Ki67 localises in the 
nuclei) divided by the total number of nuclei. For this analysis immunofluorescence was 
performed, the primary Ki67 Antibody used was the same as described in the previous 
paragraph while the secondary was a fluorescent rabbit antibody (Alexa-Fluor 546, 
Invitrogen, Zug, Switzerland). DAPI was used as our reference for counting the total number 
of nuclei. The total and Ki67 positive cells are counted with Image J software that analyses 
the number of particles. We selected three slides per mouse taken at different depth and we 
took seven pictures per slide using a Nikon 40x lenses equipped with an appropriate filter 
block specific for DAPI and for the Alexa 536 Antibody (Nikon Corporation Eclipse E600, 
Tokio, Japan).    
CaIX index was calculated with the same formula as Ki67 index and in this case IHC was 
performed as described before. The analysis was performed visually counting the total 
number of cells with haematoxylin. In this case we selected three slides per mouse at 
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different depth and we took six pictures per slide using the same microscope Nikon 
microscope mentioned above. 
3.3.10 VESSEL AREA 
To calculate the vessel area in each tumour model, immunofluorescence using CD31 
antibody (Abcam, Cambridge, UK), marker for endothelial cells, was performed on 8um 
primary tumour sections: the procedure was the same as described in the previous 
paragraph. 
For each mouse three slides from different depth were cut, stained with CD31 and three 
pictures per slide were taken via visible light and 10x lens with a Zeiss Observer.Z1 inverted 
microscope (Zeiss 43) (Carl Zeiss MicroImaging GmbH, Göttingen, Germany).  
For the calculation of the vessel area we used the software Image J with a MACRO designed 
by Csaba Balazs (Light Microscope Center, ETH-Hönggerberg, Zurich).  
The percentages of vessels present in the whole area for the three sections were averaged 
and for each model the analysed mice were averaged: 5 mice in the case of 143B, 2 mice in 
the case of LM8 and 4 mice in the case of SaOS-2/Caprin-1 model.   
3.3.11 AUTORADIOGRAPHY OF THE LUNGS 
To perform autoradiography on the lungs of the mice, the mice were first scanned by PET 
imaging and later sacrificed to perfuse and excise the organs, lungs were embedded in OCT 
(Optimal Cutting Temperature) embedding medium and snap-frozen. The autoradiography 
was performed only on lungs of mice injected with 18F-FDG, 18F-FMISO and 18F-Fluoride: one 
mouse for the 143B model and one mouse for the SaOS-2/caprin-1 model were used for 
each tracer. Mice lungs from LM8 model were not analysed since this model does not 
metastasise in the lung. Lung sections of 20um thickness were cut and exposed to a 
FUJIFILM BAS-MS2025 based imaging plate and developed with a BAS 5000 phosphor imager 
to reveal the tracer uptake. A mouse that did not receive tumour cell injection and where 
the different tracers were injected was used as our background reference for the 143B and 
SaOS-2/caprin-1 models. After lung autoradiography, the same sections were stained for 
H&E to confirm the presence of metastases. 
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3.3.12 STATISTICS 
Statistical analysis was performed with GraphPad Prism® 5.01 Network. The ratios between 
the tumour and the control SUVs were compared among the three OS models by two tailed 
Student’s t-test and the p-value <0.05 was evaluated as statistical significant and p-value 
<0.01 as highly statistical significant. The SUV values in the table were reported as Mean ± 
SEM.  
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4 EVALUATION OF EFFICACY OF 
PHOTODYNAMIC THERAPY IN OS  
4.1 RESULTS 
In this chapter the second project of this thesis will be presented with a focus on the in vitro 
and in vivo results, on the discussion, outlook and on the material and methods used to 
achieve the results.  
4.1.1 HIGHER PS UPTAKE IN THE HIGHLY METASTATIC OS CELL  
Foslipos® uptake was evaluated in two different OS cell systems consisting of parental low 
metastatic cell lines (HOS and MG63) and derivative high metastatic cell lines (143B and 
MG63-M8). The uptake was analysed over 24hrs and each parental cell line was compared to 
its derivative: y-values were calculated considering the value at 24hrs in the parental cell 
lines as 100%.  
In both cell line systems there is a higher uptake in the highly metastatic cell line compared 
to the low metastatic ones which is visible already 2hrs after PS addition (Fig. 3.8).  
In order to confirm this finding we decided to focus on one cell line system (HOS-143B). For 
the 143B cell line system, the mouse model is also well established. In this cell line system 
we measured the Foslipos® uptake in a time- and dose-dependent way. Furthermore the 
results were normalized to the cell area which was approximated to the one of a sphere and 
to the total number of cells (Fig. 3.9). In accordance with the previous findings the highly 
metastatic 143B cells take up more than the low metastatic cell line in a dose- and time-
dependent way. Indeed an increase of intracellular concentration of Foslipos® between 340 
and 520 times could be detected 5hrs after incubation with the concentration of 10µgml-1 
Foslipos®. In view of these observations and of a future in vivo validation of PDT for the 
treatment of metastasising OS, additional experiments in vitro have been performed using 
only the highly metastatic 143B cell line, because, in vivo, different from their parental low 
metastatic HOS cells, these cells generate an aggressive form of OS in an intratibial xenograft 
model in SCID mice: metastases as in the human situation are found mainly in the lung. For 
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the in vivo experiment we made use of LacZ tagged cells which enables us to confirm the 
presence of primary tumour and to visualise the metastases ex vivo.   
  
 
Fig.4.1: Foslipos® uptake over time in two human OS cell line systems: (A) Parental cell line HOS (yellow) and its 
corresponding highly metastatic subline 143B (red), (B) Parental cell line MG-63 (light blue) and its 
corresponding highly metastatic subline M8 (dark blue).  Data represent means +/- SEM (n ≥ 3). 
 
 
 
Fig.4.2: Foslipos® uptake in one human OS cell line system: (A) Time-dependent uptake in parental cell line HOS 
(orange circles) and its corresponding highly metastatic subline 143B (dark red squares), (B) Dose-dependent 
uptake in parental cell line HOS (orange columns) and its corresponding highly metastatic subline M8 (dark red 
columns).  Data represent means +/- SEM (n ≥ 3). 
 
In the 143B cells we investigated the uptake using a confocal laser scanning microscope for 
an evaluation of the subcellular localisation of Foslipos®, therefore the cells were incubated 
with increasing concentrations of Foslipos® for 5hrs and we found that Foslipos® mainly 
localises in the cytoplasm around the nuclei (Fig.3.10). The Foslipos® uptake became 
detectable in all cells at a concentration of Foslipos® ≥ 0.6 μgml-1. The absence of nuclear 
localisation implies that the Foslip® is not genotoxic and therefore it does not induce further 
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replication of newly mutated cells that can be more aggressive or resistant to further 
treatments. 
 
 
Fig.4.3: Confocal microscopy pictures of Foslipos® uptake in 143B cells after incubation with different 
concentration of the PS: DAPI was used to highlight the nuclei and the merge between the two channels was 
used to confirm the cytosolic localisazion of Foslipos®.   
4.1.2 143B CELLS ARE HIGHLY SENSITIVE TO THE PDT TREATMENT 
After measuring the uptake of Foslipos® in the 143B, we, afterwards, investigated the effect 
of dark- and photo-toxicity of the PS on the cells. 143B cells were incubated with different 
concentration of PS for 5hrs and kept either in the dark or illuminated with 652nm light. 
After 24hrs, a WST-1 assay was performed to measure the cell viability and cell number was 
counted in the different conditions (with or without illumination). Dark-toxicity in the cells 
was visible in a decrease of cell viability and in the number of cells only with concentrations 
of Foslipos® higher than 2.5 μgml-1 (Fig. 3.11A). Phototoxicity was already detectable at 
doses of 0.075 µgml-1 Foslipos® or higher, independent of the light dose and was dependent 
on the concentration of Foslipos® and on the laser light dose which was used (2.5, 5, 10Jcm-
2) (Fig. 3.11B). Half-maximal lethal doses (LD50) of Foslipos® in cells illuminated with the 
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different laser light dose ranged from 0.012 µgml-1 (+/-0.008 SEM) to 0.047 µgml-1 (+/-0.007 
SEM).  
 
Fig.4.4: Dark- and photo-toxicity in 143B cells after incubation with different concentrations of Foslipos® for 
5hrs: (A) 143cells received PS but were kept in the dark (dark-toxicity); (B) 143B cells received PS and were 
illuminated (photo-toxicitiy) Data represent means +/- SEM (n ≥ 3). 
In summary 143B cells are sensitive to PDT but mechanism for the induction of the cellular 
death is not yet clear. 
4.1.3 APOPTOSIS -INDUCED PHOTO-TOXICITY 
To clarify the mechanism that is responsible for the PDT-mediated cellular death, we focused 
on the apoptosis which is known in the literature to be the most common mechanism 
activated after PDT.   
We checked for apoptosis activation by western blotting after incubating the cells with 
Foslipos® for 5hrs and illuminating them with 5Jcm-2 energy dose. Caspases and PARP 
cleavage, implying apoptosis activation, occurs already 90min after illumination with 0.6um 
ml-1 demonstrating the direct induction of apoptosis after PDT. Indeed the cells kept in the 
dark did not show any unspecific activation of the apoptosis (Fig. 3.12A). To further confirm 
the specificity of the PDT-mediated apoptotic stimulation, we used the pan-caspase 
inhibitor, Z-VAD-FMK, in different concentrations (50µM and 100μM). The incubation with Z-
VAD-FMK for 1hr before the illumination suppressed the caspase-dependent PARP cleavage 
in a dose-dependent manner (Fig. 3.12B). 
  
 
113 
 
Fig.4.5: PDT-mediated apoptosis in 143B cells after 5hrs incubation with Foslipos®: (A) cleavage of PARP, 
caspase 3, 7 and 9 was evaluated after 5hrs incubation of the cells with different concentration of Foslipos® 
and then illuminated with 5Jcm
-2
 or kept in the dark; (B) inhibition of PARP PDT-induced cleavage after 1hr 
incubation with a pan-caspase inhibitor (Z-VAD-FMK) before illumination was performed. 
4.1.4 HIGHLY SELECTIVITY OF PS UPTAKE IN VIVO 
For the in vivo experiments we used Foslip, as mentioned in the Material & Methods part, 
which differs from Foslipos® only for the dissolving liquid: 5% glucose in the case of Foslip® 
and water in the case of Foslipos®. Further we made use also of LacZ tagged cells for the 
indentification ex vivo of metastatic foci. The uptake in vivo was evaluated with two OS 
mouse models: one xenograft and one syngeneic where human 143BLacZ and murine 
LM8LacZ cells respectively were injected into the left tibia. The reason why we used both 
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models is dependent on the in vivo results about the treatment studies that will be 
described in the next paragraph. Briefly the absence of a curative effect after PDT in the 
xenograft model can be related to the lack of T-cell response in the xenograft model 
therefore we decided to further investigate the Foslip® uptake a syngeneic OS mouse model 
where the immune system is totally functional.    
Concerning the 143BLacZ model the uptake experiment was started on day 21 when the 
mice showed an average volume of 106mm3. In general the three mice showed a similar 
pattern of tumour growth over the three weeks (Fig.3.13). 
 
 
Fig.4.6: Tumour growth curve of three 143BLacZ tumour bearing mice.  
 
This preliminary experiment showed high specificity of the Foslip® uptake in the tumour leg 
as it is visible in the spectrum of a representative mouse that covers wavelength from 550 to 
800nm. A single peak is visible at 652nm with a value of 153 relative fluorescence units (RFU) 
(excitation wavelength of the Foslip®) which reaches the highest value 6hrs after intravenous 
injection of the PS (Fig. 3.14A).  
When we combine the results of the three mice we observe that the peak of uptake at 6hrs 
is consistent in all three mice. The limited number of mice used in this experiment does not 
allow us to evaluate and explain the second peak at 24hrs that was also observed by Biolitec 
in other animal models but in our case it can also depend on the high standard deviation 
that we can see at 12 and 24hrs (Fig. 3.14B).  
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Fig.4.7: Foslip® uptake in vivo in the primary tumour leg measured at different time points after intravenous 
injection of 1.5mgkg
-1 
of Foslip®: (A) spectrum from 550 to 800nm of the tumour leg uptake of one 
representative mouse with the peak at 652nm; (B) averaged relative fluorescence units (RFU) of the three mice 
tumour leg over time after Foslip® injection. Values are represented as means +/- SEM (n ≥ 3).  
Foslip® uptake in these three mice was measured also in the liver and in the lung: both 
organs showed a similar pattern of uptake with the highest peak 6hrs after Foslip® injection. 
Then slowly the RFU over time decreased. Interestingly the RFU values in the lung and liver 
were much lower than in the primary tumour (167.1±55.1) which underlines the high 
specificity of this compound for tumour tissue. Furthermore we observed also that the lung 
uptake was higher at 6hrs more (50.94±1.41) than the one measured in the liver (33.7±3.4) 
which is explainable with the presence of pulmonary metastases that can take up more 
Foslip® compared to the liver which is the organ of metabolism (Fig. 3.15).    
 
Fig.4.8: Foslip® uptake in vivo in the lung and in the liver measured at different time points after intravenous 
injection of 1.5mgkg
-1 
of Foslip®. Values are represented as means +/- SEM (n ≥ 3). 
In the LM8LacZ model the procedure of the experiment was the same and we performed 
two experiments. In the first experiment the mice received the injection with 1.5mgkg-1 of 
Foslip® at day 25 after tumour cell injection. The time point was chosen on the basis of the 
tumour growth. The mouse, named “Mouse 1”, was the only one with a large tumour 
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growth (762mm3) at day 20 after tumour cell injection while the “Mouse 2” showed a final 
tumour volume of 43.21mm3 (Fig. 3.16).  
 
Fig.4.9: Tumour growth curve of two LM8LacZ tumour bearing mice.  
The other 7 mice had to be sacrificed before the uptake experiment could be started due to 
high frequency of metastases in several organs. Despite the remarkable difference in the 
tumour volume the pattern of uptake in these two mice was similar in respect to each other 
but quite different compared to the 143BLacZ model because the uptake in the tumour leg 
increased over time till 48hrs and the RFU values are 3 to 5 fold lower compared to 
143BLacZ. Mouse 1 shows a peak of 57.9 at 48hrs and the mouse 2 shows a peak of 32.3 at 
48hrs (Fig. 3.17).  
 
Fig.4.10: Foslip® uptake measured in the primary tumour (tumour) and healthy legs (ctrl) in two different LM8 
mice (MOUSE 1 and 2). 
Furthermore mouse 2 shows a drop in the value at 24hrs but this can be due to an error in 
the measurement. Differently from the previous uptake experiments performed with 
143BLacZ model, we measured here also the Foslip® uptake in the control healthy leg to 
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confirm the specificity of tumour uptake and indeed we could detect a real specific signal in 
none of the measured time points. 
In the second experiment the uptake study was started a bit earlier, at day 21 after tumour 
cell injection in order to have a higher number of mice and in total we could measure 7 mice. 
The tumour growth curve shows that the tumour volume of the 7 mice was quite small with 
an average of 21.7mm3 (Fig. 3.18). 
 
 
Fig.4.11: Tumour growth curve of seven LM8LacZ tumour bearing mice: second round of uptake experiment.  
 
The uptake results from the second round of mice were quite different compared to the first 
one. The tumour leg and the control leg do not show any difference in Foslip® uptake and 
the RFU values are so low that one could consider this signal as background (Fig. 3.19).  
 
  
Fig.4.12: Foslip® uptake over 48 hrs measured in the primary tumour (tumour) and healthy legs (ctrl): average 
of the uptake from 7 mice is shown in the graph.  
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One explanation for this is that the tumour volumes of the second round of mice were so 
small that it was difficult to penetrate deeply with the optic fiber since the excitation 
wavelength is 405nm. When the tumours are larger, there are higher chances to touch with 
the optic fiber the tumour region.  
4.1.5 OPTIMIZAZION OF PDT PROTOCOLS FOR OS TREATMENT IN 
MICE  
Treatment studies were performed in a xenograft OS mouse model where 143BLacZ cells 
were injected in the left tibia of the mice. As mentioned in the Material & Methods 
(Treatment protocol) we decided to be as close as possible to the human situation starting 
the treatment only when the tumour could be visualised by x-ray. In the 143BLacZ model 
which is well established, we usually manage to see some lytic lesions which are typical of 
this model at day 14.  
In the first study we selected Foslip® concentrations of 0.15mgkg-1 which is applied 
successfully in various subcutaneous mouse models (see the Discussion). The main question 
of this first experiment was the determination of the most effective energy dose between 10 
and 40Jcm-2. The study consisted of 6 groups of mice among which 4 were negative controls. 
The scheme is shown below (Table 3.2): the first two groups included mice that received 
0.15mgkg-1 and either 10 or 40Jcm-2; the third group of mice received only Foslip®; the 
fourth and fifth groups of mice received only the energy dose of 10 or 40Jcm-2 and the last 
group did not get any injection. 
 
 
Table 4.1: Scheme with the description of the 6 groups of mice used in the first PDT experiment. 
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To analyse the effect of the PDT treatment on this OS mouse model we, qualitatively, 
evaluated the amount of lytic lesions present in the x-rays, calculated the primary tumour 
volume and counted the number of metastases.  
No effect was visible in the four negative control groups demonstrating that the single 
elements (Foslip® or energy dose) do not have any effect on their own.  
Surprisingly the treatment induced strong side effects and complications in the mice treated 
with 40Jcm-2 and 0.15mgkg-1 therefore we had to sacrifice the mice the day after performing 
the treatment (day 15) and they were not included in our further evaluation.  
The other treated group of mice (0.15mgkg-1 plus 10Jcm-2) showed a strong swelling with a 
starting process of necrosis at the level of the leg where the illumination was performed 
within 1 week from the treatment (day 21) therefore we decided to finish the experiment at 
this time point.  
In the four negative controls groups tumour growth was comparable and no significant 
difference was noticed in the tumour volume; instead, the treated group (Foslip® plus 
10Jcm-2) shows a non-significant but larger tumour volume compared to all the other groups 
which is provoked by the swelling process that was induced by PDT (Fig. 3.20).  
Since this process did not regress and the legs started to be necrotic we decided to repeat 
the experiment and change the treatment protocol by reducing the concentration of Foslip®. 
 
Fig.4.13: Tumour growth curve of the different groups of 143BLacZ tumour bearing mice: one group received 
Foslip® and energy dose (10Jcm
-2
); one group received only Foslip®; the other two groups received only energy 
dose (either 10Jcm
-2
 or 40Jcm
-2
) and the last group received neither Foslip® nor energy dose. 
X-ray pictures do not show any visible difference in the extent of lytic lesions in the left tibia 
of the mice (Fig. 3.21). 
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Fig.4.14: Representative x-ray pictures of a mouse from each different group: the x-ray pictures were taken at 
day 20 after tumour cell injection. The last picture is from the control non injected healthy leg for comparison. 
Interestingly macro-metastases (diameter >0.2mm) did not significantly differ in the five 
groups while micro-metastases (diameter <0.2mm) were significantly lower in the treated 
group compared to two negative control groups: the group that received only Foslip® or only 
the energy dose of 10Jcm-2 (p<0.05). The difference in the number of micro-metastases was 
not significantly different comparing the treated group with the untreated one because of 
high heterogeneity in the last mentioned group (p=0.1023) and close to significance 
compared to the group that received only energy dose (40Jcm-2) (p=0.0615) (Fig. 3.22). 
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Fig.4.15: Graphs showing the number of micro- (diameter < 0.2mm) and macro-metastases (diameter > 0.2mm) 
in the five different groups. 
In summary we conclude that the PDT protocol used in this first experiment has to be 
further optimized and we can assess that if PS and energy dose are not combined no effect 
can be visualised since the negative controls group did not show any difference in tumour 
growth, osteolysis and number of metastases.  
In order to find an optimal concentration of Foslip® that would have an effect without 
causing strong effect in the mice we designed a second treatment study. In this experiment 
we kept the energy dose of 10Jcm-2 and reduced the Foslip® concentration to 0.05, 0.015 
and 0.005mgkg-1. As a negative control mice received only the highest dose of Foslip® among 
the ones used for the treatment (0.05mgkg-1) (Table 3.3).  
As for the first experiment, also in this experiment the treatment was started at day 14 when 
lytic lesions could be visualised by x-ray in all the mice. 
 
 
Table 4.2: Scheme with the description of the 4 groups of mice used in the second PDT experiment. 
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The tumour volume was comparable in 3 of the 4 groups. In the group where mice received 
0.015mgkg-1, the mice showed in tendency a higher tumour volume which is not statistically 
significant and supposingly not dependent on the treatment (Fig. 3.23). 
 
Fig.4.16: Tumour growth curve of the different groups of 143BLacZ tumour bearing mice: either they received 
Foslip® with a specific dose (0.05, 0.015 or 0.005mgkg
-1
) and energy dose of 10Jcm
-2
 or only 0.05mgkg
-1
 of 
Foslip® (negative control). 
The x-rays show that the mice treated with 0.05mgkg-1 and an energy dose of 10Jcm-2 have a 
smaller extent of osteolysis around the tibia compared to the mice from the other three 
groups: the control non injected healthy leg is shown to evaluate the degree of the lysis as 
non-lytic bone (Fig. 3.24).   
 
Fig.4.17: Representative x-ray pictures of a mouse from each different group: the x-ray pictures were taken at 
day 20 after tumour cell injection. The last picture is from the control non injected healthy leg for comparison. 
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Fig.4.18: Graphs showing the number of micro- (diameter < 0.2mm) and macro-metastases (diameter > 0.2mm) 
in the five different groups. 
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4.2 DISCUSSION & OUTLOOK 
The focus of this study was the evaluation of the efficacy of PDT in OS in vitro and in vivo. 
In vitro we investigated two different OS cell line systems consisting of the highly metastatic 
human 143B and MG63-M8 cell lines and their respective low metastatic parental cell lines 
HOS and MG63. Importantly, we showed that the highly metastatic 143B and MG63-M8 OS 
cells take up more PS than the low metastatic parental HOS and MG63 cells (Reidy, 
Campanile et al. 2012). To our knowledge, previous studies exclusively compared the uptake 
of PS in tumour tissue with that in normal tissues, but the uptake by low and highly 
metastatic tumour cells has so far not been compared. Differences in uptake between 
normal and tumour tissue have been explained by higher proliferation rates of tumour 
compared to normal cells, by a high permeability or leakage of tumour blood vessel, low pH 
values in tumour tissue and by non-functional lymphatic drainage (Jori 1996; Juzeniene, 
Peng et al. 2007). If active uptake of PS is considered, the differences in uptake between low 
and highly metastatic tumour cells may be explained by different levels of transporter 
protein expression. Such mechanisms have not been examined here and need to be 
investigated in future studies. 
In preparation for future investigations in vivo, additional in vitro experiments focused 
exclusively on the 143B cell line that, upon injection into the tibia of SCID mice, precisely 
reproduces the subtype of the human disease with a primary osteolytic bone tumour that 
predominantly metastasises to the lung.  
In 143B cells, we first examined the subcellular localisation of PS. Confocal microscopy 
revealed perinuclear accumulation of the PS observed over time. This finding is consistent 
with that of Lassalle et al., who observed in HeLa cells accumulation of PS also preferentially 
in the perinuclear region (Lassalle, Wagner et al. 2008). In contrast, another study in MCF-7 
cells showed a selective uptake in the endoplasmic reticulum and in the Golgi apparatus 
(Teiten, Bezdetnaya et al. 2003). Moreover, in human nasopharyngeal carcinoma and murine 
myeloid leukemia cells the PS was found localised predominantly in the mitochondria and in 
colon carcinoma PS was observed in lysosomes (Kessel 1999; Yow, Chen et al. 2000; Leung, 
Sun et al. 2002). Interestingly, these differences in subcellular accumulation had no effect on 
PDT efficacy in the different cell types (Reidy, Campanile et al. 2012).  
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Dark- and photo-toxicity of the photosensitizer mTHPC used in our studies in 143B cells were 
observed at concentrations ≥ 2.5µg/ml and ≥ 0.075 µg/ml, respectively, upon incubation of 
the cells with PS for 5 hrs. Previous studies in gall bladder and bile duct cancer cells revealed 
dark-toxicity at 10-100 µg/ml PS after 20 hrs of incubation. This suggests that 143B cells are 
more sensitive to PDT than other tumour cell lines (Kiesslich, Berlanda et al. 2007). This is 
also reflected by the photo-toxic potency of mTHPC in 143B cells. The LD50 of mTHPC at a 
laser-light dose of 2.5 J/cm2 was 0.047 µg/ml (±0.007 SEM), which is 10 times less than what 
was reported for human colon carcinoma (LD50 0.45 ± 0.15 µg/ml at 3 J/cm
2) (Leung, Sun et 
al. 2002; Reidy, Campanile et al. 2012). A similar result was obtained in gall bladder and bile 
duct cancer cells with the same formulation Foslip® used in our study. The respective LD50 
were 0.061 and 0.056 µg/ml at 1.5 J/cm2 illumination (Kiesslich, Berlanda et al. 2007). Of 
note, the study with the human colon carcinoma cells was performed with a different 
mTHPC formulation (Foscan®) and an incubation time of 20 hrs, which can definitively 
influence the results. Indeed, the liposomal formulation increased the speed of PS uptake in 
the tumour cells since they express high levels of lipoproteins in the plasma membrane 
(Guelluy, Fontaine-Aupart et al. 2010). Taken together, the high sensitivity of 143B cells to 
mTHPC-mediated PDT is promising for future treatment studies in vivo.  
In view of these promising results, it was of particular interest to investigate the mechanisms 
of cell death provoked by PDT, which apparently differs in different cell types. In 143B cells 
we observed caspase-dependent apoptosis already at 90 min after activation of the PS laser-
light illumination. Other studies showed the same result. Apoptosis rather than necrosis was 
an important finding because necrosis induces a stronger inflammatory response than 
apoptosis and consequently more severe side effects (Leung, Sun et al. 2002; Oleinick, 
Morris et al. 2002; Juarranz, Jaen et al. 2008).  
It is well established that apoptosis in response to PDT frequently occurs in cancer in which 
PS is localised in the mitochondria. Autophagy, on the other hand, is believed to occur 
primarily in cells that accumulate PS in late endosomes, the endoplasmic reticulum and 
mitochondria. Autophagy has also been observed in cells expressing defective apoptosis 
signaling molecules. This has been demonstrated in the human mammary carcinoma cell line 
MCF with a mutation affecting the activity of caspase-3 (Guelluy, Fontaine-Aupart et al. 
2010; Reiners, Agostinis et al. 2010). In summary, the results of the here presented in vitro 
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studies justify investigations in vivo to optimize PDT protocols in orthotopic OS mouse 
models that reproduce the human disease. 
The aim of a first series of experiments was the evaluation of the uptake of the liposomal 
formulation Foslip® of mTHPC and of the effects of illumination on primary tumour 
development and lung metastasis in order to move a step forward towards an intraoperative 
application of PDT in OS. 
In the 143B cell-derived intratibial OS model in SCID mice, the uptake of intravenously 
administered Foslip® peaked at between 6 and 24 hrs. A similar study performed in a mouse 
model of mammary sarcoma showed maximal uptake of Foslip® at between 6 and 15 hrs, 
which is in good agreement with our study (Lassalle, Dumas et al. 2009). Comparable results 
were also found when a pegylated mTHPC (Fospeg®) was used in a mouse model of 
mammary tumours. The peak of PS uptake in the tumour was reached 15 hrs after PS 
injection. Foscan®, a formulation of mTHPC, in ethanol and propylene glycol, on the other 
hand, showed a maximal uptake by tumour tissue at between 24 and 48 hrs after PS 
injection (Lassalle, Dumas et al. 2009). These findings pointed to a faster uptake of liposomal 
and pegylated formulations of mTHPC by tumour cells. Along these lines it was suggested 
that the pegylation does not increase the amount of internalized PS into the cell, but, as 
described previously, increases the stability of the molecule in the circulation by reducing 
the kidney clearance and interactions with cellular membrane proteins (Harris and Chess 
2003). 
A next series of here reported experiments aimed at optimizing a PDT treatment efficacy in 
our orthotopic OS mouse model. Previous PDT studies in experimental tumour models in 
mice were exclusively carried out in subcutaneous models addressing questions concerning 
PS bio distribution and effects of tumour oxygenation on the success of PDT treatment 
(Chen, Huang et al. 2002; D'Hallewin, Kochetkov et al. 2008; Lassalle, Dumas et al. 2009). In 
these studies, side effects of PDT treatment, such as damage to healthy organs, tissues and 
blood vessels close to the tumour were not considered. A comparison between the results 
presented here and those of studies with subcutaneous models showed that the treatment 
conditions need to be redefined in orthotopic models. PS doses tolerated and not causing 
severe side effects due to damage of healthy tissue in our intratibial OS mouse model 
amounted to between 0.05 and 0.1mg/kg mTHPC, whereas in subcutaneous models 
routinely used mTHPC doses were between 0.15 and 0.3 mg/kg. Mice with intratibial OS, 
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treated in the here reported study with 0.15 mg/kg mTHPC, showed a strong inflammatory 
response, reflected by tumour leg swelling, and areas of necrotic skin and subjacent tissue 
were observed in the illuminated leg.  
The PDT treatment efficacy was also remarkably low. Despite a reduction in lytic lesions 
recognized by X-ray in treated compared to control animals, the primary tumour volumes 
were indistinguishable. A significant reduction in the number of pulmonary micro-
metastases was only observed in the group of mice that received 0.15 mg/kg mTHPC and, 
consequently, as outlined above, developed serious adverse effects (necrosis and swelling) 
in the tumour leg. 
Plausible explanations for the low efficacy of PDT in our study are provided by a paper of 
Korbelik et al. (Korbelik, Krosl et al. 1996). This study compared tumour responses to PDT in 
BALB/c, nude and SCID mice. Interestingly, PDT was curative in the BALB/c mice but not in 
the nude and SCID mice. These findings suggested that the lack of a fully functional immune 
system in nude and SCID mice impaired PDT efficacy. This interpretation of the data was 
further supported by the observations that only bone marrow transplantations and not only 
a T-cell transfer rescued the PDT efficacy in immune compromised such that it became 
comparable to that observed in immunocompetent BALB/c mice. From all these 
observations, we conclude that effective PDT is dependent on a two-phase activation of the 
immune system. First, PDT activates the migration of myeloid inflammatory cells to the 
tumour and second it triggers a long lasting T-cell reaction (de Vree, Essers et al. 1996; 
Korbelik, Krosl et al. 1996).  
Thus, additional studies in a syngeneic mouse OS model providing an intact immune system 
are required, but the here presented study revealed helpful data for a final optimization of a 
PDT protocol for the treatment of intratibial OS in mice. 
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Additional experiments are needed in order to further evaluate the potential of PDT for 
intraoperative treatment of OS in patients. 
Based on the here presented result, PDT experiments need to be done in animals with an 
intact immune system that sustains the treatment effect. The SCID mice lack a T-cell 
response and therefore cannot reproduce an adaptive immune response, which is needed 
for a fully effective PDT. Thus, and OS model in mice with an intact immune system that fully 
reproduces human OS is needed. Unfortunately, the syngeneic intratibial LM8 OS that has 
been established in the laboratory metastasises to the ovaries, the kidney, the liver and the 
lung, a pattern that is not observed in OS patients. Accordingly, we are currently in the 
process of establishing two new orthotopic syngeneic mouse models with the parental low 
metastatic mouse OS cell line K12 and the highly metastatic K7M2 derivative thereof with 
these two models we aim at reproducing predominant lung metastasis in experimental OS. 
A success-limiting property of PDT in experimental and clinical applications is the remarkably 
low selective uptake of PS by tumour compared to healthy tissue. The uptake experiments 
performed in this thesis showed that the tumour leg takes up more PS than the liver or lung. 
The liposomal formulation that we used in the here presented study is considered to 
improve the selective uptake of the PS by tumour tissue. However, in recent years, new 
efforts have been made to conjugate PS to antibodies selective for tumour cell surface 
proteins in order to more specifically target tumour cells for PDT. Together with the only 
local illumination of tumour affected tissue, this considerably enhances the tumour 
selectivity of the treatment. In collaboration with Prof. Patrick Boisseau (Grenoble, France) 
and with Biolitec (Jena,Germany) a new project was started in 2010 aiming at the generation 
of mTHPC containing nanoparticles decorated with antibodies to CXCR4, which is abundantly 
expressed on the surface of some OS tumour cell lines. Depending on the results obtained 
with antibody-coated-nanoparticles, the next step is to aim for a clinical application. 
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4.3 MATERIAL & METHODS 
4.3.1 MATERIAL AND OS CELL LINES 
Foslipos® and Foslip®, two liposomal formulations of the PS called 5,10,15,20-tetrakis(meta-
hydroxyphenyl)chlorine (mTHPC), were kindly provided by Biolitec AG, Jena, Germany in a 
9:1 mixture of dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylglycerol 
(DPPG) (>99% purity). Foslipos® was finally dissolved in water while Foslip® in 5% with a final 
concentration of 1.5mgml-1 mTHPC. Human OS low metastatic parental HOS (CRL 1543) cells 
were obtained from the American Type Culture Collection, Rockville, MD while the highly 
metastatic derivative 143B cells were purchased from ECACC (Salisbury, UK). HOS and 143B 
cells used in this study were stably transduced with a LacZ gene (143BLacZ, HOSLacZ cells), 
which will be needed in future in vivo studies  for post-mortem visualisation of X-gal stained 
tumor tissue and metastases in mouse models at high sensitivity and resolution as reported 
previously (Arlt, Banke et al. 2011). Human OS low metastatic parental MG63 cells were 
kindly provided by Dr. G. Sarkar (Mayo Clinic, Rochester, MN, USA) while the highly 
metastatic derivative MG63-M8 by Dr. W.T. Zhu (Tongji Hospital, Huazhong University of 
Science and Technology, Wuhan, China): both cell lines were used only in vitro to confirm 
the uptake results in two different cell systems, therefore they are not LacZ tagged. MG63 
and MG63-M8 were cultured in a humidified atmosphere of 5% CO2 in DMEM (4.5 g/l 
glucose)/Ham F12 (1:1) supplemented with 10% heat-inactivated FCS (cell culture medium). 
143BLacZ and HOSLacZ were cultured in the same medium described above with the 
addition of 1200μgml-1 G418 for selection for neomycin resistance and stable expression of 
the LacZ gene. Experiments were also performed under these conditions. The pan-caspase 
inhibitor Z-VAD-FMK (BD Pharmingen AG, Allschwil, Switzerland) was administered to the 
cells at 50 or 100µM 1 h prior to illumination until harvesting. 
4.3.2 FOSLIPOS® UPTAKE 
All the cell lines were seeded in 96-well plates (10’000 per well) and incubated at different 
time points (from 0 to 24hrs) with 2.5μgml-1. After each time point the fluorescence intensity 
was measured at 652nm after excitation at 452nm with a Spectramax Gemini XS plate 
reader (Molecular Devices, Sunnyvale, CA) and the values from 143BLacZ and MG63 in the 
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individual graphs were normalized to that of the respective parental, low metastatic cell 
lines HOSLacZ and MG63-M8 at 24 hours (100%).  
In order to get a fluorescent value that would take into account the diameter and the 
number of the cells HOSLacZ and 143BLacZ cells were seeded in 6-well plates (0.2 x 106 cells 
per well) and allowed to adhere overnight. They were then incubated with the same 
concentration of Foslipos® (0.6μgml-1) for 2.5, 5 or 10hrs or with indicated concentrations of 
Foslipos® (0-10 μgml-1) for 5hrs in the dark. The medium was removed and the cells were 
washed three times with PBS. They were then detached with trypsin/EDTA, centrifuged at 
400 x g for 5min, washed twice with PBS, collected by centrifugation and the cell pellets 
were resuspended in PBS. Intracellularly accumulated Foslipos® was quantified by measuring 
the fluorescence of 20’000 cells in 100μl PBS at 652nm with excitation at 417nm with a 
Spectramax Gemini XS plate reader (Molecular Devices, Sunnyvale, CA). A standard curve 
with known dilutions of Foslipos® in 100μl PBS was used for quantification. The mean 
diameter of cells in suspension was calculated from 20 trypsinized cells with a Zeiss 
Observer.Z1 microscope (Axio Observer, Axio Vision Release 4.6.3 SP1, Jena, Germany) and 
the cell volume calculated with the equation for spheres. Foslipos® fluorescence was then 
normalized to the cell volume. Subcellular localisation of Foslipos® by confocal laser scanning 
microscopy (CLSM) was carried out with 30`000 cells per well seeded on coverslips in 24-well 
plates and grown for 48 hrs. The cells were incubated at 37°C for 5hrs in cell culture medium 
containing indicated concentrations of Foslipos®. Subsequent manipulations were all carried 
out at room temperature. The cells were first washed once with PBS and then fixed with 4% 
paraformaldehyde for 10min and washed three times with PBS. Cells were then 
preincubated in PBS/0.1% BSA/0.1% saponin for 10min and subsequently stained with 
0.3nM DAPI in PBS/0.1% BSA/0.1% saponin for 15min in the dark. After another 3 washing 
steps with PBS/0.1% BSA/0.1% saponin, cover slips were briefly rinsed with tap water and 
mounted with Immumount (Thermo Shandon, Pittsburg, PA). CLSM was done with a Leica 
SP5 confocal microscope (Leica, Heidelberg, Germany; Center of Microscopy at the 
University of Zurich). Fluorescent probes were excited at 405nm (DAPI) and 415nm 
(Foslipos®) and emitted light collected at 435-468nm for DAPI and at 591-705nm for 
Foslipos®. CLSM images of 1024 x 1024 pixel size in 8 bit were recorded under an oil 
immersion objective with a 63-fold magnification and a numerical aperture of 1.4. The 
  
 
133 
pinhole diameter was set to 1 Airy unit with a size of 114.74μm. Images were processed with 
Leica LCS Lite software. 
4.3.3 CYTOTOXICITY ASSAY 
143B cells were seeded at a density of 3’000 cells per well in 96-well plates and allowed to 
adhere overnight. The cells were incubated with Foslipos® in cell culture medium at 
indicated concentrations for 5hrs in the dark. The medium was then removed and the cells 
washed twice with 100μl PBS before 100μl fresh medium were added. The cells were then 
either kept in the dark or illuminated with a 652nm diode laser (Applied Optronics Corp., 
South Plainfield, NJ), equipped with a fiber-based frontal light distributor (Medlight SA, 
Ecublens, Switzerland). Energy dose of 2.5Jcm-2, 5Jcm-2 or 10Jcm-2 was applied at a fluence 
rate of 11.3 mWcm-2. Dark- and photo-toxicity were assessed 24hrs later by measuring cell 
metabolic activity with the water-soluble tetrazolium (WST-1) reagent (Roche Diagnostics 
AG, Rotkreuz, Switzerland). The % of viability was calculated as the ratio of absorbance at 
415nm of extracts of treated and non-treated cells multiplied by 100. For the determination 
of the number of 143B cells after PDT treatment, cells were seeded at a density of 20’000 
cells per well in 24 well plates and allowed to adhere overnight. They were then incubated 
with Foslipos® at indicated concentrations for 5hrs and subsequently illuminated with 5Jcm-2 
as described above. 24hrs later the cell culture medium was collected and the cells were 
washed once with PBS and then trypsinized. The collected medium, the PBS wash fraction 
and the trypsinized cells were pooled and centrifuged at 400 x g for 5min. The supernatant 
was discarded and the cells resuspended in 200µl fresh medium. The cell suspension was 
transferred to a 96-well plate and the cells counted with a Guava EasyCyte machine (Guava 
Technologies Inc.). 
4.3.4 WESTERN BLOT ANALYSIS 
2.5 x 106 143B cells were seeded in 10cm dishes and allowed to adhere overnight. They were 
then incubated with Foslipos® at 0, 0.03, 0.15, 0.6, 1.25µgml-1 for 5hrs and subsequently 
illuminated with 5Jcm-2 as described above. Ninety min after illumination, the cells were 
washed three times with PBS/0.05% EDTA on ice. Washed cells and cells in the wash 
fractions were collected in one pellet. Cell pellets were lysed in 50mM tris-
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hydroxyethylaminomethan, pH 7.5, 150mM NaCl, 1% NP-40, 0.5% deoxycholic acid (DOC), 
0.1% SDS, 1mM PMSF, sonicated and incubated at 4°C for 1hr. Cell lysates were cleared by 
centrifugation at 20’800 x g and 4°C for 20min. Equal amounts of protein were loaded and 
separated by SDS-PAGE in 15% gels for cleaved caspase 3, in 12% gels for cleaved caspase 7 
and full length and cleaved caspase 9 and in 8% gels for full-length and cleaved PARP. 
Proteins were transferred to nitrocellulose membranes by semi-dry blotting. Cleaved 
caspase 3 and -7 and intact and cleaved caspase 9 as well as intact and cleaved poly-ADP-
ribose polymerase (PARP) were detected with respective antibodies (Cell Signaling 
Technology, MA, USA). β-actin, used as a protein loading control, was detected with β-actin 
antibodies (Chemicon, Dietikon, Switzerland). Horseradish peroxidase (HRP)-tagged 
antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and 
immunostained proteins were visualised by detection of HRP substrate Immobilon 
(Millipore, Billerica, MA) chemoluminescence with a VersaDocTM Imaging System (Bio-Rad, 
Munich, Germany).  
4.3.5 MOUSE MODELS 
Animal care and experiments were conducted in accordance with Swiss Animal Welfare 
legislation and were approved by the Veterinary Office of Canton Zurich, Zurich, Switzerland. 
Six to eight weeks old female immunosuppressed SCID and immunocompetent C3H mice 
were purchased from Charles River Laboratories (Sulzfeld, Germany), kept in pathogen-free 
conditions. The mice have always reached the mouse facility at least 1 week before starting 
any experiment. Before injection, cells were detached with trypsin-
ethylenediaminetetraacetic acid (EDTA), washed twice with PBS containing 0.05% EDTA and 
finally re-suspended in PBS-EDTA at a final concentration of 5x107 cellsml-1. An aliquot of the 
cell suspension (10 µl) was orthotopically injected into the medullar cavity of the left tibia of 
the mice. Primary tumour development was monitored by X-ray (Faxitron, USA) weekly for 
143B and LM8 cell-derived tumours.  
Primary tumour volume was measured with a caliper along the length and the width of the 
leg and calculated according to the formula: (L x W2)/2. With the same formula the volume 
in the control healthy leg was calculated and subtracted to the volume in the tumour leg to 
exclude from the tumour volume the part coming from the bone and from the physiological 
growth of the mice. 
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The 143BLacZ injected mice were sacrificed between days 21 and 23 after tumour cell 
inoculation; LM8LacZ mice between day 21-28.  
Sacrifice was performed using an optimized protocol which is specific for LacZ tagged cells. 
After anaesthetizing the mice 10% Ketamin, 2% Xylazin and 10% Acepromazin, the mice 
were opened and lungs were first perfused through the right ventricle with PBS 1x and then 
with PFA 3% from the right ventricle and from the trachea. While the lungs have been fixed, 
the primary tumour and the healthy control leg were removed. The last step involved the 
excision of the lungs which were, first, washed with PBS 1x and finally excised.  Primary 
tumour and lungs were then kept in fixing solution (PFA 2%) for 30min, the organs were 
stained with X-Gal staining solution for at least 3hrs and after washing them 3 times with 
PBS 1x they were kept for long-term storage in 4% PFA (Arlt, Banke et al. 2011). 
Micro- (diameter larger than 0.2mm) and macro-metastases (diameter larger than 0.2mm) 
were counted on the surface of the whole lung using the Olympus SZX 10 microscope 
(Olympus, Southend on Sea, UK). 
4.3.6 FOSLIP® UPTAKE IN VIVO  
The in vivo uptake was measured with a PDT fluorometer package (JETI Technische 
Instrumente GmbH, Jena-Germany) provided by Biolitec containing the fluorometer and a 
measuring fiber. In the 143BLacZ model we evaluated the uptake in the tumour leg, in the 
liver which is the metabolic organ and in the lung where metastases appear in this model. 
Mice (n=3) were injected at day 21 after tumour cell injection intravenously with 1.5mgml-1 
Foslip® and the uptake was measured in vivo with the optic fiber in contact with the tumour 
area. We measured the uptake at different time points (from 0 to 48hrs) at three different 
locations of each organ to get more reliable results and we used a mouse as the background 
for the fluorometer that was injected only with 5% glucose. The excitation of the violet LED 
lamp which is contained in the fluorometer is 405nm and the result is shown in a spectrum 
from 550 to 800nm. The integration time for the measurement was kept fixed at 7500ms. 
Since Foslip® has the maximum emission peak at 652nm we used the relative fluorescence 
unit from this wavelength and calculated the average from the three measurements 
obtained from each mouse and from each organ.   
In the experiment performed with the LM8LacZ model the procedure was the same but the 
Foslip® was injected in the mice at day 26 (n=2) in one experiment and at day 21 (n=7) in the 
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second experiment since in the first experiment most of the mice had to be sacrificed before 
the experiment could be finished. Since in this model the metastases develop in liver, 
ovaries, kidney and lung we measured only the uptake in the tumour leg and in the healthy 
control leg to evaluate the specificity of the Foslip® uptake. 
4.3.7 TREATMENT PROTOCOL 
The therapy experiments were performed only with the 143BLacZ model and the therapy 
was started as soon as lytic lesions could be visualised by x-ray (day 14 after tumour cell 
injection). 
In this study one group received nothing; one group received only 0.15mgkg-1 of Foslip®; a 
third and fourth group were only exposed to light dose (10Jcm-2 or 40Jcm-2) and the fifth and 
sixth group received 0.15mgkg-1 Foslip® and later they received either 10Jcm-2 of energy 
dose or 40Jcm-2 energy dose. After irradiation mice were checked each day and one group of 
mice (0.15mgkg-1 plus 40Jcm-2) had to be sacrificed already the day after the treatment 
because of strong side effects (necrosis in the leg, swelling, breathing affection and reduced 
motility). The experiment was concluded on the day 21 when also the second treated group 
(0.15mgkg-1 plus 10Jcm-2) showed complications related to a strong inflammatory response 
in the tumour leg.  
In the second pilot study the PS concentration were reduced and three dilutions were tested 
to 0.05, 0.015 and 0.005mgkg-1. The negative control group in this experiment received only 
Foslip® (0.05mgkg-1). No further control groups were used since no difference could be 
reported in tumour volume and number of metastases among the groups of negative control 
used in the first experiment. The mice were sacrificed at day 24. 
The analysis of this experiment consisted in comparing the tumour volume among the 
groups, evaluating visually the osteolysis by x-ray and in counting the total number of micro- 
and macro-metastases. 
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5 CONCLUSIONS  
Principle aims of the studies reported in this thesis were the evaluation of metabolic imaging 
by PET and its prognostic power in experimental intratibial OS models, making use of 
clinically approved tracers for PET, and an assessment of the potential of PDT for 
intraoperative OS treatment with the ultimate goal to improve long-term survival of OS 
patients. 
Current routinely used non-invasive tumour imaging techniques, including x-ray, CT and MRI, 
are mainly diagnostic with little prognostic power, except when they are used to monitor the 
success of chemo- or radiotherapy, e.g. by CT. Monitoring of tumour treatment success is 
frequently also performed with PET with 18F-FDG as a tracer, which rapidly and rather 
selectively accumulates in tissues with a high glucose metabolism. However, in recent years, 
additional PET tracers have been developed for clinical use and are compounds that are 
substrates in distinct biological processes and consequently indicators of metabolic 
conditions in e.g. tumour tissue. The three distinct intratibial OS mouse models that we used 
for our PET studies individually represent distinct phenotypes of pathophysiological relevant 
conditions in OS tissue, including rapidly proliferating or hypoxic tumour domains and 
rapidly remodelled bone-like structures. The results presented in the thesis demonstrate 
that, with the use of 18F-FDG, indicating high glucose metabolism and rapid proliferation, of 
18F-FMISO, indicating hypoxia, or of 18F-Fluoride as an indicator of bone formation and 
remodelling, we were able to differentiate between pronounced and mild osteoblastic and 
osteolytic OS phenotypes, represented by the three experimental models investigated here. 
The detection of hypoxia in OS tumour tissue is of particular relevance because there is 
strong evidence for increased resistance of hypoxic OS tissue to chemotherapy with the 
consequence of a poor prognosis for the patient. All findings taken together, we can 
conclude that PET of OS tumours with a combination of the three metabolic tracers 18F-FDG, 
18F-FMISO and 18F-Fluoride has relevant prognostic potential in OS.  
However, the presented results also demonstrate that we failed to detect even severe lung 
metastasis in the animal models investigated here with the PET scanner that was available to 
us. In order to take advantage of the also extremely important disease outcome predictor 
“metastasis” in OS, the signal to background ratio and the sensitivity of lung PET scans of 
mice need to be significantly improved. Efforts to achieve these improvements are 
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worthwhile, because we were able to demonstrate selective uptake of the PET tracers and 
even calcification, indicated by 18F-Fluoride uptake, in individual metastatic lesions of an 
osteoblastic model by ex-vivo autoradiography of lung tissue sections. Based on the results 
presented here and the fact that the PET tracers used are all clinically approved, prognostic 
PET imaging in OS patients can be envisaged. Prognostic differentiation of metabolic 
phenotypes of OS tumours by PET together with well-established histological grading of 
tumour biopsies will likely be of significant help for the design of effective, tumour 
phenotype-specific treatment regimens with the benefit of fewer side effects for the 
patients but maintained or even improved efficacy.  
Along these lines, PDT, which is already clinically used for the treatment of epithelial 
tumours, is considered for intraoperative OS treatment to target rather frequently occurring 
OS-satellites in healthy tissue beyond tumour margins, which give rise to recurrences. The 
results of the experiments carried out in this thesis are encouraging. They demonstrate that 
an already clinically approved lipid formulation of the photosensitizer mTHPC is more 
efficiently taken up and accumulated by aggressive highly metastatic human 143B OS cells 
than by the parental low metastatic HOS cells. Moreover, 143B cells are more sensitive to 
dark- and photo-toxicity and undergo apoptosis rather than necrosis, which in living 
organisms will cause fewer side effects. The in vivo studies carried out so far in intratibial OS 
mouse models indicate that future experiments, required for a preclinical assessment of PDT 
as novel intraoperative treatment modality in OS, need to be performed in syngeneic 
intratibial OS mouse models with metastasis predominantly to the lung, because local 
immune responses in the tumour-affected tissue are crucial for maximising treatment 
efficacy.  
In conclusion, the results of the studies presented in this thesis pave the way for further 
development of novel clinically applicable PET imaging strategies for early detection and 
prognosis of OS in patients and the design of more tumour-type tailored treatment. Based 
on the results obtained with PDT in our in vitro and in vivo experimental OS systems, there is 
considerable potential for intraoperative treatment of OS with this novel modality in 
combination with the well-established protocols of neo-adjuvant chemotherapy and, when 
required, radiotherapy. 
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design 
PET and PDT 
Josefine Bertz Technical support and  
experiment planning 
PET and PDT 
Prof. Walter Born Study design PET and PDT 
Dr. Sander Botter Technical support PDT 
Dr. Patrick Brennecke Animal work PET and PDT 
Christopher Bühler Technical support PET and PDT 
Carmen Campanile Study design, experiment 
conduct, data analysis 
PET and PDT 
Cindy Fischer Material provider PET 
Prof. Bruno Fuchs Study design PET and PDT 
Dr. Ana Gvozdenovic Animal work PET and PDT 
Dr. Michael Honer Experimental design and 
analysis evaluation 
PET 
Dr. Knut Husmann Animal project leader 
(proposals) and material 
provider 
PET and PDT 
Claudia Keller Technical support and 
experiment planning 
PET 
Dr. Stefanie D Krämer Animal project leader PET 
Dr. Ram Kumar Technical support PDT 
Prof. Roman Muff Study design PDT 
Dr. Adrienne Müller Animal responsible PET 
Mathias Nobst Material provider PET 
Dr. Kerstin Reidy Study design and experimental 
work (in vitro), animal design 
PDT  
Dr. Adam A Sabile Material provider PET 
Prof. Roger Schibli Study design PET 
Petra Wirth Technical support PET 
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